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Facioscapulohumeral muscular dystrophy (FSHD [OMIM 158900]), an inherited 
myo pathy that is predominantly characterized by progressive, often asymmetric, 
weakness and wasting of the facial, shoulder and upper arm muscles [1], does not seem 
to be caused by structural mutations within a specific disease gene. Instead, increasing 
evidence suggests a significant role for a complex epigenetic mechanism, resulting in the 
perturbation of transcriptional control over multiple disease genes. This introduction 
aims to discuss the epigenetic changes observed in the FSHD locus and the possible 
epigenetic disease mechanism that may be associated with and contribute to FSHD 
pathogenesis.
2	 GenetIc	chanGes	assocIated	wIth	Fshd
FSHD is inherited in an autosomal dominant fashion. The majority of FSHD cases show 
linkage to the subtelomere of chromosome 4q which harbors the macrosatellite repeat 
D4Z4 (4q-linked FSHD or FSHD1) [2]. In the general population, this polymorphic 
repeat array varies between 11 and 100 units of 3.3 kb each. In patients with FSHD1, 
the D4Z4 repeat array is contracted to 1–10 units on one allele [3, 4]. The smallest 
residual repeat sizes are correlated with the more severe phenotypes, although a clear 
linear inverse relationship between residual repeat size and clinical severity has not been 
observed [5-7]. As monosomy of 4qter is not associated with FSHD, a critical role for 
the D4Z4 repeat array and flanking sequences in FSHD pathogenesis is to be expected 
[8]. Interestingly, in ~1% of patients presenting with a classic FSHD phenotype, a 
partial D4Z4 deletion extending in the proximal direction has been identified [9-11]. In 
these cases, an inverted D4Z4 repeat unit that is present 42 kb upstream of the D4Z4 
repeat array and the candidate gene FRG2 (FSHD region gene 2) can be deleted [11]. 
Thus far, the role of this inverted repeat in FSHD is unknown. The role of FRG2 in 
FSHD pathogenesis will be discussed below. D4Z4-like repeat arrays are not restricted 
to chromosome 4qter. Sequences homologous to D4Z4 have been identified on many 
chromosomes, especially on the acrocentric chromosomes [12]. In addition, as a result of 
an ancient duplication, the subtelomere of chromosome 10q contains a repeat array that 
is highly homologous to D4Z4 [13, 14] (Figure 1). In ~10% of the population, subtelomeric 
exchanges between the D4Z4 repeats on 4qter and 10qter have been observed [15]. 
These rearrangements can result in the formation of hybrid alleles containing a mixture 
of 4-type and 10-type repeat units [9]. Translocated repeat arrays on chromosome 10q 
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are more homogeneous than translocated repeat arrays on chromosome 4q, the latter 
being almost always comprised of both 4- and 10-derived repeat units [16]. Importantly, 
FSHD is uniquely linked to chromosome 4q. Although ~10% of chromosomes 10q 
have been identified with a repeat array <11 repeat units, no contractions on 10qter 
have been reported to result in FSHD [17, 18]. Contraction of a translocated 4-type allele 
on chromosome 10q does not result in disease either [9, 15, 16]. Some years ago, two allelic 
variants of the 4q subtelomere, termed “4qA” and “4qB”, were identified [19] (Figure 1). 
Figure 1 
Schematic map of 4qA, 4qB and 10q
The subtelomere of chromosome 10q contains a repeat array that is highly homologous to D4Z4 on 
4qter. The homology extends both in proximal (~40 kb upstream) and distal direction. In addition, two 
allelic variants of the 4q subtelomere have been identified. The presence of beta satellite DNA distal to 
D4Z4 on 4qA-type alleles is the most prominent difference between these allelic variants.
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Although both variants are equally common in the population, FSHD is exclusively 
associated with a shortened D4Z4 repeat on a 4qA type allele [20]. A FSHD-sized repeat 
array on a 4qB-type allele does not cause FSHD [21]. The most prominent difference 
between these two allelic variants is the presence of 6.2 kb beta satellite DNA distal to 
D4Z4 on 4qA-type alleles [19]. An additional rare 4qter subtype was identified in two 
FSHD cases [22]. Recently, with the identification of 9 different haplotypes of chromosome 
4q on basis of sequence variations in the FSHD locus, the picture became even more 
complex. Thus far, only contraction in one of these haplotypes, termed “4qA161”, 
was found to cause FSHD, while contractions in other common 4q haplotypes such as 
“4qA166” and “4qB163” are non-pathogenic [23]. Currently, it is unclear what determines 
the difference in pathogeneticity between the different haplotypes. Haplotype-specific 
single nucleotide polymorphisms (SNPs) can be identified in the FSHD locus and are 
speculated to have an effect on the transcriptional activity of FSHD candidate genes 
or on the binding of proteins to the D4Z4 repeat array. Finally, a small percentage of 
FSHD cases (<5%), referred to as patients with phenotypic FSHD or FSHD2, shows no 
contraction of D4Z4 on one of their chromosomes 4q [24]. Currently, no disease locus has 
been identified for this heterogeneous patient group. Genes encoding the components 
of the D4Z4 repressor complex (see below) and MYOD1 have been excluded as disease 
genes for this group of patients [25].
3	 epIGenetIc	chanGes	assocIated	wIth	Fshd
Over the years, because of the lack of evidence for transcription emanating from D4Z4 
(see below), FSHD studies shifted towards understanding the chromatin structure of 
D4Z4. Each D4Z4 repeat unit harbors two classes of GC-rich sequences, namely the 
low-copy-repeats hhspm3 and LSau. This type of repetitive DNA is predominantly 
found in heterochromatic regions of the genome [26]. Moreover, D4Z4 is overall very 
GC rich and has characteristics of a CpG island. Therefore, it has been hypothesized 
that repeat contraction-induced changes in chromatin conformation leading to 
inappropriate regulation of FSHD candidate genes, thus an epigenetic mechanism, 
may underlie FSHD pathogenesis. Major epigenetic mechanisms accounting for 
and contributing to human disease are changes in DNA methylation and histone 
modifications. An overview of studies on changes in DNA methylation and histone 




3.1 DNA methylAtioN iN FShD
In mammalian DNA, the cytosine of CpG dinucleotides can be methylated by DNA 
methyltransferases like DNMT1, DNMT3A and DNMT3B. Generally, the presence 
of methyl groups on DNA is associated with increased chromatin condensation and 
gene silencing. When a promoter region is methylated, transcription factors with 
CpG dinucleotides in their DNA recognition sequence cannot bind. Reports on the 
methylation-sensitive binding of proteins, including E2F, CTCF (CCCTC-binding 
factor) and YY1 (Ying Yang 1), are numerous [27-29]. On the other hand, the methyl 
binding domain (MBD) proteins bind specifically to methylated DNA. Subsequently, 
these proteins can recruit histone deacetylases and histone methyltransferases, 
resulting in increased chromatin condensation and recruitment of the chromatin 
silencer heterochromatin protein 1 (HP1), respectively [30, 31]. An initial study on DNA 
methylation in the D4Z4 repeat array did not show a change in this epigenetic marker in 
FSHD since high methylation levels, consistent with heterochromatin, were observed 
at several CpG dinucleotides in both normal and FSHD cell lines and somatic tissues. 
However, the methylation level of both chromosome 4q and 10q repeat arrays was 
analyzed simultaneously [32]. A few years later, studying two different CpG dinucleotides 
and discriminating between chromosomes 4q and 10q, significant hypomethylation 
of the contracted allele was observed in patients with FSHD compared to controls 
and individuals with non-FSHD muscular dystrophies. Although this study was 
predominantly performed on lymphoblast DNA, a similar level of hypomethylation was 
identified in a small group of DNA samples isolated from FSHD muscle. Importantly, 
low D4Z4 methylation levels were observed at both chromosome 4q alleles in FSHD2 
patients who are clinically indistinguishable from FSHD1 patients but who show no 
D4Z4 contraction [33]. Interestingly, part of the proximal D4Z4 repeat unit seems to 
be resistant to DNA methylation, as was observed in cancer tissues presenting with 
high DNA methylation throughout the D4Z4 repeat array. In addition, this 2 kb region 
showed differential DNaseI accessibility compared to the remainder of the repeat array. 
These results may suggest the presence of a boundary element at the junction of D4Z4 
and the proximal AT-rich p13E-11 region [34]. Such a boundary element can be essential 
in physically separating active and inactive genomic regions [35]. Further, a subregion 
within each D4Z4 repeat unit, 1.4 kb from the single KpnI site within D4Z4, also 
showed resistance to cancer-linked hypermethylation. This subregion contains stretches 
of G residues that are hypothesized to form stable G-quadruplexes that can play an 
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important role in D4Z4 chromatin organization [34]. Intriguingly, homodimers of the 
myogenic regulatory factor MyoD may specifically recognize these G-quadruplexes 
[36]. These results on cancer-linked hypermethylation were only confirmed at a 
lower intensity in somatic control DNA samples and not in FSHD DNA samples [34]. 
Currently, the precise role of D4Z4 hypomethylation in FSHD pathogenesis remains to 
be established. Altogether, FSHD alleles are hypomethylated compared to controls, but 
methylation levels can vary substantially between individuals. Generally, patients with 
residual repeat sizes between 10 and 20 kb are severely affected and show very low 
DNA methylation levels, while patients with repeat sizes between 20 and 31 kb show 
large interindividual variation in both clinical severity and D4Z4 hypomethylation [37]. 
In addition, asymptomatic gene carriers show the same reduction in D4Z4 methylation 
as FSHD1 patients and strong D4Z4 hypomethylation is also reported in patients 
with immunodeficiency, centromeric instability and facial anomalies syndrome (ICF 
syndrome [OMIM 242860]) [33, 38]. Patients with ICF syndrome present with severe 
immunodeficiency, resulting in recurrent respiratory and gastrointestinal infections, 
and non-myopathic facial anomalies. In ~60% of patients with ICF, mutations in the 
DNA methyltransferase gene DNMT3B have been identified [39]. As these mutations 
reduce the methyltransferase activity of DNMT3B, hypomethylation of several repeat 
arrays, including satellite 2 (Sat2), satellite 3 (Sat3), the NBL2 repeat and the D4Z4 
repeat, is observed in patients with ICF [38-40]. Other (epigenetic) factors that differ 
between FSHD and ICF may contribute to the development of FSHD.
3.2 hiStoNe moDiFicAtioNS iN FShD
Chromatin is the assembly of DNA, histone proteins and other chromosomal proteins. 
A major function of chromatin is to accommodate the packaging of the DNA in the 
nucleus. The smallest structural unit of packaging is the nucleosome that consists of 
~146 bp of DNA wrapped around eight core histone proteins. Histone proteins may 
undergo several posttranslational modifications, such as acetylation, methylation, 
phosphorylation and ubiquitination [41]. Currently, two models explaining the function 
of these histone modifications prevail. Histone modifications may directly affect 
chromatin structure by preventing transcription factor binding, altering the interactions 
between nucleosomes or changing the interactions of the histone tails with the DNA 
in the nucleosome [42]. On the other hand, histone modifications may serve as a site for 




Epigenetic modifications at the D4Z4 repeat array in controls and patients with 
FSHD
In control individuals methylation levels of 50% are identified at two CpG dinucleotides while 
in patients with FSHD significant hypomethylation is found at these sites (~25% methylation). 
Interestingly, part of the proximal repeat unit seems to be resistant to DNA methylation (0% 
methylation) and is more accessible to DNaseI in cancer tissues, suggesting the presence of a 
boundary element at the junction of D4Z4 and p13E-11. Finally, a subregion within each D4Z4 
repeat unit that may form a G-quadruplex also shows resistance to cancer-linked hypermethylation 
(0% methylation). In somatic control DNA samples similar results were obtained, although at a 
lower intensity. FSHD DNA samples have not yet been tested (?% DNA methylation). The presented 
nucleotide positions are based on AF117653 (GenBank).
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As a consequence, downstream events generating a particular chromatin state may occur 
[43]. Specific histone modifications seem to be associated with either transcriptional 
activation or transcriptional repression. Methylation at lysine residues 4, 36 and 
79 of histone H3 has been correlated with transcriptional activation. Acetylation of 
arginine residues of histone H3 and H4 is also characteristic for euchromatin and gene 
activation [44]. In contrast, methylation at lysine residues 9 and 27 of histone H3 and 
at lysine residue 20 of histone H4 are typically linked to heterochromatin and gene 
repression [45, 46]. Using chromatin immunoprecipitation (ChIP) assays, the hypothesized 
heterochromatic nature of the D4Z4 repeat array was studied. The level of histone H4 
acetylation of D4Z4 in chromosome 4-containing somatic cell hybrids was higher than 
expected for a heterochromatic structure. Further, histone H4 acetylation levels at 
the p13E-11 region immediately proximal to D4Z4 were similar to those observed 
in the 5’ regions of the FSHD candidate genes FRG1 (FSHD region gene 1) and ANT1 
(adenine nucleotide translocator 1) and did not differ significantly between control 
and FSHD lymphoid cells. In conclusion, these results suggested that the nature of 
D4Z4 chromatin is that of unexpressed euchromatin rather than that of constitutive 
heterochromatin [47]. In a second study, other heterochromatin marks were studied 
using immunofluorescence in situ hybridization (immuno-FISH) methods. The FSHD 
locus at 4qter did not colocalize in control and FSHD myoblasts with DAPI-intense 
loci, not with heterochromatic foci in interphase nuclei and not with chromatin regions 
enriched in HP1α or histone H3 methylated at lysine 9. In addition, no late replication 
in S-phase, characteristic for constitutive heterochromatin, was observed. On the 
other hand, histone H3 methylation at lysine 4 and histone H4 acetylation at lysine 
8, both characteristics for highly expressed gene regions, was observed in FSHD and 
control myoblasts [48]. Again these results indicated a more euchromatic or facultative 
heterochromatic structure at the D4Z4 repeat. 
4	 epIGenetIc	dIsease	mechanIsm	oF	Fshd
The exact pathogenetic mechanism causing FSHD is still unknown. Over the years, 
several disease mechanisms for FSHD have been postulated, implying either a direct 
(protein coding) or an indirect (non-protein coding) role for D4Z4 in the development 
of FSHD. A number of observations need to be considered when proposing a disease 
mechanism for FSHD. First, a critical number of D4Z4 repeat units is associated 
with FSHD pathogenesis. In general, patients with FSHD carry a D4Z4 repeat array 
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that is contracted to 1–10 repeat units [3, 4] while monosomy of 4qter does not cause 
FSHD [8]. Second, despite the high homology between D4Z4 repeat arrays derived 
from chromosomes 4qter and 10qter, only contraction in one of the 4qter haplotypes, 
termed 4qA161, results in FSHD [20, 23]. FSHD-sized repeat arrays on chromosome 10q 
or on 4qA166 and 4qB163 alleles do not cause FSHD [21, 23]. Third, a specific change 
in chromatin structure is observed, namely D4Z4 hypomethylation [33]. At present, it 
is unknown whether these changes in chromatin structure are causative for FSHD or 
arise as a consequence of the primary genetic defect. Therefore, it is also unclear what 
the contribution of these chromatin changes is to the FSHD phenotype. However, a 
small group of patients presents with a FSHD phenotype but does not show a D4Z4 
contraction. Importantly, these patients show both D4Z4 hypomethylation [33]. Thus, it 
will be imperative to study the functional consequences of this chromatin change.
4.1 role oF D4Z4 trANScriptioN iN FShD pAthogeNeSiS
Initially, a putative promoter and the putative double homeodomain gene DUX4 
were identified within each D4Z4 repeat unit. As D4Z4 was considered to be of 
heterochromatic nature, it was hypothesized that partial deletion of the D4Z4 repeat 
array resulted in destabilization of the D4Z4 heterochromatin and in the inappropriate 
upregulation of DUX4 [26, 49]. DUX4 overexpression may induce cell death by apoptosis, 
induce caspase 3/7 activation and alter emerin distribution at the nuclear envelope 
[50]. In addition, DUX4 overexpression may activate PITX1 (paired-like homeodomain 
transcription factor 1), as was determined for both a reporter gene fused to the 
Pitx1 promoter and the endogenous Pitx1 gene. Interestingly, upregulation of the 
PITX1 protein was also observed in muscle biopsies of patients with FSHD [50, 51]. 
Nevertheless, for a long time, the functionality of the DUX4 gene was questioned, 
because of lack of introns and polyadenylation signals and absence of evidence for in 
vivo transcription [26, 49, 52-54]. Recently however, D4Z4 homologues have been identified 
in several mammalian species and it was established that the DUX4 open reading frame 
(ORF) shows evolutionary conservation, disputing the non-functionality of DUX4 and 
suggesting a coding role, possibly during development. Interestingly, not only the ORF 
of DUX4, but also their organization in an array is evolutionary conserved. Importantly, 
this study provided evidence for bidirectional transcription of the mouse Dux array 
[55]. Next, expression of two different DUX4 transcripts in cells transfected with D4Z4 
elements and in FSHD myoblasts was reported. The first transcript lacks introns and 
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is transcribed from internal D4Z4 repeat units, while the second transcript has two 
introns and is transcribed from the most distal D4Z4 repeat unit. Interestingly, the 
pLAM sequence distal to the second transcript may provide a polyadenylation signal [50, 
51]. Thus far, DUX4 expression seems to be restricted to FSHD myoblasts [50, 51]. As most 
homeodomain proteins have a function as transcriptional regulators in developmental 
processes, DUX4 expression may normally be restricted to embryogenesis [56]. In fact, 
the DUX4 homeodomain shares high homology with the homeodomain of the proteins 
Pax3 and Pax7, which are involved in the development of skeletal muscle [57]. As FSHD 
is specifically linked to the 4qA161 haplotype [23], sequence variations residing within or 
close to the D4Z4 repeat array may play a role in the regulation of DUX4 transcription. 
Therefore, it is very interesting that differences between 4qA and 4qB alleles are observed 
in the pLAM region, possibly affecting the polyadenylation signal [20, 51]. However, these 
data need to be extended. At the same time, lower DNA methylation levels at D4Z4 
may also influence the regulatory process of DUX4, explaining the occurrence of FSHD 
in FSHD2 patients without a D4Z4 contraction.
4.2 role oF geNe DeregulAtioN In	cIs iN FShD pAthogeNeSiS
Other models have predicted an indirect role for the D4Z4 contraction in FSHD 
pathogenesis. Chromatin structure alterations at D4Z4, like D4Z4 hypomethylation, 
may cause loss of transcriptional control over the expression of candidate genes in cis. The 
identification of a DNA-binding complex, consisting of YY1, HMGB2 (high-mobility 
group box 2) and nucleolin and acting as a transcriptional repressor, supported the cis-
model of gene deregulation. In controls, the presence of a threshold number of D4Z4 
repeats may repress 4q35 genes, while in FSHD patients, because of a strong reduction 
in the number of bound YY1-HMGB2-nucleolin complexes, the transcriptional 
repression is abrogated, resulting in inappropriate overexpression [58]. A second line of 
evidence for deregulation in cis was recently provided by the identification of a nuclear 
matrix attachment site (S/MAR) associating with the nuclear matrix immediately 
upstream of D4Z4 [59]. S/MAR sequences are important for the organization of DNA 
into loop domains as part of a higher order chromatin structure [60]. In normal cells, 
the S/MAR is located between the upstream FSHD candidate genes FRG1 and FRG2 
and the D4Z4 repeat array, thus separating them into two distinct DNA loop domains. 
In myoblasts from patients with FSHD, dissociation of the S/MAR from the nuclear 
matrix seems to occur, what may result in the presence of the FRG1 and FRG2 genes 
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in the same loop as the D4Z4 repeat array [59]. Since the 5’ end of the D4Z4 repeat 
array was shown to contain a strong transcriptional enhancer, as a consequence FRG1 
and FRG2 expression may be upregulated in patients with FSHD [61]. Although initial 
testing showed that FRG1, FRG2 and ANT1 were indeed transcriptionally upregulated 
in FSHD muscle [58], several follow-up studies could not reproduce these findings [47, 52, 
53, 62]. The use of different techniques and different sources of RNA may partly explain 
this lack of reproducibility. The highly conserved nuclear protein FRG1 is a component 
of the human spliceosome and may have a role in pre-messenger RNA splicing [63-65]. 
Importantly, mice that overexpress FRG1 25- or 40-fold in skeletal muscle develop a 
muscular dystrophy phenotype. In addition, missplicing of muscle-specific mRNAs was 
observed in skeletal muscle of these transgenic mice, in FRG1-expressing C2C12 cells 
and in FSHD myoblasts [66]. Although an independent follow-up study could not confirm 
a splicing defect in FSHD muscle [53], a potential role for FRG1 in FSHD pathogenesis has 
to be considered. FRG2, mapping 37 kb proximal to D4Z4 and specifically upregulated 
in differentiating myoblasts of patients with FSHD, is a less attractive FSHD candidate 
gene, as it is absent in some FSHD patients with a proximally extended deletion [9-11, 67]. 
Also, mice that overexpress FRG2 do not present with muscular dystrophy. The same 
holds for mice overexpressing ANT1; these mice do not seem to develop a muscular 
dystrophy phenotype [66]. Interestingly, ANT1 protein levels were shown to be increased 
in both unaffected and affected FSHD muscles compared to muscles from controls and 
patients with Duchenne muscular dystrophy (DMD). An increased expression of ANT1 
may sensitize muscle cells to oxidative stress and apoptosis [68]. Thus, ANT1 remains 
an attractive candidate gene and further studies addressing the role of ANT1 in FSHD 
pathogenesis are warranted.
4.3 role oF geNe DeregulAtioN In	trans iN FShD pAthogeNeSiS
Several studies support an important trans-sensing effect in FSHD. An initial study on global 
gene expression profiles of FSHD muscle suggested a FSHD-specific defect in myogenic 
differentiation [52]. Since then, both gene and protein expression follow-up studies have 
been performed, presenting new interesting affected pathways, such as an impairment 
of slow-to-fast fiber differentiation, increased sensitivity to oxidative stress and a possible 
link with retinal vasculopathy [53, 62]. As the somatic pairing frequency between the 4q 
subtelomere and the 10q subtelomere was observed to be slightly but significantly 
increased in patients with FSHD, a trans-sensing effect of the D4Z4 contraction on gene 
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regulation on 10qter is expected [69]. Evidence supporting this hypothesis is the observation 
of a distinct level of FRG2 expression on chromosome 10q in differentiating myoblasts of 
patients with FSHD [67] and a significant trans effect on myotube formation when D4Z4 
repeats were transfected in C2C12 myoblasts [70]. However, a recent study employing 
chromatin conformation capture (3C) to investigate the three-dimensional structure of 
the 4q subtelomeric region showed that the majority of interactions at the 4q35 locus 
occur in cis and not in trans between chromosomes 4q and 10q [71].
As discussed above, each D4Z4 unit contains a 27 bp D4Z4 binding element (DBE) 
which binds a multi-protein complex consisting of YY1, HMGB2 and nucleolin [58]. 
Loss of this repressor complex at the disease allele in patients with FSHD may not only 
have an effect on transcriptional regulation of 4q35 genes. Genome-wide effects can 
be expected as well as a result of a local unbalance of D4Z4 binding of these proteins 
and subsequent interaction with different proteins at the disease allele. HMGB2 is a 
chromatin-associated DNA binding protein and a member of the high-mobility group 
(HMG) proteins [72]. Binding of HMGB2 to DNA may have a profound effect on the 
maintenance of heterochromatic regions, as HMGB2 interacts with SP100B which in 
turn binds to HP1, which has a function in the establishment and maintenance of higher 
order chromatin structures [73, 74]. Nucleolin, a nucleolar RNA-binding protein involved in 
several steps of ribosome biogenesis [75], may have the opposite effect on heterochromatin 
maintenance. Nucleolin has been shown to interact with histone H1 which may result in 
chromatin decondensation by displacement of histone H1 from linker DNA [76]. Finally, 
YY1 may also effect the chromatin structure at D4Z4, since it is the homologue of the 
Drosophila PcG protein pleiohomeotic (PHO). PcG multiprotein complexes control 
chromatin accessibility and maintain transcriptional repression during embryogenesis 
[77]. Depending on its relative concentration, the presence of coactivators or corepressors 
and the promoter context, YY1 can act as a transcriptional activator or repressor. A local 
unbalance in YY1 binding at D4Z4 may have multiple consequences. First, YY1 binding 
to regulatory regions of transcriptionally inactive muscle-specific genes seems to be 
required for recruitment of the histone lysine methyltransferase Ezh2 in proliferating 
mouse myoblasts. During myoblast differentiation, the YY1-Ezh2 complex disassociates 
from the DNA and consequently the transcription factor MyoD, having a key role in the 
differentiation of all skeletal muscle lineages, is recruited [78]. Thus, an unbalance in YY1 
binding at D4Z4 in patients with FSHD may affect muscle differentiation, especially 
during embryonic development when Ezh2 is expressed [79]. Second, an unbalance in 
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YY1 binding may influence chromatin structure at or around its target site by recruiting 
the histone H4-specific methyltransferase PRMT1, resulting in methylation of arginine 
residue 3 of histone H4 and gene activation [80]. Third, an unbalance in YY1 binding may 
influence the interaction with the protein CTCF, a chromatin insulator that seems to be 
essential for homologous X-chromosome pairing [81]. Possibly, YY1-CTCF may have a 
similar function in pairing between the 4q subtelomere and the 10q subtelomere.
4.4 role oF NucleAr orgANiZAtioN iN FShD pAthogeNeSiS
Appropriate nuclear organization is essential for normal gene expression. Chromosomes 
are compartmentalized into discrete nuclear territories. The location of a gene within 
such a nuclear territory determines the availability of regulatory proteins and the 
accessibility of the DNA to the transcriptional apparatus [82]. The nuclear envelope 
(NE), consisting of an inner (INM) and outer nuclear membrane (ONM), forms the 
boundary of the nucleus [83]. The INM is covered with a protein meshwork, the nuclear 
lamina, which maintains the shape of the nucleus and provides mechanical strength to 
the nucleus. Besides, it has a role in many nuclear activities, including DNA replication, 
RNA transcription, nuclear and chromatin organization, cell cycle regulation, cell 
development and differentiation, nuclear migration and apoptosis [84]. A large group 
of inherited human diseases, collectively termed the “laminopathies”, is caused by 
mutations in components of the nuclear lamina. Most commonly, adipose tissue, bone 
and connective tissue, heart and importantly skeletal muscle are affected by these 
mutations [85]. The 4q subtelomere is preferentially localized in the outer nuclear rim, 
both in controls and in patients with FSHD. Other subtelomeric regions, including 
10qter, localize more to the interior of the nucleus [86, 87]. This peripheral localization of 
4qter seems to be caused by an intrinsic property of 4qter as the X chromosome showed 
a more peripheral localization in a cell line with a X;4 translocation containing the distal 
4 Mb of 4qter [87]. A region proximal to D4Z4 seems to be primarily responsible for the 
perinuclear localization [86, 87]. These results may explain the different nuclear localization 
of 10q subtelomeres, since the homology between 4qter and 10qter is restricted to the 
40 kb proximal to D4Z4. A major role for a correct integrity of the nuclear lamina 
in the peripheral organization of 4qter is to be expected as the peripheral localization 
of 4qter is lost in fibroblasts lacking lamin A/C, a protein of the nuclear lamina [86]. 
Although no change in the localization of disease chromosomes compared to healthy 
chromosomes was observed, the interaction between 4qter and the nuclear envelope 
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may be disturbed in FSHD because of alterations in chromatin structure at D4Z4 and 
the consequent loss of binding of specific proteins that may interact with the nuclear 
lamina. A possible defective pathway could be via HP1g and its interacting partner the 
lamin B receptor (LBR) of the INM [88]. Interestingly, other neuromuscular disorders, 
like X-linked and autosomal dominant Emery–Dreifuss muscular dystrophies (EDMD), 
are caused by mutations in emerin and lamin A/C, respectively [85]. Moreover, six nuclear 
envelope transmembrane proteins (NETs) were identified that are predicted to have an 
important function in myoblast differentiation and/or muscle maintenance [89]. Finally, 
transcriptome studies showed that FSHD and EDMD are highly related [90] and DUX4 
overexpression may redistribute emerin at the nuclear envelope [50]. In conclusion, it is 
hypothesized that FSHD may arise from improper chromatin interactions at the nuclear 
envelope.
5	 thesIs	outlIne
As discussed above, an epigenetic change is observed in the FSHD locus and a 
possible epigenetic disease mechanism may be associated with and contribute to 
FSHD pathogenesis. However, D4Z4 hypomethylation is also observed in patients 
with the ICF syndrome [33, 38]. ICF patients present with non-myopathic symptoms 
including facial anomalies, like a flat nasal bridge and hypertelorism, and severe 
immunodeficiency leading to recurrent infections mainly affecting the respiratory and 
gastrointestinal systems [91]. To determine whether the epigenetic similarities between 
patients with FSHD and patients with ICF are restricted to D4Z4 hypomethylation 
and to determine whether FSHD2 may be caused by a defect in a similar pathway as 
the ICF syndrome, in Chapter 2 a study is presented that searched for commonalities 
and differences between both disorders. First, the DNA methylation of non-D4Z4 
repeat arrays (satellite 2, satellite 3, α-satellite and NBL2) is determined in patients 
with FSHD2. In patients with ICF hypomethylation of these repeat arrays is observed 
[38-40]. Second, lymphocytes of FSHD2 patients are treated with phytohaemagglutinin 
(PHA) and studied for pericentromeric abnormalities. PHA-stimulated lymphocytes of 
patients with ICF tend to form chromosomal abnormalities, including the formation of 
radial chromosomes, mainly involving chromosomes 1, 9 and 16 [92]. Third, the levels 
of the immunoglobulins IgA, IgG and IgM are determined in patients with FSHD2, as 
the levels of these immunoglobulins may be extremely low in patients with ICF [91]. 
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Next, in Chapter 3 a study is presented that searched for additional epigenetic factors 
discriminating between patients with FSHD and patients with ICF. Therefore, the histone 
modification status of the D4Z4 repeat array on chromosomes 4q and 10q is examined 
by ChIP. Trimethylation of lysine 9 and 27 of histone H3 (H3K9me3 and H3K27me3), 
dimethylation of lysine 4 of histone H3 (H3K4me2) and acetylation of histone H3 
(H3Ac) is studied in lymphoblasts, fibroblasts and myoblasts of control individuals, 
patients with FSHD1, patients with FSHD2, patients with ICF and patients with non-
FSHD muscular dystrophies. In addition, the binding of the proteins HP1g and cohesin 
to the D4Z4 repeat array on chromosomes 4q and 10q is studied by ChIP in these cell 
lines. To further scrutinize the role of D4Z4 hypomethylation in FSHD pathogenesis, 
in Chapter 4 a detailed DNA methylation analysis of the D4Z4 repeat arrays on 
chromosomes 4q and 10q is presented. Unlike before, not only the methylation status 
of the proximal D4Z4 repeat unit is determined by methylation-sensitive Southern blot 
analysis, but also the methylation status of internal D4Z4 repeat units is studied, both 
on chromosome 4q and on chromosome 10q. Importantly, DNA material of control 
individuals carrying a short D4Z4 repeat array on a non-pathogenic 4q haplotype or 
on chromosome 10q is included in this study. Finally, in Chapter 5 a pilot study is 
presented that focuses on the reclosing of the D4Z4 chromatin structure in patients 
with FSHD1 and patients with FSHD2 by folic acid and methione supplementation for 
three months. Outcome measures for this study include clinical severity score, D4Z4 
methylation, genome-wide DNA methylation, serum folate levels, serum vitamin B12 
levels and plasma homocysteine levels.
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Background: Patients with facioscapulohumeral muscular dystrophy (FSHD) show 
a contraction of the D4Z4 repeat array in the subtelomere of chromosome 4q. This 
D4Z4 contraction is associated with significant allele-specific hypomethylation of the 
repeat. Hypomethylation of D4Z4 is also observed in patients with phenotypic FSHD 
without contraction of D4Z4 and in patients with the immunodeficiency, centromeric 
instability, and facial anomalies (ICF) syndrome, an unrelated disease that does not 
present with muscular dystrophy and is in part caused by DNMT3B mutations.
Methods: In order to identify the gene defect and to find the pathogenetic 
epigenetic pathway in phenotypic FSHD, we have aimed to identify the differences and 
commonalities in phenotypic FSHD and ICF by 1) investigation of DNA methylation 
of non-D4Z4 repeat arrays, 2) analysis of mitogen-stimulated lymphocytes to detect 
pericentromeric abnormalities involving chromosomes 1, 9, and 16, 3) determination 
of IgA, IgG, and IgM levels, and 4) mutational analysis of candidate genes to identify a 
second disease locus involved in the pathogenesis of phenotypic FSHD.
Results: Our results do not show epigenetic or phenotypic commonalities between 
phenotypic FSHD and ICF other than the earlier observed D4Z4 hypomethylation. We 
could not identify any mutations in the candidate genes tested for.
Conclusion: Our data suggest that in phenotypic FSHD hypomethylation is restricted 
to D4Z4 and that phenotypic FSHD and ICF do not share a defect in the same molecular 
pathway.
IntroductIon
Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) presents with 
progressive muscular weakness and wasting of the face, shoulders, and upper arms [1]. 
FSHD is caused by contraction of the polymorphic macrosatellite repeat D4Z4 on the 
subtelomere of chromosome 4q [2]. In patients with FSHD, this contraction is always 
associated with a specific variant of chromosome 4, termed 4qA [3, 4]. Few patients 
with FSHD, referred to as patients with phenotypic FSHD, show normal-sized D4Z4 
repeats on both chromosomes 4. Interestingly, in both 4q-linked FSHD and phenotypic 
FSHD patients, the D4Z4 repeat shows reduced levels of DNA methylation. The D4Z4 
hypomethylation is more prominent and present on both chromosomes 4 in phenotypic 
FSHD, whereas in 4q-linked patients it is restricted to the disease chromosome [5]. 
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Low methylation levels of D4Z4 are also found in patients with the immunodeficiency, 
centromeric instability, and facial anomalies (ICF) syndrome [6]. Patients with ICF 
syndrome have recurrent respiratory and gastrointestinal infections, as a result of 
a reduction in serum immunoglobulin levels. Further, because of decondensation 
of juxtacentromeric heterochromatin regions, characteristic rearrangements of 
chromosomes 1,9, and 16 are found in phytohemagglutinin-stimulated lymphocytes 
of these patients. Patients with ICF show a wide variety of facial anomalies but do not 
present any myopathic symptoms [7].
ICF syndrome is caused in 60% of patients by mutations in the DNA methyltransferase 
gene DNMT3B [8,9]. Mutations in the catalytic domain of DNMT3B reduce its 
methyltransferase activity, resulting in hypomethylation of the classic repeat arrays 
satellite 2 (Sat2) and satellite 3 (Sat3), the NBL2 repeat, and the D4Z4 repeat 
[8]. Approximately 40% of patients do not have mutations in DNMT3B (ICF2). 
Nevertheless, in patients with ICF2, these repeats are also hypomethylated in addition 
to hypomethylation of  α-satellite DNA [10]. As patients with phenotypic FSHD and 
patients with ICF share an epigenetic hallmark, we hypothesized that a more genome-
wide impairment of DNA methylation, as seen in ICF, may explain the pathogenesis 
of phenotypic FSHD. To determine whether phenotypic FSHD is caused by a defect in 
the same molecular pathway as ICF, we compared patients with phenotypic FSHD and 
patients with ICF at the phenotypic and the epigenetic level.
materIal	and	methods
SubjectS
Seven Dutch phenotypic FSHD families were included in this study (Figure 1). Families 
1, 2 and 3 were reported earlier on basis of their D4Z4 hypomethylation [5]. The other 
families are reported here for the first time. Although D4Z4 methylation is not very low in 
Families 6 and 7, these families were included on basis of their FSHD-like phenotype. All 
patients were referred under the diagnosis of FSHD on a clinical basis and all patients and 
their relatives were examined by one of the authors (M.W. and G.P.) familiar with FSHD. 
For this study, DNA was not available for all clinical examined family members. The clinical 
diagnosis of FSHD is based on asymmetric weakness and atrophy of the facial and shoulder 
girdle muscles with early scapular winging and elevation of the scapula when trying to 
anteflex the arms. Focal involvement of the deltoid muscle, severe and often asymmetric 
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upper arm weakness, early involvement of abdominal muscles, and asymmetric weakness 
of the foot-extensors is present in more advanced disease [1].
Patients with phenotypic FSHD are patients with the clinical diagnosis of FSHD but 
without contraction of the D4Z4 repeat array. A muscle biopsy was performed in all 
families, except Family 4 (Table 1). The biopsies showed mild aspecific dystrophic or 
nonspecific myopathic findings as varying of muscle fiber diameter with no indications 
of specific myopathies such as acid maltase deficiency or inclusion body myositis. Most 
biopsies were performed at a time when extensive immunohistochemistry was not 
available. Genetic testing or immunobiochemical analysis in muscle tissue to exclude 
dominant or recessive limb girdle dystrophies was performed in two patients (Table 
1). 
Family members were assigned as nonaffected when they did not show any symptoms or 
signs of FSHD on examination at 20 years or older. A summary of the clinical findings, 
including clinical severity scores, and D4Z4 allele sizes and D4Z4 methylation levels of 
all individuals is presented in Table 1 [11, 12]. All phenotypic FSHD cases showed normal-
sized D4Z4 alleles, as determined by pulsed field gel electrophoresis [13].
Genomic DNA was isolated from peripheral blood lymphocytes using a standard salt 
extraction protocol [14]. DNA from a FSHD1 patient with a D4Z4 contraction (C1) and 
a nonaffected relative (C2) were included as negative controls. Also, DNA was isolated 
from both ICF type 1 (I1) and ICF type 2 (I2) EBV-transformed lymphoblastoid cell 
lines (LCLs) as positive controls.
SoutherN blot ANAlySiS uSiNg methylAtioN-SeNSitive reStrictioN eNZymeS
Digestions were performed using the following restriction enzymes: Eco52I, Bsp119I, 
HhaI, and HpaII (MBI Fermentas, Germany). For HpaII digestion, its non-methylation-
sensitive isoschizomere MspI (MBI Fermentas, Germany) was used as a control for 
complete digestion. In short, 2 μg of genomic DNA was digested with 20 units of the 
appropriate restriction enzyme according to the manufacturer’s specifications. DNA 
digests were separated on a 0.8% agarose gel and blotted overnight on a hybond-XL 
membrane (Amersham Bioscience, Piscataway, NJ). Probes were labeled by random 
priming with 32P-dCTP using the Megaprime DNA labeling system (Amersham 
Pharmacia Biotech, Piscataway, NJ). The probes targeted against the NBL2 repeat and the 
α-satellite repeats on chromosomes 3, 9, 11, 13/21, 16, and 18 were obtained through 
standard PCR, followed by ligation of the PCR products into the pCR2.1-TOPO vector 
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Figure 1 
Seven Dutch families with phenotypic facioscapulohumeral muscular dystrophy 
(FSHD) included in the study.
Closed circles/squares represent affected individuals; open circles/squares represent unaffected 
family members. All patients were referred under the diagnosis of FSHD on a clinical basis and all 
patients and their relatives were examined by one of the authors (M.W., G.P.) familiar with FSHD, 
as represented in the figure by x. Family 1 consists of three patients (1.1, 1.2, and 1.3) and two 
nonaffected family members (1.4 and 1.5). Family member 1.5 showed an asymmetric mouth and 
her eyelashes on the right side did not disappear while closing her eyes tightly, which was insufficient 
clinical certainty of FSHD. Family 2 consists of an affected sibling pair (2.3 and 2.4) and two 
healthy parents (2.1 and 2.2); the mother in this family also shows D4Z4 hypomethylation but 
no muscular symptoms. Patients 3.1 and 3.2 have the same family name and grew up in the same 
region of the Netherlands. The parents of both patients lost contact with their family, but they are 
possibly related to each other. Patient 3.1 showed disputable signs of facial weakness and weakness 
of the right shoulder girdle muscles weakness without wasting Family members of Patient 3.2, 
such as his affected father, were not available for our examination.In Family 4, one individual is 
affected (4.2), while his two brothers are unaffected (4.1 and 4.3). Both Families 5 and 6 consist 
of an affected child (5.2 and 6.2) and an unaffected parent (5.1 and 6.1). Patient 5.2 previously 
presented with a scapuloperoneal syndrome and at age of examination his pelvic girdle muscles were 




















F S E P Muscle
biopsy
1.1 A 50A 90B 25A 75A 21 5 10 56 + + + + +
1.2 A 50A 135B 75A 125A 20 4 9 34 + + + + –
1.3 A 48B 90B 25A 90A 49 41 6 52 + + + – +
1.4 N 90B 128B 25A 150A 52 53 0 31 – – – – –
1.5 ? 90B 130B 25A 150A 58 63 0 30 ? – – – –
2.1 N 96A 173B 35A 85A 58 68 0 63 – – – – –
2.2 N 75B 170A 55A 65A 35 16 0 59 – – – – –
2.3* A 96A 170A 65A 85A 26 12 7 38 + + + + +
2.4 A 96A 170A 65A 85A 44 19 7 35 + + + + +
3.1 ? 38B 70B 15A 45B+ 30 31 2 42 ± ± – – –
3.2 A 48A 120B 15A 70A 24 13 4 38 + + + – +
4.1 N 70A 160B 47A 75A 62 56 0 46 – – – – –
4.2 A 50A 70A 38A 47A 36 15 6 54 + + + + –
4.3 N 85B 160B 47A 75A 60 55 0 56 – – – – –
5.1 N 65A 75B 60B+ 90A 70 47 0 79 – – – – –
5.2 A 65A 110A 90A 100A 33 17 7 53 + + + + +
6.1 N 170B 300A 23A 55A 33 25 0 74 – – – – –
6.2* A 65A 170B 50A 200A 31 34 8 46 + + + + +
7.1 N 48B 90B 65A 185A 36 46 0 62
7.2 A 48B 94B 25A 33A 44 42 7 55 + + + + +
– – – – –
Table 1
Summary of clinical and genetic findings in seven Dutch families with phenotypic 
facioscapulohumeral muscular dystrophy. 
Clinical status, D4Z4 allele sizes, D4Z4 methylation levels (BsaAI and FseI), clinical severity score 
(CSS) on a scale from 0 to 10, age at examination, involvement of facial muscles (F), shoulder girdle 
muscles (S), extensors of the foot (E), and pelvic muscles (P) (+ = affected muscle; – = nonaffected 
muscle), and whether a muscle biopsy was taken (+ = muscle biopsy was taken; – = no muscle 
biopsy was taken). Numbers in the table correspond with numbers in Figure 1. 
* In Individuals 2.3 and 6.2, genetic testing or immunobiochemical analysis in muscle tissue 
was performed. DNA of Patient 2.3 showed no mutations for proximal myotonic myopathy 
(PROMM). Muscle tissue of Patient 6.2 was screened negative for Becker muscular dystrophy 
and for limb-girdle muscular dystrophy type 2A and type 2B. + Trisomic cases; individuals carry 
three 4q-type repeat arrays, of which one is located on chromosome 10q.
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and transformation of the vector into Top 10 chemically competent E coli (Invitrogen 
Carlsbad, CA). The primers for the NBL2 probe were described previously, whereas 
the primers for the various α-satellite repeats were designed using Primer3 software 
(Whitehead Institute for Biomedical Research) based upon the probes used in earlier 
studies [6, 15]. Primer sequences are available upon request. For sequence verification, all 
probes were sequenced by the Leiden Genome Technology Center (LUMC, Leiden, The 
Netherlands). The oligonucleotide probes for classic satellites 2 and 3 were as described 
previously [10]. Hybridizations were carried out overnight at 65 °C with 100 μg/ml fish 
sperm DNA (Roche, Basel, Switzerland) in formamide hybridization mixture, except 
for the hybridization with the NBL2 probe, which was performed in NaPi/PEG/SDS 
hybridization mixture [16]. After washing in SSC/SDS buffers with a diminishing gradient, 
digestion patterns were visualized using a phosphor-imaging screen (Storm, Amersham 
Bioscience). For the Sat 2 and Sat 3 oligonucleotide probes, hybridization and washing was 
carried out at 45 °C in SSPE/SDS buffer.
periceNtromeric AbNormAlitieS iNvolviNg chromoSomeS 1, 9, AND 16
Cytogenetic analysis was performed on lymphocytes from peripheral blood cultures 
after stimulation with phytohemagglutinin for 96 hours. A minimum of 50 GTG-
banded metaphases were examined for pericentromeric abnormalities [17].
hypogAmmAglobuliNemiA
White blood cell counts and morphologic differentiations were performed on a 
hematology analyzer (Advia, Bayer). The immunoglobulins (IgG, IgA, and IgM) were 
quantified by an Immage nephelometer from Beckman Coulter. All reagents were 
obtained from Beckman Coulter. Immunophenotyping studies were performed on 
heparinized blood specimens. Immune fluorescent staining was performed on 100 μl 
whole blood with fluorochrome-labeled antibodies against CD3, CD4, CD8, CD19, 
CD56, and CD45. All antibodies were purchased from Beckman Coulter (Miami, FL), 
except CD56 (Becton, Dickinson and Company, San Jose, CA). Next, all erythrocytes 
were lysed for 10 minutes in the dark by means of icecold 155 mM NH4Cl (pH 7.4) 
according to the lyse/no wash method. Staining of cells was determined in four-color 
analysis using a Beckman Coulter Epics XL flow cytometer (Beckman Coulter, Hialeah, 
FL). All measurements were performed on a minimum of 50,000 cells. Data (collected 
in list mode) were analyzed using the EXPO32 ADC software (Beckman Coulter).
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mutAtioNAl ANAlySeS oF cANDiDAte geNeS 
The coding regions of several candidate genes for phenotypic FSHD were sequenced 
(Table 2). Each exon was amplified by PCR using primers in flanking introns. Primer 
sequences are available upon request. PCR was performed for 35 cycles using SilverStar 
DNA polymerase (Eurogentec, Seraing, Belgium) in 1.5 mM MgCl2 PCR buffer (pH 
9.0). After an initial denaturation at 94 °C for 3 minutes, PCR cycles were as follows: 
40 seconds at 94 °C, 40 seconds at 55 °C, and 1 minute at 72 °C, to be concluded with 
a final extension at 72 °C for 5 minutes. Sequencing reactions were performed by the 
Leiden Genome Technology Center (LUMC, Leiden, The Netherlands).
StAtiSticAl ANAlySiS
Independent-sample t tests were performed to compare serum IgG, IgA, and IgM levels 
between the patients with phenotypic FSHD and their nonaffected family members 
(P<0.05 was considered as significant).
Table 2
Candidate genes for phenotypic facioscapulohumeral muscular dystrophy. 
The coding regions of several candidate genes playing a role in chromatin structure were sequenced 
in three patients with phenotypic facioscapulohumeral muscular dystrophy.
UniGeneID Gene name Function Chromosome
Hs.202672 DNMT1 Maintenance DNA methyltransferase 19p13.2
Hs.515840 DNMT3A de novo DNA methyltransferase 2p23
Hs.643024 DNMT3B de novo DNA methyltransferase 20q11.2
Hs.592165 DNMT3L Stimulation of DNMT3B 21q22.3
Hs.459049 MTHFS Component of folate cycle 15q24.3
Hs.594444 LMNA Component of nuclear lamina 1q21.2-q21.3
Hs.368410 CBX2 Component of PRC1 complex 17q25.3
Hs.632724 CBX5 Component of heterochromatin 12q13.13
Hs.522639 SUV39H1 Histone methyltransferase Xp11.23
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results
hypomethylAtioN iS reStricteD to the D4Z4 repeAt ArrAy iN pheNotypic FShD. 
To determine whether an overall impairment of DNA methylation in repeat arrays is 
also present in phenotypic FSHD, the non-D4Z4 repeats known to be hypomethylated in 
ICF were investigated by Southern blot analysis using methylation-sensitive restriction 
enzymes. The methylation status of the NBL2 repeat, the classic satellite repeats Sat2 
and Sat3, and the α-satellite DNA repeat on chromosomes 3, 9, 11, 13/21, 16, and 18 
was studied in three Dutch phenotypic FSHD families, both in patients and their healthy 
relatives (Figure 1; Families 1, 2, and 3). As a negative control, the methylation status 
from a 4q-linked FSHD patient and a nonaffected relative were studied. As a positive 
control, DNA of two patients with ICF (both ICF1 and ICF2) was included in the study. 
Significant hypomethylation of the NBL2, Sat2, and Sat3 repeat arrays was only detected 
in the two patients with ICF, while hypomethylation of the α-satellite DNA repeat array 
was restricted to the patient with ICF2, as reported previously [10]. Non-D4Z4 repeats 
were not hypomethylated in patients with phenotypic FSHD. Their methylation levels 
were comparable to their unaffected family members and the 4q-linked FSHD patient 
and a nonaffected relative. In Figure 2, results of the NBL2 Southern blot analysis for 
Families 1 and 2 and the α-satellite on chromosome 11 Southern blot analysis for 
Families 2 and 3 are shown. All results, including the results for the other repeat arrays, 
are summarized in Table 3.
No heterochromAtic AbNormAlitieS iNvolviNg chromoSomeS 1, 9, AND 16 iN pheNotypic 
FShD 
To search for pericentromeric abnormalities in patients with phenotypic FSHD, 50 
phytohemagglutinin-stimulated lymphocyte metaphases were studied for the presence 
of characteristic rearrangements involving chromosomes 1, 9, and 16. All members of 
the seven phenotypic FSHD families, including the nonaffected relatives, were studied. 
Abnormalities involving the heterochromatic regions of chromosomes 1, 9, and 16, 
such as whole-arm deletions, pericentromeric breaks, multibranched chromosomes, 
isochromosomes, and translocations that can be found in patients with ICF, were not 
detected in either patients with phenotypic FSHD or their healthy family members [7].
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No hypogAmmAglobuliNemiA iN pAtieNtS with pheNotypic FShD
Patients with ICF have recurrent infections as a result of hypogammaglobulinemia, a 
reduction in serum immunoglobulin levels (IgG, IgM, and IgA levels), with B cells. 
To investigate the occurrence of hypogammaglobulinemia in patients with phenotypic 
FSHD, several biomarkers, including serum immunoglobulin levels, were measured 
in blood of all patients with phenotypic FSHD included in this study and in their 
nonaffected relatives. The serum immunoglobulin levels were within the normal range 
in all phenotypic FSHD cases; no significant differences within these immunoglobulin 
levels between patients and healthy control individuals were found (Figure 3). Also, 
the other tested biomarkers were within normal range in the patients with phenotypic 
FSHD and no significant differences were observed between patients and controls (data 
not shown).
Figure 2
DNA methylation analysis in families with phenotypic facioscapulohumeral 
muscular dystrophy (FSHD). 
A. NBL2 Southern blot analysis in phenotypic FSHD Families 1 and 2. Numbers in figure 
correspond with numbers in figure 1. NBL2 repeat array is only significantly hypomethylated in 
I1, a patient with ICF1. 
B. α-satellite on chromosome 11 Southern blot analysis in phenotypic FSHD Families 2 and 
3. Numbers in figure correspond with numbers in figure 1α-satellite 11 repeat array is only 
significantly hypomethylated in I2, a patient with ICF2.
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Serum immunoglobulin levels in g/L in patients with phenotypic FSHD and their unaffected family 
members (shown as mean ± SD).
Individual NBL2 Sat2 Sat3 α-sat-9 α-sat-11 α-sat-13/21 α-sat-18α-sat-3
C1 + + + + + + + +
C2 + + + + + + + +
I1 – – – + + + + +
I2 – – – – – – – –
1.1 + + + + + + + +
1.2 + + + + + + + +
1.3 + + + + + + + +
1.4 + + + + + + + +
1.5 + + + + + + + +
2.1 + + + + + + + +
2.2 + + + + + + + +
2.3 + + + + + + + +
2.4 + + + + + + + +
3.1 + + + + + + + +
3.2 + + + + + + + +
Table 3
Methylation status of non-D4Z4 repeat arrays (NBL2, Sat2, Sat3, and α-satellite 
on chromosomes 3, 9, 11, 13/21 and 18) in three phenotypic FSHD families. 




DNmt1, DNmt3A, DNmt3b, DNmt3l, mthFS, lmNA, cbX2, cbX5, AND 
Suv39h1 Are uNlikely cANDiDAte geNeS For pheNotypic FShD
In search for a second disease locus that may play a role in the pathogenesis of phenotypic 
FSHD, mutational analyses of several candidate genes (Table 2) with a role in chromatin 
structure or methyl cycle were performed in three patients with phenotypic FSHD 
from three different families (Figure 1; 1.1, 2.4, and 3.2). DNMT1, DNMT3A, and 
DNMT3B are all genes that encode a DNA methyltransferase, either predominantly 
functioning in maintenance of DNA methylation during cell division or acting as a de 
novo DNA methyltransferase. As mentioned before, 60% of ICF cases can be explained 
by the presence of a mutation in DNMT3B [8]. DNMT3L encodes a catalytically inactive 
DNA methyltransferase. However, by association with DNMT3B it can stimulate DNA 
methylation [18]. Interestingly, two DNMT3B mutations have been reported that do not 
affect the methylation activity of the enzyme itself, but rather diminish the interaction 
with DNMT3L, also leading to the ICF syndrome [19]. MTHFS (5,10-methenyl-
tetrahydrofolate synthetase) catalyzes the transformation of 5-formyl-tetrahydrofolate 
to other reduced folates and as such has an important function in the initial step of the 
folate cycle, thus having an influence on DNA methylation [20]. Moreover, this gene is 
located in a candidate interval that was identified some years ago in a possible non-
4q-linked FSHD family [21]. The protein lamin A/C, encoded by the LMNA gene, is a 
component of the nuclear lamina, which provides nuclear stability and may also interact 
with chromatin. Mutations in LMNA may lead to several diseases affecting a wide variety 
of organs, such as muscle, fat, bone, nerve, and skin [22]. More importantly, this protein 
is required for the proper localization of the FSHD 4qter region to the nuclear envelope 
[23]. As interconnectivity between the Suv39h-HP1 histone methylation system and 
Dnmt3b in mammals was demonstrated before, the exonic regions of the genes 
CBX2 (chromobox protein homolog 2), CBX5 (chromobox protein homolog 5), and 
SUV39H1 (suppressor of variegation 3-9 homolog 1) were screened for mutations [24]. 
CBX2 is a component of the polycomb repressive complex 1 (PRC1). This complex 
has a function in the maintenance of the transcriptional repressive state of genes during 
development. It acts via chromatin remodeling and histone modification by mediating 
the monoubiquitination of histone H2A [25]. CBX5, better known as HP1α, is an 
important component of heterochromatin, as it may recognize and bind to histones H3 
and H1 [26]. SUV39H1 is a histone methyltransferase that methylates lysine 9 of histone 
H3. As a consequence, transcriptional repression may occur by the recruitment of the 
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HP1 proteins [27]. In addition to earlier reported single nucleotide polymorphisms (data 
not shown), no mutations were detected in the exonic regions of all abovementioned 
candidate genes, excluding them as likely candidate genes for phenotypic FSHD.
dIscussIon
Patients with phenotypic FSHD present with hypomethylation of the D4Z4 repeats 
similar to the D4Z4 hypomethylation observed in patients with the ICF syndrome. 
Patients with ICF do not present a myopathic phenotype. As patients with ICF die at 
a very young age, before the usual onset of FSHD in the second decade of life, this 
may explain the lack of symptoms of muscular dystrophy in these patients. However, 
the occurrence of severe progressive infantile FSHD argues against this explanation. 
As D4Z4 hypomethylation has been found on both 4qA and 4qB chromosome ends of 
patients with ICF, the lack of muscular dystrophy cannot be explained by the specific 
association of ICF with the 4qB-type allelic variant [28]. We therefore aimed to investigate 
the commonalities and differences between FSHD and ICF at the clinical, molecular, 
and epigenetic level.
Unlike in 4q-linked FSHD, the hypomethylation found in patients with phenotypic 
FSHD is present on both D4Z4 alleles and not associated with a contraction of the 
D4Z4 repeat array. In a previous study, we identified five phenotypic FSHD cases with 
hypomethylation of D4Z4 [5]. Consistent with 4q-linked FSHD, these patients carry 
at least one 4qA chromosome. In the current study, we identified additional family 
members and independent cases on the basis of their phenotype. With the exception 
of Individuals 1.3 and 7.2, all cases with a phenotype consistent with FSHD including 
recognizable facial weakness carry at least one 4qA allele and show hypomethylation of 
D4Z4, with the restriction enzyme FseI being most informative. Individuals 1.5 and 3.1 
also have 4qB-type alleles only, but there was insufficient clinical certainty of FSHD in 
these cases. Individual 1.5 only showed an asymmetric mouth and her eyelashes on the 
right side did not disappear while closing her eyes tightly and Individual 3.1 showed 
disputable signs of facial weakness and weakness of the right shoulder girdle muscles 
without wasting. One individual (5.2) with a distinct scapuloperoneal phenotype and 
no facial involvement is also hypomethylated and carries a 4qA allele. These individuals 
at the both ends of the clinical and genetic spectrum emphasize our inability to clearly 
define the boundaries of the FSHD spectrum. Moreover, the lack of evidence for 
42
chapter 2
hypomethylation, most notably in Individual 7.2 and to a lesser extent in Individual 
6.2, which have a phenotype consistent with FSHD, substantiates these issues.
As patients with phenotypic FSHD and patients with ICF share a similar epigenetic 
hallmark in D4Z4 hypomethylation, we hypothesized that a more overall impairment 
of DNA methylation of specific repeats, as in ICF, may also be observed in phenotypic 
FSHD, providing clues to its pathogenesis. We therefore compared several epigenetic 
and clinical features between patients with FSHD and patients with ICF. Southern blot 
analyses using methylation-sensitive restriction enzymes showed no hypomethylation of 
the NBL2 repeat, Sat2 repeat, Sat3 repeat, and α-satellite repeat on chromosomes 3, 9, 
11, 13/21, 16, and 18 in three phenotypic FSHD families. The lack of hypomethylation 
of non-D4Z4 repeat arrays in patients with phenotypic FSHD is in agreement with the 
absence of DNMT3B mutations in these patients. However, in some 40% of patients 
with ICF, the so-called patients with ICF2, DNMT3B mutations have not been detected 
either, leaving the possibility open that both phenotypic FSHD and ICF2 are caused 
by a defect in the same gene or same molecular pathway [9]. Considering the very 
different clinical symptoms observed in phenotypic FSHD and ICF, the additional 
hypomethylation of several repeat arrays may well explain these phenotypic differences. 
However, at this moment, little is known about how mutations in the DNMT3B gene 
and how hypomethylation of several repeat arrays can cause the phenotype observed in 
patients with ICF. ICF-specific deregulation of several genes having a role in immune 
function was reported. However, these changes cannot be explained by significant 
differences in promoter methylation [29].
Compared to the Sat2 repeat, Sat3 repeat, and α-satellite repeat, D4Z4 is of a different 
type, being a non-satellite repeat. Besides the D4Z4 repeat array, NBL2 is the only 
other non-satellite repeat that is reported to be hypomethylated in ICF, making perhaps 
NBL2 the most interesting target for investigation in phenotypic FSHD. However, no 
hypomethylation of the NBL2 repeat array was observed in patients with phenotypic 
FSHD. Since D4Z4 hypomethylation is more prominent in patients with ICF compared 
to patients with phenotypic FSHD, this could also be the case for the NBL2 repeat array. 
As Southern blot analysis using methylation-sensitive restriction enzymes is usually 
not very sensitive to determine hypomethylation, the NBL2 repeat array was also 
studied with sodium bisulphite PCR sequencing (data not shown). However, the results 
from this assay were comparable to the results obtained by Southern blot analysis; no 
hypomethylation of the NBL2 repeat was detected in patients with phenotypic FSHD.
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In addition to the comparative analysis of patients with phenotypic FSHD and patients with 
ICF at the epigenetic level, two studies were performed to compare these patients at the 
genotypic and phenotypic level. As D4Z4 hypomethylation is more subtle in phenotypic 
FSHD compared to ICF, subclinical values with relation to pericentromeric abnormalities 
and serum immunoglobulin levels could have gone unnoticed in patients with phenotypic 
FSHD. However, examination of 50 GTG-banded metaphases in each patient with phenotypic 
FSHD revealed no pericentromeric abnormalities. Further, serum immunoglobulin levels 
and other immunologic biomarkers were within normal range in all phenotypic FSHD cases 
and no significant differences between patients with phenotypic FSHD and healthy control 
individuals were identified. These results suggest that there is little or no phenotypic overlap 
between FSHD and ICF, not even at the subclinical level. Therefore, it seems very unlikely 
that both conditions are caused by a disturbance in the same molecular pathway.
Finally, no mutations were detected in the exonic regions of the genes DNMT1, DNMT3A, 
DNMT3B, DNMT3L, MTHFS, LMNA, CBX2, CBX5, and SUV39H1, making them less likely 
candidate genes for phenotypic FSHD. However, since only the exonic regions of these genes 
were analyzed in this study, intronic mutations affecting splicing and mutations in the promoter 
region remain possible. Before studying this in more detail, more substantial evidence for the 
involvement of one of these candidate genes and the occurrence of phenotypic FSHD has to 
be generated.
In this study, we showed that the hypomethylation seen in patients with phenotypic FSHD 
is restricted to the D4Z4 repeat array. Apart from the D4Z4 hypomethylation, no further 
commonalities between patients with phenotypic FSHD and patients with ICF were 
identified, either at the epigenetic level or at the phenotypic level. At this moment, the 
cause of the D4Z4 hypomethylation in FSHD, both 4q-linked FSHD and phenotypic FSHD, 
remains unknown. As hypomethylation of D4Z4 has also been observed in non-penetrant 
gene carriers, we hypothesize that D4Z4 hypomethylation is necessary but not sufficient to 
explain the occurrence of FSHD [5]. Apparently, other, possibly epigenetic, factors at D4Z4 
differ between FSHD and ICF and as such control for the development of FSHD. For future 
research, the mechanism of D4Z4 methylation needs to be investigated in more detail to 
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Facioscapulohumeral dystrophy (FSHD) is an autosomal dominant muscular dystrophy 
in which no mutation of pathogenic gene(s) has been identified. Instead, the disease 
is, in most cases, genetically linked to a contraction in the number of 3.3 kb D4Z4 
repeats on chromosome 4q. How contraction of the 4qter D4Z4 repeats causes 
muscular dystrophy is not understood. In addition, a smaller group of FSHD cases are 
not associated with D4Z4 repeat contraction (termed “phenotypic” FSHD), and their 
etiology remains undefined. We carried out chromatin immunoprecipitation analysis 
using D4Z4-specific PCR primers to examine the D4Z4 chromatin structure in normal 
and patient cells as well as in small interfering RNA (siRNA)-treated cells. We found that 
SUV39H1-mediated H3K9 trimethylation at D4Z4 seen in normal cells is lost in FSHD. 
Furthermore, the loss of this histone modification occurs not only at the contracted 4q 
D4Z4 allele, but also at the genetically intact D4Z4 alleles on both chromosomes 4q and 
10q, providing the first evidence that the genetic change (contraction) of one 4qD4Z4 
allele spreads its effect to other genomic regions. Importantly, this epigenetic change 
was also observed in the phenotypic FSHD cases with no D4Z4 contraction, but not in 
other types of muscular dystrophies. We found that HP1g and cohesin are co-recruited 
to D4Z4 in an H3K9me3-dependent and cell type-specific manner, which is disrupted 
in FSHD. The results indicate that cohesin plays an active role in HP1 recruitment and is 
involved in cell type-specific D4Z4 chromatin regulation. Taken together, we identified 
the loss of both histone H3K9 trimethylation and HP1g/cohesin binding at D4Z4 to be 
a faithful marker for the FSHD phenotype. Based on these results, we propose a new 
model in which the epigenetic change initiated at 4q D4Z4 spreads its effect to other 
genomic regions, which compromises muscle-specific gene regulation leading to FSHD 
pathogenesis.
author	summary
Most cases of facioscapulohumeral muscular dystrophy (FSHD) are associated with a 
decrease in the number of D4Z4 repeat sequences on chromosome 4q. How this leads 
to the disease remains unclear. Furthermore, D4Z4 shortening is not seen in a small 
number of FSHD cases, and the etiology is unknown. In the cell, the DNA, which 
encodes genetic information, is wrapped around abundant nuclear proteins called 
histones to form a “beads on a string”-like structure termed chromatin. It became 
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apparent that these histones are modified to regulate both maintenance and expression 
of genetic information. In the current study, we characterized the chromatin structure 
of the D4Z4 region in normal and FSHD patient cells. We discovered that one particular 
histone modification (trimethylation of histone H3 at lysine 9) in the D4Z4 repeat region 
is specifically lost in FSHD. We identified the enzyme responsible for this modification 
and the specific factors whose binding to D4Z4 is dependent on this modification. 
Importantly, these chromatin changes were observed in both types of FSHD, but not in 
other muscular dystrophies. Thus, this chromatin abnormality at D4Z4 unifies the two 
types of FSHD, which not only serves as a novel diagnostic marker, but also provides 
new insight into the role of chromatin in FSHD pathogenesis.
IntroductIon
FSHD is the third most common heritable muscular dystrophy [1]. It is characterized by 
progressive weakness and atrophy of facial, shoulder, and upper arm musculature, which 
can spread to the abdominal and foot-extensor muscles [2]. It can be accompanied by 
hearing loss and retinovasculopathy. The genetics underlying FSHD are highly unusual, 
as no pathogenic mutation(s) of a disease causing gene(s) has been identified. Instead, 
the majority (>95 %) of FSHD cases involve mono-allelic deletion of D4Z4 repeat 
sequences at the subtelomeric region of chromosome 4q (termed “4q-linked” FSHD, 
FSHD1A (OMIM 158900); designated as “4qF” in this study) [2]. There are between one 
and ten repeats in the contracted 4qter allele in FSHD patient cells, in contrast to up 
to 11~150 copies in normal cells. In addition, <5 % of FSHD cases are not associated 
with D4Z4 repeat contraction (termed “phenotypic” FSHD, FSHD2; referred to as “PF” 
in this study), and their etiology remains undefined.
How contraction of the 4qter D4Z4 repeats causes muscular dystrophy is not 
understood. A previous study reported the YY1-nucleolin-HMGB2 repressor complex 
binding to D4Z4, and it was postulated that reduction of the repeat number may result 
in decreased repressor complex binding, leading to derepression of neighboring genes 
[3]. Consistent with this model, overexpression of the neighboring 4q35 genes was 
demonstrated in the same study, and the same group recently showed that muscle-
specific overexpression of the neighboring gene FRG1 indeed causes muscular dystrophy 
in mice [4]. Curiously, however, microarray and quantitative expression studies by other 
laboratories revealed that many genes located elsewhere in the genome important for 
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myoblast differentiation are dysregulated, but unanimously provided no evidence for 
abnormal upregulation of FRG1 and other 4q35 genes in FSHD [5-7]. Furthermore, the 
model cannot explain the mechanism of phenotypic FSHD in which there is no D4Z4 
repeat contraction.
Cytological analyses revealed that the 4q telomeric region uniquely associates with the 
nuclear periphery, consistent with the hypothesis that this region is heterochromatic [8, 
9]. However, since the D4Z4 repeat contraction in 4qF did not lead to any significant 
localization changes, the functional relevance to FSHD remains uncertain [8, 9].
A recent study demonstrated that the 4qter D4Z4 region is hypermethylated at the DNA 
level in normal cells, but is hypomethylated in both 4q-linked and phenotypic FSHD [10]. 
This was the first evidence that 4qter D4Z4 is also involved in phenotypic FSHD. DNA 
methylation is an important mechanism for epigenetic regulation of gene transcription, 
and is generally associated with transcriptional silencing [11]. Thus, the results suggested 
that the D4Z4 repeat array organizes a transcriptionally suppressive heterochromatic 
environment, which is disrupted in FSHD. However, DNA hypomethylation, more 
severe than that seen in FSHD, at D4Z4 was also observed in another hereditary 
disorder, the “immunodeficiency, centromere instability and facial anomalies (ICF)” 
syndrome, due to a mutation in DNA methyltransferase 3B (DNMT3B) [10, 12]. Since 
the clinical presentation of ICF syndrome shares no similarity with the FSHD disease 
phenotype [13], the relevance of DNA methylation changes in FSHD is unclear and the 
molecular events underlying the D4Z4-linked disease process remain an open question.
Here we describe the first characterization of the chromatin of the 4q and 10q D4Z4 
repeats and a comparison between normal, FSHD and other muscular dystrophy 
cells. Our results demonstrate that there is a distinct change of histone modification 
and downstream factor binding that is specifically associated with both 4q-linked and 
phenotypic FSHD, suggesting that epigenetic alteration plays a critical role in FSHD 
pathogenesis.
materIal	and	methods
cellS AND DNA mAppiNg pANel
HeLa cells were grown as described previously [14]. The undifferentiated and differentiated 
normal myoblasts and the FSHD patient myoblasts were grown in SkBM-2 (Skeletal 
51
H3K9me3 and HP1g/cohesin binding loss in FSHD
Muscle Cell Basal Medium, Cambrex Bio Science, NJ). Myoblast differentiation was 
induced by 2% horse serum as previously described [5]. Five normal and five 4q-linked 
FSHD myoblast lines were used. Control (KI-I, KI-II, NFGr), ICF (ICF1 and ICF2), 
4q-linked FSHD (91RD217, 423/16, F2625, 508) and phenotypic FSHD (KII-I, KII-II, 
Rf394.2, RF394.3) fibroblasts were grown in DMEM/F-12 (1:1) supplemented with 
10% FBS, penicillin/streptomycin, 2mM GLUTAMAXTM I, 10mM HEPES buffer and 
1mM sodium pyruvate (Invitrogen-Gibco, CA) [10, 15]. For comparison among different 
muscular dystrophies, one 4q-linked FSHD (508) and two phenotypic FSHD (Rf394.2 
and Rf394.3) patient fibroblast samples, five OPMD patient fibroblast samples (376, 
395, 396, 54030922, and 203241), four DMD patient fibroblast samples (d1137.5, 
6103, 5639.1, and dl90.3), three LGMD patient fibroblast samples (00-288, 01-196, 
99-305) [16, 17], two ICF patient fibroblast samples [18], and four IBMPFD patient samples 
(two fibroblast and two lymphoblast) (JH-FIB, MJ-FIB, 307/98, and RS-LCL) [19] were 
used. Control (256.1 LCL), ICF (10759 ICF LCL), and FSHD (B8-1) lymphoblast cells 
were grown in RPMI-1640 supplemented with 10% FBS, penicillin/streptomycin, and 
2mM L-Glutamine (Invitrogen-Gibco, CA). Human ES cells H1 and H9 were grown 
as described [20]. Mouse somatic cell hybrids containing chromosome 4, 10, 13, 14, 
15 or 21 (GM11687, 11688, 11689, 10479, 11715, 08854, respectively, from Coriell 
Cell Repositories, Camden, NJ) were grown in DMEM/F-12 (1:1) medium with the 
same supplements as the fibroblasts. Chromosomes 13, 14, 15, and 21 are known to 
contain D4Z4-like repeat sequences [21]. The NIGMS Human/Rodent Somatic Cell 
Hybrid Mapping Panel #2, version 3 was from Coriell Cell Repositories, in which 
chromosome 1, 16, 17, 20, and 21 hybrids are from mice while the others are from 
Chinese hamsters.
ANtiboDieS
Antigen affinity-purified rabbit polyclonal antibodies specific for Rad21, hSMC1, 
hCAP-G, and the pre-immune IgG control were published previously [14, 22]. Antibodies 
against H3K4me2, H3K4me3, H3K9me3, H3K27me3, H3Ac, H4Ac, HP1g , SUV39H1, 
and G9a (Upstate Biotech, MA), against H3K9me3 (Abcam, Cambridge, MA) and 
against HP1α (Novus Biologicals, CO) were used. Antibody against 5-methylcytidine 




The ChIP analysis was performed as recommended by the Upstate ChIP assay kit. 
Briefly, we crosslinked the cells with 1% formaldehyde and used 1X106 cells for 
one histone ChIP and 3X106 cells for the other ChIP assays. Protein A beads were 
preincubated with 1mg/ml BSA and 0.2mg/ml ssDNA for 20min at 4 °C. Typically, 
4-8μg of affinity-purified IgG was used per assay. The mixtures of antibody and nuclear 
extracts pre-cleared with protein A beads were incubated at 4 °C overnight followed 
by precipitation with protein A beads. After washing, immunoprecipitated materials 
were eluted with 0.1M NaHCO3 and 1% SDS, and crosslinks were reversed at 65 °C 
for 4-6 hrs. Primer sequences are listed in Supplemental Table 1. PCR primers specific 
for chromosome 1 α-satellite (α-sat) and satellite 2 (sat2), chromosome 4 α-satellite 
(α-sat), DXZ4, RS447, and NBL2 sequences were used [6, 12, 23]. In addition, a PCR 
primer pair specific for the c-Myc region was used as a control for G9a depletion as 
previously described [24]. The primers for rDNA are located in the intergenic region. 
All of the end-point PCR experiments were repeated at least three times. The endpoint 
gel quantitation of the ChIP-PCR products was carried out using the Gel-Doc Imager 
and Quantity One software (Bio-Rad). Real-time Q-PCR primers were designed 
using Lasergene software. Q-PCR was performed using the iCycler iQ Real-time PCR 
detection system (Bio-Rad) with iQ SYBR Green Supermix (Bio-Rad). The ChIP PCR 
signal was normalized by the subtraction of the preimmune IgG ChIP PCR signal, which 
was further divided by input genomic PCR (for normalization of different D4Z4 repeat 
numbers in different cells) minus PCR with no template. Results were an average of 
three PCR reactions, and the arbitrary value of 1.0 was assigned to the normal control 
sample. Double-ChIP analysis was performed according to the published protocol [25].
5-AZAcytiDiNe (5-AZAc) treAtmeNt AND methylcytiDiNe chip (mecip) ASSAy
The 5-AzaC treatment was performed as previously described [26]. Briefly, 50μM of 
5-AzaC was added to HeLa cells at 80% confluency and after 24hr incubation, the cells 
were harvested for ChIP experiments. The MeCIP assay was performed according to 
the published protocol [27]. After the cell samples were harvested and sonicated, they 
were treated with proteinase K overnight and the DNA from these samples was purified 
by the QIAquick gel purification kit (QIAGEN). Four μg of the purified DNA was used 
per MeCIP assay. The DNA was denatured at 95 °C for 10min and incubated with 4μl 
antibody against 5-methylcytidine in 500μl IP buffer (10mM sodium phosphate, pH7.0, 
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140mM NaCl, 0.05% Triton X-100) at 4 °C for 2hrs. The DNA: antibody mixtures 
were further incubated with protein A beads at 4 °C for an additional 2hrs. The beads 
were washed with 700μl IP buffer three times and treated with proteinase K at 50 °C 
for 3hrs. Finally, the DNA was recovered using the gel purification kit and analyzed by 
PCR.
SirNA trANSFectioN
HeLa cells were transfected three times 24 hours apart with siRNAs at 
a final concentration of 10nM using HiPerFect Transfection Reagent per 
manufacturer’s instructions (Qiagen). The target sequences for SUV39H1 and 
G9a were previously described [28, 29]. Other siRNA target sequences include 
hSMC1 (5’-CACCATCACACTTTAATTCCA-3’), HP1g (5’-CTAAGTTAAATGAACATTTAA-3’), Scc2 
(5’-CTAGCTGACTCTGACAATAAA-3’), and negative control (5’-AATTCTCCGAACGTGTCACGT-3’). 
Cells were used for ChIP and western blot analyses at 48 hours after the third 
transfection.
coimmuNoprecipitAtioN (co-ip)-weSterN ANAlySiS
HeLa nuclear extracts were used for co-IP using antibody specific for Scc2 or cohesin 
(Rad21) as previously described [14, 22]. Briefly, precipitated materials were washed four 
times with a buffer containing 0.1M KCl, then eluted with 1.0M KCl (“wash”) and 
finally eluted with 2.0M guanidine-HCl (“eluate”). Proteins in the wash and eluate 
fractions were precipitated by trichloroacetic acid (TCA) and analyzed by SDSPAGE 
and western blotting using antibody specific for HP1g.
results
We examined the histone modification status of the D4Z4 region and whether this is 
altered in FSHD using chromatin immunoprecipitation (ChIP). Analysis of 4q D4Z4 
chromatin has been difficult since D4Z4 repeat sequences are present in a similarly 
large cluster on both chromosomes 4q and 10q (though FSHD is associated only with 
D4Z4 contraction at 4q) [30]. In addition, D4Z4-like repeats are present on several 
other chromosomes [9]. We identified and used primer pairs that amplified products 
exclusively from chromosomes 4 and 10, but not from any other chromosome (Figure 
1A). This was confirmed using DNA from somatic cell hybrids carrying individual 
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human chromosomes as templates (Figure 1B and D). Furthermore, the regions 
amplified by the “Q-PCR” primer pairs contain specific nucleotide polymorphisms that 
allow us to distinguish 4q- and 10q-derived D4Z4 sequences (Figure 1C) [30]. Thus, in 
this study, the ChIP DNA amplified by Q-PCR primer pairs was cloned and sequenced 
to identify the chromosome of origin (Supplemental Table 2).
Figure 1
Specific PCR amplification of D4Z4 repeat sequences.
A. A schematic diagram of the 4qter D4Z4 repeat region and a single D4Z4 repeat. PCR products 
for Q-PCR and 4qHox primer pairs are indicated by black bars. The DUX4 ORF and a GC-rich 
sequence homologous to the low-copy repeat HHSPM3 [31] are shown.
B. PCR analysis of a DNA mapping panel consisting of genomic DNA isolated from mouse and 
hamster somatic cell hybrids containing individual human chromosomes using the 4qHox and 
Q-PCR primer pairs. The “B” PCR primer pair also binds to a region within D4Z4. However, it 
amplified not only chromosomes 4 and 10, but also several other chromosomes presumably due to 
crossreactivity to other D4Z4-like repeat sequences, and therefore, was not used for the experiments. 
For control PCR reactions, primers corresponding to the mouse β-globin locus [32] were used for the 
chromosome 1, 16, 17, 20, and 21 hybrids, while primers for hamster rDNA regions were utilized for 
the other hybrids. PCR analysis of additional mouse somatic cell hybrids for human chromosomes 4, 
10, 13, 14, 15, and 21 also yielded similar results (data not shown).
C. Sequence polymorphisms between 4q and 10q D4Z4 [30, 33]. The nucleotide positions (nt) of 
the sequence polymorphisms are based on AF117653 in the GenBank/EMBL Nucleotide Sequence 
Database.
D. PCR analysis using the 4qA161-1 primer pair against genomic DNA from mouse somatic cell 
hybrids containing human chromosomes 4, 10, 13, 14, 15, and 21.
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D4Z4 coNtAiNS both heterochromAtic AND euchromAtic DomAiNS
We found trimethylation of H3K9 (H3K9me3) and H3K27 (H3K27me3) at D4Z4, 
both of which frequently represent transcriptionally repressive heterochromatin [34, 
35], as well as H3K4 dimethylation (H3K4me2) and H3 acetylation (H3Ac), which 
mark transcriptionally permissive euchromatin [36] (Figure 2A). H3K9me3 signals 
were confirmed by two different antibodies specific for H3K9me3 which have slightly 
different binding preferences [37] (Figure 2A, lanes 10-14). Recent studies demonstrated 
that H3K9me3 can also be associated with transcriptionally active gene regions [37, 
38]. However, no significant H3K4me3, which is coupled to transcription-associated 
H3K9me3 [37], was detected using the same primer pairs (Figure 2A, lane 4). Although it 
is possible that H3K4me3 may be present elsewhere in the D4Z4 repeat, it is at least not 
present within the promoter and 5’ regions of the putative open reading frame (ORF) for 
DUX4 where 4qHox and the Q-PCR primers bind (Figure 1A). Furthermore, double-
ChIP analysis revealed that H3K9me3 coincides with H3K27me3, but not H3K4me2, 
suggesting that the D4Z4 repeat cluster contains a distinct heterochromatic domain 
marked by both H3K9me3 and H3K27me3 as well as a euchromatic domain containing 
H3K4me2 (Figure 2B). Notably, PCR amplification of the first proximal D4Z4 repeat 
revealed that this end is euchromatic, consistent with a previous report that the region 
proximal to the D4Z4 repeat is euchromatic [6] (Figure 1A and 2C). Both H3K4me2 
and H3K9me3 are present at D4Z4 in human embryonic stem (hES) cells, suggesting 
that D4Z4 chromatin domains are marked by these histone modifications early in 
development and are maintained during differentiation (Figure 2D). This is in contrast 
to H3Ac, which is absent in hES cells and appears to be added at later stages (compare 
Figure 2A, lane 7 and Figure 2D, lane 5). Taken together, unlike the previous model that 
implies that D4Z4 is a uniformly transcriptionally repressive domain [3], we found that 
D4Z4 repeats are composed of both euchromatic and heterochromatic domains with 
possibly the proximal repeats being euchromatic. Importantly, the presence of both 
4q- and 10q-specific nucleotide polymorphisms (Figure 1C) was confirmed by ChIP 
sequencing, indicating that a similar spectrum of histone modifications are present in 
the 4q and 10q D4Z4 regions (Supplemental Table 1).
h3k9me3 iS SpeciFicAlly loSt iN both 4q-liNkeD AND pheNotypic FShD
We next examined the chromatin modifications in FSHD patient-derived primary 
cells compared to normal cells from healthy individuals. The H3K9me3 signal at D4Z4 
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Figure 2 (eXplANAtioN See NeXt pAge)
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was significantly decreased in D4Z4-contracted FSHD myoblasts and fibroblasts while 
H3K27me3 and H3K4me2 remained unaffected (Figure 3A and B, 4qF). Importantly, 
the loss of H3K9me3 is site-specific because no significant change was observed at the 
ribosomal DNA (rDNA) region (Figure 3A, lower panels, and Figure 3B, lanes 7-11) or 
in the amount of total H3K9me3 detected by western blot (Figure 6B; data not shown). 
Similarly, no loss of H3K9me3 was observed at other repeat sequences, including 
chromosome 1 α-satellite and satellite 2, chromosome 4 α-satellite, NBL2, DXZ4, 
and RS447, in FSHD patient cells compared to normal cells (Supplemental Figure S1). 
The failure to detect H3K9me3 at D4Z4 is not due to an insufficient number of D4Z4 
copies since the ChIP signals were normalized to input DNA to reflect D4Z4 repeat 
number changes, and the loss of H3K9me3 was also observed in phenotypic FSHD 
(PF) cells with no repeat contraction. It is unlikely to be the result of a drastic change in 
antibody accessibility since H3K27me3, which resides in the same region according to 
the double-ChIP results (Figure 2B), is unchanged (Figure 3A and B). The persistence 
of H3K27me3 at D4Z4 also eliminates the possibility that only one allele is intrinsically 
organized as heterochromatin and deletion of this particular allele leads to FSHD. This 
is in agreement with previous observations that there is no clear paternal or maternal 
Figure 2 (See previouS pAge)
D4Z4 chromatin contains both euchromatic and heterochromatic histone 
modifications.
A. Antibodies specific for H3K4me2, H3K4me3, H3K9me3, H3K27me3, H3Ac, and acetylated 
H4 (H4Ac), as well as control preimmune IgG, were used for ChIP in HeLa cells. The ChIP DNA 
was amplified using 4qHox primers and primers specific for regions on chromosomes 10 and 19 
containing short Alu repeat sequences. The presence of H3K9me3 was confirmed by two different 
antibodies (lanes 10-14) [37].
B. Double-ChIP analysis of D4Z4 histone modifications. H3K9me3 ChIP (1st ChIP) was eluted 
and followed by the second (2nd) ChIP reactions using antibodies specific for H3K4me2, H3K9me3, 
H3K27me3, or preimmune IgG. The ChIP DNA was amplified using 4qHox primers.
C. The proximal region of the D4Z4 cluster is euchromatic. ChIP analysis of the first proximal D4Z4 
repeat using the 4qA161-1 primer pair (See Figure 1D for sequence amplification specificity) was 
performed in HeLa, normal human fibroblasts (FB), myoblasts (MB), and lymphoblasts (LB).
D. Histone ChIP in human ES cells. ChIP DNA derived from the ES cell lines H1 and H9 was 
amplified by 4qHox primers. Antibodies used for ChIP are indicated at the top.
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bias of disease transmission suggestive of imprinting, which could differentially organize 
the chromatin structure of the two alleles [2, 39]. Consistent with this, no significant 
difference in subnuclear localization of the two 4qter regions was found by the previous 
FISH analyses [8, 9].
Interestingly, the total numbers of D4Z4 repeat copies (i.e. the numbers of 4q and 10q 
repeats combined) are comparable between normal and FSHD patient cells (Figure 3B, 
bottom panel). Since the analysis in normal cells indicate that 10q D4Z4 also contains 
similar H3K9me3 modification (see above), the low level of H3K9me3 ChIP signal in 
FSHD patient cells cannot simply be attributed to the chromatin change at 4q D4Z4. This 
suggests that the loss of H3K9me3 also occurs at 10q D4Z4. This is further supported 
by the fact that both 4q and 10q polymorphisms were found in the residual H3K9me3 
ChIP Q-PCR products of PF (KII-I) and 4qF (RD217) samples (Supplemental Table 2). 
The results provide the first evidence that 10q D4Z4 chromatin is co-regulated with 4q 
D4Z4 chromatin and undergoes similar loss of H3K9me3 in FSHD.
Figure 3
Histone H3 lysine 9 trimethylation is specifically lost at D4Z4 in both 4q-linked 
and phenotypic FSHD.
A. ChIP analysis of H3K9me3 and H3K27me3 at D4Z4 in normal and FSHD (4qF) myoblasts. The 
rDNA region (445/446) serves as a positive control.
B. H3K9me3 is specifically lost in FSHD fibroblasts. Endpoint PCR analysis with 4qHox primers by 
agarose gel electrophoresis and quantitation of real-time PCR with Q-PCR primers are shown. The 
rDNA region, which was positive for HP1 and cohesin binding, was used for comparison (445/446) 
(See Figure 5). PCR signals were normalized with preimmune, input, and no template PCR signals. 
Primary cells derived from healthy (normal) (H), phenotypic (PF), and 4q-linked (4qF) individuals 
were analyzed as indicated. D4Z4 repeat numbers for 4q and 10q alleles as well as the total D4Z4 
repeat numbers are shown in the table. The asterisk indicates a clinically unaffected individual with 
DNA hypomethylation at D4Z4, whose two offspring developed phenotypic FSHD (KII-I and KII-II).
C. H3K9me3 ChIP analysis of different muscular dystrophy patient cells. The graph contains one 
4q-linked FSHD (508) and two phenotypic FSHD (Rf394.2 and Rf394.3) patient fibroblast 
samples, five OPMD patient fibroblast samples carrying alanine repeat insertions in the PABPN1 
gene (376, 395, 396, 54030922, and 203241), four DMD patient fibroblast samples with 
mutations in the dystrophin gene (d1137.5, 6103, 5639.1, and dl90.3), three LGMD patient 
next page
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(Figure 3 coNtiNueD)
fibroblast samples with heterozygous mutations in the LMN gene (00-288, 01-196, 99-305) [16, 
17], two ICF patient fibroblast samples [18], and four IBMPFD patient samples (two fibroblast and two 
lymphoblast) with mutations in the VCP gene (JH-FIB, MJ-FIB, 307/98, and RS-LCL) [19]. KI-I 
(normal) and 91RD217 (RD217, 4q-linked FSHD) fibroblast samples serve as controls. H3K9me3 
was also retained in two additional control fibroblast samples (302, 557/96) (data not shown).
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The loss of H3K9me3 at D4Z4 was observed not only in FSHD patient myoblasts and 
fibroblasts, but also in lymphoblasts, indicating that this chromatin change is not a mere 
non-specific epiphenomenon associated with the dystrophic state of the muscle cell 
(Figure 3A and B and Figure 4A). Presently, we have examined 14 normal and 14 FSHD 
patient cell samples of different origins and obtained consistent results. Importantly, no 
significant loss of H3K9me3 at D4Z4 was observed in cells from Duchenne muscular 
dystrophy (DMD), limb-girdle muscular dystrophy (LGMD), oculopharyngeal 
muscular dystrophy (OPMD), and inclusion body myopathy associated with Paget’s 
disease of bone and frontotemporal dementia (IBMPFD) (Figure 3C). Therefore, the 
loss of H3K9me3 at 4q and 10q D4Z4 is a specific change uniquely associated with both 
4q-linked (4qF) and phenotypic (PF) FSHD.
loSS oF h3k9me3 iS DiStiNct From DNA hypomethylAtioN
DNA and heterochromatic histone methylation are often co-regulated [40]. Although 
DNA methylation is more frequently a downstream consequence of H3K9 methylation 
[41], DNA methylation in some instances was shown to promote H3K9me3 [42]. Thus, we 
next addressed whether the loss of H3K9me3 is simply a downstream event of DNA 
hypomethylation previously observed in FSHD and clinically unrelated ICF syndrome 
cells [10]. We found that H3K9me3 is largely intact at D4Z4 in ICF cells, though there 
appears to be an increase in H3K4me2 and H3Ac, as indicated by ChIP analysis (Figure 
3C and 4A). Similarly, H3K9me3 is unaffected at another non-satellite repeat sequence 
called NBL2 in ICF cells, which was also shown to be DNA-hypomethylated in these 
cells (Figure 4B) [12]. Furthermore, no significant loss of H3K9me3 was observed in cells 
from a clinically unaffected individual with significant DNA hypomethylation at D4Z4 
(Figure 3B, KI-II) [10]. Finally, treatment of cells with 5-Azacytidine (5-AzaC), which 
blocks DNA methylation, did not affect H3K9me3 despite the significant reduction 
of DNA methylation at D4Z4 (Figure 5E). Taken together, DNA methylation is not 
required for H3K9me3 at D4Z4, and H3K9me3 loss clearly distinguishes FSHD from 
ICF, implying that loss of H3K9me3 at D4Z4, rather than DNA hypomethylation, is 
causally involved in FSHD.
hp1g AND coheSiN Are SpeciFicAlly recruiteD to D4Z4, which Are loSt iN FShD
What happens as a result of the loss of H3K9me3 at D4Z4? To investigate the 
consequences of H3K9me3 loss in FSHD, we examined factors that bind to this region. 
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Heterochromatin binding protein HP1 is recruited to heterochromatic regions by direct 
binding to the methylated H3K9 residue and plays an important role in transcriptional 
silencing [43, 44]. Swi6, an HP1 homolog in S. pombe, was also shown to recruit the essential 
sister chromatid cohesion complex “cohesin” to the pericentromeric heterochromatin 
where it mediates centromeric sister chromatid cohesion critical for mitosis [45, 46]. 
Although the study in yeast indicated that cohesin does not play any role in transcriptional 
repression at heterochromatic regions [46], HP1 and cohesin are valid candidates for the 
downstream effectors of H3K9me3 at D4Z4 in human cells. In mammals, there are 
three HP1 variants: HP1α, HP1β and HP1g. We found that HP1g specifically binds to 
Figure 4
H3K9me3 at D4Z4 is maintained in ICF patient cells.
A. ChIP analysis by endpoint PCR using 4qHox primers was performed using normal, ICF, and 
4q-linked FSHD (4qF) lymphoblasts with antibodies specific for H3K4me2,H3K9me3, and H3Ac, 
and preimmune IgG as indicated at the top. The rDNA region (445/446) serves as a positive 
control. ChIP analysis by real-time PCR using Q-PCR primers for H3K4me2, H3K9me3, and 
H3Ac is also shown. Similar results were obtained with ICF fibroblasts (Q-PCR results are shown 
at the bottom right).
B. H3K9me3 is intact at the NBL2 repeat region in ICF cells. Similar ChIP analysis was performed 




The binding of HP1g and cohesin to D4Z4 is lost in FSHD patients.
A. HP1g, but not HP1α, binds to D4Z4 in HeLa cells. 4qHox endpoint PCR of ChIP DNA using 
antibodies against HP1g and HP1α is shown. Immunoprecipitation with protein A beads alone serves 
as a negative control.
B. Comparison of ChIP analyses using antibodies specific for two different subunits of cohesin (hSMC1 
and hRad21). Preimmune IgG and protein A beads alone were used as negative controls. Two different 
amounts of ChIP DNA were used for endpoint PCR with 4qHox primers as indicated. The remainder of 
the cohesin ChIP experiments were carried out using anti-hRad21 antibody.
C. Cohesin binds to the 4qHox region in undifferentiated and differentiated primary human myoblasts. 
Cohesin ChIP was compared to that of condensin, another major SMC-containing complex, and protein 
A beads control.
D. ChIP PCR analyses using 4qHox primers of HP1g and cohesin binding in H, PF and 4qF fibroblasts 
as in Figure 3B. Representative samples of the 4qHox PCR products on an agarose gel are shown. 
PCR primers corresponding to the rDNA locus serve as positive (445/446) and negative (347/348) 
controls for HP1 and cohesin binding. Real-time PCR analysis using Q-PCR primers of HP1g and 
cohesin ChIP is shown underneath. A similar loss of HP1g and cohesin was also observed in 4qF 
myoblasts (data not shown).
E. The effect of DNA hypomethylation on cohesin and HP1g binding and H3K9me3. HeLa cells were 
treated with 5-AzaC and ChIP-PCR assays were performed using antibodies specific for Rad21 (“cohesin”), 
HP1g and H3K9me3 and Q-PCR primers specific for D4Z4. Hypomethylation of DNA was confirmed 
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D4Z4 (Figure 5A). Cohesin binding to D4Z4 was also detected using antibodies against 
two of its subunits (i.e. hSMC1 and hRad21), indicating the presence of the holo-
complex (Figure 5B). Cohesin binding was observed in both undifferentiated myoblasts 
and differentiated (mitotically inactive) myotubes, suggesting a role beyond mitosis at 
this site (Figure 5C). Importantly, similar to H3K9me3, HP1g and cohesin binding was 
also compromised at D4Z4, but not at the rDNA, DXZ4, and chromosome 1 α-satellite 
and satellite 2 repeat regions where H3K9me3 appears intact, in both 4qF and PF cells 
(Figure 5D; Supplemental Figure S2). The results indicate that H3K9me3, HP1g, and 
cohesin form heterochromatin at D4Z4, and suggest that the loss of HP1g and cohesin 
binding to D4Z4 is a significant downstream consequence of the loss of H3K9me3 in 
FSHD. Similar to H3K9me3, treatment of cells with 5-AzaC did not affect cohesin and 
HP1g binding to D4Z4, further separating H3K9me3 and HP1g/cohesin binding from 
DNA methylation (Figure 5E).
Suv39h1 iS reSpoNSible For h3k9me3, which iS NeceSSAry but Not SuFFicieNt For 
hp1g/coheSiN recruitmeNt to D4Z4
The methyltransferase responsible for H3K9me3 and the relationship between 
H3K9me3, HP1g and cohesin were addressed using small interfering RNAs (siRNAs). 
SiRNA against SUV39H1, which has no effect on SUV39H2, abolished H3K9me3 
at D4Z4 but not at rDNA, suggesting that SUV39H1 has a non-redundant function 
at D4Z4 (Figure 6A). Supporting this notion, depletion of G9a, another H3K9 
methyltransferase, decreased H3K9me3 at the c-Myc region [24], but had no effect 
at D4Z4 or rDNA (Figure 6A). Abolishment of H3K9me3 by SUV39H1 depletion 
also impaired HP1g and cohesin binding at D4Z4 but not at rDNA, confirming that 
SUV39H1-mediated H3K9me3 is necessary for HP1g and cohesin binding specifically 
at D4Z4. Neither HP1g nor cohesin depletion affected the level of H3K9me3 at D4Z4, 
placing them downstream of H3K9me3 (Figure 7A, lane 5).
(Figure 5 coNtiNueD)
by MeCIP using antibody specific for 5-methylcytidine. The ChIP and MeCIP signal intensity was 
normalized by genomic DNA input control and pre-immune control. No significant decrease of cohesin 
and HP1g binding and H3K9me3 was observed. Western analysis of cohesin, HP1g and H3K9me3 




SUV39H1 HMTase is solely responsible for H3K9me3 at D4Z4, which is necessary, 
but not sufficient for, the recruitment of HP1g and cohesin.
A. SUV39H1 is responsible for H3K9me3 and HP1g/cohesin association at D4Z4. HeLa cells were 
treated with siRNA specific for SUV39H1, G9a, or control siRNA, and ChIP analysis using 4qHox 
primers was performed for the presence of cohesin, HP1g and H3K9me3 (lanes 1-16). Preimmune 
IgG serves as a negative control. The rDNA (445/446) and c-Myc regions were used for comparison. 
Western-blot analysis of G9a and SUV39H1 siRNA depletion is also shown (lanes 17-21). Depleted 
proteins are indicated at the top and proteins detected by western blot analysis are indicated on the left. 
α-tubulin serves as a loading control.
B. HP1g and cohesin binding to D4Z4 is cell type-specific. ChIP analysis of D4Z4 and rDNA regions 
was performed using normal and 4qF lymphoblasts (lanes 1-10). Western blot analysis comparing the 
level of H3K9me3 between HeLa and lymphoblasts (256 (normal) and B8-1 (4qF)) is also shown 
(lanes 11-13). Coomassie staining of core histones is included as a loading control.
C. Not all H3K9me3-positive repeats are bound by HP1g and cohesin. Six different repeat sequences 
(as in Supplemental Figure S1) were tested for cohesin and HP1g binding in HeLa cells. While 
H3K9me3 was detected at all six repeat sequences tested, cohesin and HP1g binding was found at only 
three repeats (α-sat and sat2 on chromosome 1 and DXZ4).
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Interestingly, HP1g and cohesin binding to D4Z4 is significantly low in normal 
lymphoblasts, even with intact H3K9me3 at D4Z4 (Figure 4A), when compared to 
other cell types (Figure 6B). This is not due to a general decrease of HP1g and cohesin 
binding in lymphoblasts since HP1g and cohesin binding was clearly observed at four 
other repeat sequences tested (i.e., rDNA, α-satellite and satellite 2 on chromosome 1, 
and DXZ4) in both normal and FSHD lymphoblasts, similar to myoblasts and fibroblasts 
(Figure 6B and Supplemental Figure S2). Furthermore, the total level of H3K9me3 
is comparable between HeLa and both normal and FSHD lymphoblasts (Figure 6B, 
lanes 11-13). The results indicate that H3K9me3 is not sufficient and suggest that an 
additional factor(s), which may be expressed in a cell type-specific manner, is required 
for HP1g and cohesin binding to D4Z4. The requirement for an additional factor(s) is 
also supported by the observation that not all H3K9me3-positive repeat sequences are 
bound by HP1g and cohesin, even in the same cell sample (Figure 6C).
coheSiN plAyS AN Active role iN hp1g recruitmeNt to D4Z4.
Similar to the recruitment of cohesin to pericentromeric heterochromatin in S. pombe 
[45, 46], HP1 is required for cohesin binding at D4Z4 (Figure 7A). Interestingly, depletion 
of HP1g alone abolished cohesin binding at D4Z4, indicating that HP1α and HP1β 
cannot compensate for this function of HP1g at this site. In contrast, depletion of HP1g 
had no effect on cohesin binding to the rDNA region, α-satellite and satellite 2 repeats 
on chromosome 1, and DXZ4, most likely due to functional redundancy with other 
HP1 variants (Figure 7A (lanes 7-12) and B). Consistent with this notion, HP1α binding 
was detected at the α-satellite repeat, but not at D4Z4 (Figure 5A, lane 4; data not 
shown). Thus, HP1g appears to be uniquely involved in heterochromatin formation at 
D4Z4.
We found that the cohesin loading factor Scc2 [47] also binds to D4Z4, which was 
significantly decreased by depletion of HP1g to an extent similar to the decrease caused 
by depletion of Scc2 itself (Figure 7C). Consistent with this, we found an interaction 
between the endogenous HP1g and Scc2 by in vivo coimmunoprecipitation (co-IP) 
(Figure 7D). Although weak, the interaction is specific and partially resistant to a 1M salt 
wash (Figure 7D, “eluate”). Interestingly, although it was shown that HP1 interacts with 
cohesin in S. pombe [46], HP1g mainly interacts with Scc2, rather than cohesin, in human 
cells (Figure 7D). This is consistent with a previous report identifying the interaction 




D4Z4-specific co-recruitment of HP1g, cohesin, and cohesin loading factor Scc2.
A. Binding of HP1g and cohesin to D4Z4 is interdependent. ChIP analysis of HeLa cells after 
individual depletion of the cohesin subunit hSMC1, HP1g, or the cohesin loading factor Scc2 by 
siRNA as indicated (lanes 1-12). Cohesin and HP1g binding was compared between D4Z4 and rDNA 
(445/446). Real-time PCR analysis using Q-PCR primers is shown underneath. Western blot analysis 
of hSMC1, HP1g and Scc2 depletion is also shown (lanes 13-16).
B. HP1g and cohesin binding do not affect each other at other repeat sequences. Real-time PCR 
analysis of Rad21 (“cohesin”), HP1g and H3K9me3 ChIP DNA from HeLa cells treated with control, 
SMC1, HP1g, or Scc2 siRNA as indicated using Q-PCR primers specific for D4Z4, α-sat and sat2 
repeat sequences on chromosome 1, and DXZ4 (as in Supplemental Figure S2).
C. Scc2 binding to D4Z4 is compromised by HP1g depletion. Real-time PCR analysis of Scc2 ChIP 
DNA from HeLa cells treated with control, HP1g, or Scc2 siRNA as indicated using Q-PCR primers 
specific for D4Z4.
D. Coimmunoprecipitation (co-IP)-western blot analysis of cohesin and Scc2 interaction with HP1g. 
HeLa nuclear extracts were used for co-IP using antibody specific for Scc2 or cohesin (Rad21) as 
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contrast, CTCF, another factor recently shown to recruit cohesin to its binding sites 
[49-51], interacts preferentially with cohesin but not Scc2 (Figure 7D), suggesting distinct 
modes of cohesin recruitment by these factors.
In S. pombe, cohesin is downstream of HP1, and does not play any role in HP1 recruitment 
[46]. Interestingly, we found that depletion of hSMC1 impairs HP1g binding to D4Z4 
(Figure 7A). Similarly, depletion of Scc2 abolished D4Z4 binding of not only cohesin 
but also HP1g. Thus, the results provide the first evidence for an active role of cohesin in 
heterochromatin organization. This appears to be context-dependent, since the rDNA 
region, α-satellite and satellite 2 repeats on chromosome 1, and the DXZ4 region 
showed no effect on HP1g binding following depletion of hSMC1 or Scc2 (Figure 7A 
and B).
dIscussIon
In this study, we found that the loss of histone H3K9me3 and its cell type-specific 
downstream effectors HP1  and cohesin from D4Z4 repeats is the unifying molecular 
change in FSHD (Figure 8A). Importantly, this change was observed in both 4qF with 
D4Z4 contraction and PF without D4Z4 contraction. It was not found in ICF syndrome, 
despite its apparent similarity to FSHD with regard to D4Z4 DNA hypomethylation, 
or in other types of muscular dystrophies tested. This tight phenotype-epigenotype 
correlation strongly suggests that the loss of H3K9me3 at D4Z4 is critically involved 
in FSHD pathogenesis. Our results define a novel diagnostic marker for FSHD, and 
provide the first direct evidence for the specific changes of D4Z4 chromatin that are 
linked to FSHD.
(Figure 7 continued)
previously described [14, 22]. After low-salt washes, precipitated materials were eluted with 1.0M KCl 
(“wash”) and further eluted with 2.0M guanidine-HCl (“eluate”). Eluted proteins were analyzed by 
SDSPAGE and western blotting using antibody specific for HP1g. For comparison, a similar co-IP 
analysis was performed and probed with antibody specific for CTCF.
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D4Z4 repeAt cluSterS coNSiSt oF euchromAtic AND heterochromAtic DomAiNS, AND 
oNly h3k9me3, but Not h3k27me3, iS loSt From the heterochromAtic DomAiNS iN 
FShD
Although D4Z4 was thought to be a uniformly transcriptionally repressive domain [3, 
10], we found that D4Z4 regions contain a mixture of euchromatic and heterochromatic 
histone modifications; specifically, H3K4me2 and H3Ac as well as H3K9me3 and 
H3K27me3. These euchromatic and heterochromatic modifications are present in 
distinct domains within D4Z4 repeat clusters with the first proximal repeat being 
euchromatic (Figure 8B). Interestingly, only H3K9me3 is lost in FSHD, but not 
H3K27me3 from the heterochromatic region (Figure 8C). Thus, the chromatin change 
in FSHD is not a total loss of transcriptionally repressive heterochromatin. This is 
consistent with the fact that there apparently is no significant compensatory increase 
of euchromatic modifications, suggestive of expansion of euchromatic domains within 
D4Z4, in FSHD.
Figure 8
Schematic models of chromatin changes and the possible consequences in FSHD.
A. Schematic summary of key components at D4Z4 in different cell types and their loss in FSHD. HP1g 
and cohesin are dependent on each other to be recruited to D4Z4 that harbors SUV39H1-mediated 
H3K9me3. A putative cell type-specific factor(s) (or modification(s)) is required. In lymphoblasts, 
despite the presence of H3K9me3, HP1g and cohesin fail to associate with D4Z4 due possibly to the 
absence of this cell type-specific factor(s)/modification(s). Loss of H3K9me3 at D4Z4 in FSHD leads 
to abolishment of HP1g/cohesin binding in certain cell types, including myoblasts and fibroblasts, 
while the loss of H3K9me3 in lymphoblasts is without discernible effect.
B. Coordinated loss of H3K9me3 on 4q and 10q D4Z4 in 4qF and PF. H3K9me3 (shown by black 
triangles) clustered in the subdomains of D4Z4 repeat regions (distribution hypothetical) in normal 
cells is lost in both types of FSHD.
C. A possible model for the spreading of the epigenetic change at D4Z4 to other genomic regions in 
FSHD. HP1g and cohesin may contribute to the physical interactions of the heterochromatic D4Z4 
region with other genomic regions leading to the spreading of the silencing effect to putative target 
genes in normal cells. In FSHD, the loss of H3K9me3 (but not H3K27me3), HP1g, and cohesin from 
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loSS oF h3k9me3 AND D4Z4 coNtrActioN
PF and 4qF are genetically distinct. While the etiology of PF is unknown, our results 
revealed a correlation between the repeat contraction and the loss of H3K9me3 at 
D4Z4 in 4qF patient cells. This raises the possibility that repeat contraction leads to 
the loss of H3K9me3 at D4Z4 in 4qF. It is also formally possible that the upstream 
event that initially caused the repeat contraction might have also caused the loss of 
H3K9me3. It is less likely that the loss of H3K9me3 is the cause of repeat contraction, 
since there is no repeat number instability in phenotypic FSHD despite the similar loss 
of H3K9me3. Detection of H3K9me3 at D4Z4 in hES cells and multiple cell types 
indicates that H3K9me3 at this region is normally established early during development 
at a pluripotent stage, and is maintained throughout multi-lineage differentiation. The 
fact that H3K9me3 is lost even in lymphoblasts in FSHD patients indicates that this 
establishment process during early development may have gone awry.
Interestingly, our results indicate that contraction of one allele not only triggers the 
histone modification change (loss of H3K9me3) on the disease allele, but also affects 
H3K9me3 levels on other non-contracted 4q and 10q D4Z4 alleles, suggesting a 
functional communication between these homologous sequences perhaps reminiscent 
of transvection in Drosophila [52] (Figure 8B). This is in contrast to DNA hypomethylation, 
which appears to be restricted to the disease chromosome in FSHD [10, 13]. The dominant 
effect of contraction of one 4q D4Z4 allele on H3K9me3 at other D4Z4 alleles is 
consistent with the dominant nature of the disease and is in agreement with our results 
indicating that DNA hypomethylation is not required for the loss of H3K9me3. This 
strongly argues against the theory that only the contracted D4Z4 allele is involved in 
FSHD pathogenesis [3]. Rather, it is possible that both alleles of 4q D4Z4 as well as 10q 
D4Z4 may be involved in the disease process. Consistent with the coordinated chromatin 
changes observed, somatic pairing of 4q and 10q D4Z4 has been reported [53]. Although 
the mechanism is currently unclear, the results provide the first evidence that the initial 
genetic change (repeat contraction) spreads its effect to other genomic regions in 4qF. A 
similar coordinated loss of H3K9me3 at 4q and 10q D4Z4 was observed in PF, further 
emphasizing the significance of this phenomenon.
regulAtioN oF the Suv39h1 Activity At D4Z4
We identified the histone methyltransferase (HMTase) SUV39H1, but not other 
HMTases, to be responsible for D4Z4 H3K9me3 (Figure 8A). This raises the possibility 
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that misregulation of this enzyme activity is linked to the etiology of FSHD. PF may be 
caused by a genetic mutation of a factor(s) that regulates SUV39H1 activity at D4Z4. 
However, no mutation in SUV39H1 itself (either at the promoter or gene region) in 
FSHD patient cells was found [13]. Consistent with this, the total level of H3K9me3 
in the nucleus is similar between normal and FSHD cells. This suggests that a specific 
cofactor of SUV39H1, possibly important for its recruitment, and/or a specific histone 
demethylase acting at D4Z4, may be compromised. Further investigation of the site-
specific SUV39H1 (or antagonizing histone demethylase) regulation will be important 
to understand FSHD’s etiology and pathogenesis, and may shed new light onto the yet 
to be identified cause of phenotypic FSHD. It is also interesting to note that there is 
a slight but consistent decrease in HP1g binding to other repeat sequences tested in 
PF, but not 4qF, cells (Supplemental Figure S2). Although the significance of this small 
decrease is currently unclear, this may reflect the distinct etiologies of PF and 4qF and 
may provide another clue to identify the genetic defect in PF.
hp1g AND coheSiN AS cell type-SpeciFic DowNStreAm eFFectorS
We established the loss of H3K9me3 at D4Z4 to be the signature change in both types 
of FSHD, but how does this epigenetic change lead to muscular dystrophy? We identified 
two major downstream effectors of H3K9me3, the heterochromatin binding protein 
HP1g and cohesin, whose binding to D4Z4 is H3K9me3-dependent and, consequently, 
is severely compromised in FSHD. The data presented here argue for both factors having 
a role in FSHD pathogenesis. Importantly, while H3K9me3 at D4Z4 is seen in all cell 
types tested, the binding of HP1g and cohesin to D4Z4 is cell type-specific, suggesting 
that their binding is involved in cell type-specific chromatin organization (Figure 8A). 
This restricted HP1g/cohesin binding to D4Z4 may explain the tissue-specific FSHD 
disease phenotype, as their loss may be particularly deleterious to muscle function.
Interestingly, recent evidence suggests that cohesin is also involved in gene regulation. 
Although initially identified as a factor essential for mitosis, discoveries of mutations of 
cohesin components and the essential cohesin chromatin loading factor NIPBL/Scc2 in 
the developmental disorder Cornelia de Lange syndrome (CdLS) strongly suggested the 
involvement of cohesin in developmental gene regulation [54-56]. The sequence-specific 
DNA binding transcription factor CTCF was found to recruit cohesin to many of its 
binding sites, where cohesin is involved in CTCF-dependent transcriptional regulation 
[49-51]. Accumulating evidence indicates that gene regulation can be affected by physical 
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interaction between two distant chromosomal regions in cis and in trans in mammalian 
cells [57-60]. CTCF is known to be one such factor that exerts its transcriptional activity 
by directing long-distance chromatin interactions and loop formation, for example, in 
imprinting and X inactivation [61, 62]. Thus, the discovery that cohesin is an important 
mediator of CTCF transcriptional function raised the intriguing possibility that cohesin 
may dictate gene expression by facilitating such higher-order chromatin organization. 
Similar to what was proposed for sister chromatid cohesion [63], cohesin may trap two 
distant chromatin fibers inside of its ring.
We failed to detect any significant binding of CTCF concomitant with cohesin at D4Z4 
(data not shown), which is consistent with the fact that CTCF and heterochromatin 
are mutually exclusive [64]. However, cohesin may still function in a similar manner 
mediating long-distance chromatin interactions, together with HP1g in the case of D4Z4 
heterochromatin. In Drosophila, it was suggested that HP1 promotes interchromosomal 
association of heterochromatin, which may be important for coordinated gene silencing 
[65]. Evidence for gene silencing by association with distant heterochromatin was also 
found in mammalian cells, in which the temporal association of the terminal transferase 
(Dntt) gene with pericentromeric heterochromatin correlates with its silencing during 
thymocyte maturation in mice [66]. Thus, one possibility for the involvement of D4Z4 
heterochromatin in gene regulation is that it makes contact with, and represses, 
distant target genes via long-distance chromatin: chromatin interactions by spreading 
a silencing effect in normal cells (Figure 8C). H3K27me3 found in the same region 
may also contribute to this by possibly recruiting the polycomb silencing complex. We 
hypothesize that in FSHD the loss of H3K9me3 and therefore HP1g results in the loss 
of this chromatin interaction, thereby causing abnormal derepression of these distant 
target genes that leads to the dystrophic phenotype (Figure 8C). There may be different 
sets of target genes for 4q and 10q D4Z4, both of which would be affected in FSHD due 
to the concomitant loss of H3K9me3. Interestingly, some evidence for change in local 
higher-order chromatin organization and nuclear matrix association in 4q-linked FSHD 
was recently reported [67]. However, this change appears to occur in the nearby regions 
outside of the D4Z4 cluster, and how D4Z4 contraction affects this is unclear. The 
same phenomenon has not been confirmed in phenotypic FSHD. In addition, since this 
change was shown to be restricted to the contracted allele and not other D4Z4 alleles, 
the relationship to the spreading of D4Z4 chromatin changes observed in the current 
study remains to be investigated. Further studies to examine the possible chromatin 
73
H3K9me3 and HP1g/cohesin binding loss in FSHD
interactions and organization involving D4Z4 and their changes in FSHD may provide 
critical insight into the mechanism of FSHD pathogenesis.
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SupplemeNtAl tAble 1 









Mouse β-minor globin forward 5’TGCGAGGATAAGAACAGACACTAC3’
Mouse β-minor globin reverse 5’ACAGACTCAGAAGCAAACGTAAGA3’
Chinese hamster rDNA forward 5’GCAGAAGCTGCCAGGATAAC3’
Chinese hamster rDNA reverse 5’AGGGGTGGTGTCTTTGACAG3’
Sat2 from Chr1 forward 5’CATCGAATGGAAATGAAAGGAGTC3’
Sat2 from Chr1 reverse 5’ACCATTGGATGATTGCAGTCAA3’
Satα from Chr1 forward 5’TCATTCCCACAAACTGCGTTG3’
Satα from Chr1 reverse 5’TCCAACGAAGGCCACAAGA3’
Satα from Chr4 forward 5’CTGCACTACCTGAAGAGGAC3’




DXZ4 reverse 5’ TATGTTTGGGCAGGAAGATCG3’
RS447 forward 5’TGGGAAATACCTGCTACGTG3’
RS447 reverse 5’GTGACGATGACACGTTTGAG3’
Chr10 Alu forward 5’GATTCTCAACAGCAGAATTCCATGCC3’
Chr10 Alu reverse 5’CATGTTTGAGAATGTCTACTTCTTAG3’
Chr19 Alu forward 5’CCACGTGTTTATCTGTAAGGTG3’
Chr19 Alu reverse 5’GTTAGGAGCTAGAAGGAGCCTG3’
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SupplemeNtAl tAble 2
The number of input and ChIP DNA PCR clones with 4q- or 10q-specific 
nucleotide polymorphisms.


















H3K9me3 ChIP analysis of different repeat sequences in normal and FSHD patient 
cells. 
PCR primers specific for chromosome 1 α-satellite (α-sat) and satellite 2 (sat2) and chromosome 4 
α-satellite (α-sat) sequences were used. In addition, DXZ4, RS447, and NBL2-specific primers were 
used. Although sequences are unrelated, DXZ4 (on Xq23) and RS447 (primarily on 4q16.1) are 
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SupplemeNtAl Figure S2
Cohesin and HP1g binding to different repeat sequences. 
Rad21 and HP1g ChIP analysis of three repeat sequences (α-sat and sat2 on chromosome 1 and 
DXZ4) in normal and FSHD myoblasts, fibroblasts, and lymphoblasts as indicated. Endpoint PCR 
using 4qHox primers and real-time PCR analysis using Q-PCR primers are shown.
(SupplemeNtAl Figure S1 coNtiNueD)
members of the macrosatellite repeat family similar to D4Z4. NBL2 is in the acrocentric chromosomes 
and is known to be DNA-hypomethylated in ICF syndrome patient cells (see Figure 4B). The PCR primer 
sequences are listed in the Supplemental Table 1. Results of the endpoint PCR using 4qHox primers 
and real-time PCR using Q-PCR primers for (A) myoblasts (normal (N27) and 4qF (GM17940)), (B) 
fibroblasts (normal (KI-I), PF (KII-I), and 4qF (RD217)), and (C) lymphoblasts (normal (256) and 
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Facioscapulohumeral muscular dystrophy (FSHD), caused by partial deletion of the 
D4Z4 macrosatellite repeat on chromosome 4q, has a complex genetic and epigenetic 
etiology. To develop FSHD, D4Z4 contraction needs to occur on a specific genetic 
background. Only contractions associated with the 4qA161 haplotype cause FSHD. In 
addition, contraction of the D4Z4 repeat in FSHD patients is associated with significant 
D4Z4 hypomethylation. To date however, the methylation status of contracted repeats 
on non-pathogenic haplotypes has not been studied. We have performed a detailed 
methylation study of the D4Z4 repeat on chromosome 4q and on a highly homologous 
repeat on chromosome 10q. We show that patients with a D4Z4 deletion (FSHD1) have 
D4Z4-restricted hypomethylation. Importantly, controls with a D4Z4 contraction on 
a non-pathogenic chromosome 4q haplotype or on chromosome 10q also demonstrate 
hypomethylation. In fifteen FSHD families without D4Z4 contractions but with at least 
one 4qA161 haplotype (FSHD2), we observed D4Z4-restricted hypomethylation on 
chromosomes 4q and 10q. This finding implies that a genetic defect resulting in D4Z4 
hypomethylation underlies FSHD2. In conclusion, we describe two ways to develop 
FSHD; (1) contraction-dependent or (2) contraction-independent D4Z4 hypomethylation on 
the 4qA161 subtelomere. 
IntroductIon
Macrosatellite DNA is composed of large and highly homologous repeat units that are 
arranged in tandem over regions that typically exceed 50-100 kb. Thus far, several classes 
of macrosatellite repeat arrays have been identified in the human genome, most of which 
are located at centromeres. One example is satellite DNA which has an important role 
in the formation and maintenance of the centromeric chromatin structure by specific 
interactions with DNA-binding proteins and by establishing heterochromatin formation 
through an RNAi mechanism [1]. Macrosatellite repeats that are non-centromerically 
located have also been identified. Examples include the RNU2, RS447, DXZ4 and 
D4Z4 repeats. All these repeats are highly polymorphic; they usually vary between few 
and >100 units [2-5].
Currently, the only disease-associated macrosatellite repeat is the D4Z4 repeat array. 
Contraction of D4Z4 in the subtelomere of chromosome 4q is associated with autosomal 
dominant facioscapulohumeral muscular dystrophy (FSHD1 [OMIM 158900]) [6]. The 
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D4Z4 repeat array consists of 3.3 kb repeat units, normally varying in numbers between 
11 and 100 copies (>40 kb). In the majority of patients with FSHD, a contraction of 
the repeat array to 1-10 repeat units (<40 kb) is observed [7, 8]. Monosomy of 4q does 
not cause disease suggesting a critical role for the D4Z4 repeat unit in the etiology 
of FSHD [9]. Sequences homologous to D4Z4 have been identified on many, mainly 
acrocentric, chromosomes [10]. Due to an ancient duplication event, the subtelomere 
of chromosome 10q also contains a D4Z4-like repeat [11, 12] and in ~20% of individuals 
subtelomeric exchanges between repeats on 4q and 10q can be observed [13]. However, 
repeat contractions on 10q do not cause FSHD, although ~25% of chromosomes 10q 
carry a repeat array of 10 units or less [14, 15]. 
With the initial identification of two allelic variants of the 4q subtelomere, 4qA and 4qB 
[16] and the recent further specification into 9 different haplotypes of chromosome 4q 
[17], it has become evident that D4Z4 contraction alone is not sufficient to cause FSHD. 
Instead, it needs to occur on a specific genetic background, the 4qA161 haplotype. 
The 4qA161 haplotype is the most prevalent A haplotype in the Caucasian population 
and can be observed in ~39% of control individuals [17]. Thus far, only contractions in 
the 4qA161 haplotype have been shown to cause FSHD, while contractions in other 
4q haplotypes such as 4qA166 and 4qB163 are non-pathogenic [17-19]). Therefore, it 
is hypothesized that haplotype-specific sequence polymorphisms are mechanistically 
linked to FSHD pathogenesis [17]. 
Some non-centromeric macrosatellite repeat arrays, including D4Z4, are extremely GC-
rich, making them attractive candidates for DNA methylation. DNA methylation is a 
common modification of mammalian DNA which occurs at cytosine residues of CpG 
dinucleotides, a process executed by DNA methyltransferases. Often, DNA methylation is 
associated with increased chromatin condensation and gene silencing [20]. The D4Z4 repeat 
array is frequently considered heterochromatic because of the presence of the low-copy-
repeats hhspm3 and LSau, repetitive sequences that are mainly found in heterochromatic 
regions of the human genome [21]. However, several studies have indicated that D4Z4 has 
both euchromatic and heterochromatic features [22, 23]. Interestingly, DNA methylation of 
the proximal D4Z4 repeat unit on the disease allele was significantly reduced in patients 
with FSHD1, both in DNA isolated from peripheral blood lymphocytes (PBLs) and 
from muscle [24]. Also in a small group of FSHD2 patients without D4Z4 contraction 
but with clinical symptoms indistinguishable from FSHD1 patients, significant D4Z4 
hypomethylation at both chromosome 4q alleles was observed [24, 25]. 
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Thus far, a limited number of CpG dinucleotides of the ~290 CpGs in each D4Z4 repeat 
unit have been tested for DNA methylation. Because of technical limitations, only in a small 
group of patients could the methylation level of the disease allele be studied, while in all 
other cases, the observed methylation levels were confounded by the simultaneous analysis 
of D4Z4 repeats on the normal chromosome 4q carrying a normal-sized D4Z4 repeat array 
[24, 26]. These limitations have left many questions unanswered about the nature and extent of 
D4Z4 hypomethylation, including: (1) What is the methylation level of internal D4Z4 repeat 
units compared to the proximal D4Z4 repeat unit?, (2) What is the methylation level of a 
contracted D4Z4 repeat on a non-pathogenic 4q haplotype?, (3) What is the methylation 
level of a contracted D4Z4 repeat on chromosome 10q?, (4) Is there a relationship between 
D4Z4 repeat size and D4Z4 methylation? and (5) What is the methylation level of the D4Z4 
repeats on chromosome 10q in FSHD2 patients? 
To address these questions, we performed detailed methylation analyses of the D4Z4 repeat 
array using the methylation-sensitive restriction enzyme CpoI, which enabled us to interrogate 
D4Z4 methylation on proximal and internal repeat units on chromosomes 4q and 10q 
separately. Importantly, we also examined the DNA of several unique control individuals, 
including individuals carrying contracted D4Z4 repeats on non-pathogenic haplotypes. Our 
results demonstrate that a generic mechanism at the D4Z4 repeats results in significant 
hypomethylation upon contraction of the repeat array below a certain threshold, and that 
this change is observed irrespective of the haplotype on which the D4Z4 contraction occurs. 
Furthermore, FSHD2 patients show D4Z4 hypomethylation not only on both chromosomes 
4q, but also on both chromosomes 10q, which implies that in these individuals a genetic 
defect responsible for methylation of D4Z4 may exist. Importantly, all FSHD2 patients carry 
at least one copy of the pathogenic 4qA161 haplotype. In conclusion, we show that epigenetic 
changes in D4Z4 at the pathogenic 4qA161 haplotype underlie and unify both FSHD1 and 
FSHD2.
materIals	and	methods
Most protocols used in this paper and other protocols used by researchers of the Fields 
Center in FSHD and neuromuscular research are described in detail on the Fields Center 
website http://www.urmc.rochester.edu/fields-center. The Fields Center for FSHD and 
Neuromuscular Research is an international collaboration between the University of Rochester 
Medical Center (USA) and the Leiden University Medical Center (The Netherlands) that 
performs clinical and genetic research to find treatments for patients with FSHD. 
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pAtieNtS AND coNtrolS
All individuals included in this study were analyzed previously for their allele size, constitution 
of repeats arrays on chromosomes 4q and 10q and haplotypes after informed consent was 
obtained [17, 18]. In total, DNA of 70 control individuals, both family members and unrelated 
individuals (16 monosomic, 40 disomic and 14 trisomic), and DNA of 54 FSHD1 patients 
with a D4Z4 contraction (10 monosomic, 29 disomic and 15 trisomic) were analyzed. For a 
detailed explanation on monosomic, disomic and trisomic individuals see the Results section 
of this article. DNA of 18 FSHD2 patients without a D4Z4 contraction was collected from 
fifteen families.  These FSHD2 patients are mainly single cases, but also two sibling pairs and 
an affected mother and daughter are present within the group of FSHD2 patients. FSHD2 
patients present with a phenotype indistinguishable from FSHD1 patients with a contraction 
of D4Z4 on the 4qA161 haplotype.
DNA iSolAtioN AND cell liNeS
Genomic DNA was isolated from PBLs or from myoblasts and myotubes in culture. DNA 
was extracted using a standard salt extraction protocol [27]. Myoblasts were cultured in 
DMEM F-10 medium (Invitrogen) with heat-inactivated fetal calf serum (Invitrogen), 
penicillin/streptomycin (Invitrogen), basic human recombinant fibroblast growth factor 
(Promega) and dexametazone (Sigma Aldrich). When grown until 80% confluency, DNA 
was isolated from part of the myoblast culture. The remaining myoblasts were induced to 
differentiate into myotubes using DMEM medium containing glucose (Sigma Aldrich), 
L-glutamine (Invitrogen) and sodium pyruvate (Invitrogen) with heat-inactivated horse 
serum (Invitrogen).
cpoi methylAtioN ANAlySiS
For methylation analysis of the proximal D4Z4 repeat unit on either chromosome 4q or 
chromosome 10q, we applied a method illustrated in Figure 1A and 1C and modified 
from methods described previously [24]. For methylation analysis of internal D4Z4 repeats 
units on either chromosome 4q or 10q, we used the same Southern blot membranes being 
used for methylation analysis of the proximal unit, but the membrane was hybridized with 
the D4Z4 probe [28] instead of the p13E-11 (D4F104S1)  probe [7] (Figure 1B and 1D). 
Briefly, 5 μg of genomic DNA was first digested with the restriction enzymes Eco91I (MBI 
Fermentas; isoschizomer of BstEII) and either BlnI (Takara Bio Inc) or XapI (MBI Fermentas) 
for methylation analysis of chromosomes 4q or 10q, respectively. Next, the methylation-
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sensitive restriction enzyme CpoI (MBI Fermentas) was used, both for chromosome 4q 
and for chromosome 10q methylation analysis. All digestion reactions were performed 
according to the manufacturer’s instructions. After digestion, DNA was separated by 
linear gel electrophoresis on a 0.8% agarose gel (Invitrogen) followed by Southern 
blotting of the DNA on a hybond-XL membrane (GE Healthcare) and hybridization 
of the membrane first with the radioactive labeled probe p13E-11 for methylation 
determination of the proximal D4Z4 repeat unit [7] and subsequently with the D4Z4 
probe for methylation analysis of internal D4Z4 repeat units [28]. Hybridizations for p13E-
11 were performed for a minimum of 16 hours at 65 ºC in a buffer containing 0.125 M 
Na2HPO4 (pH 7.2), 0.25 M NaCl, 1 mM EDTA, 7% SDS and 100 μg/ml denatured fish 
sperm DNA (Roche). Hybridizations for D4Z4 were performed for at least 16 hours at 
62 ºC in a buffer containing 0.125M Na2HPO4 (pH 7.2), 0.25 M NaCl, 7% SDS, 50% 
formamide and 100 μg/ml denatured fish sperm DNA (Roche). After hybridization, 
membranes labeled with p13E-11 were washed with 2xSSC/0.1%SDS, followed 
by washing with 1xSSC/0.1%SDS and a final wash step with 0.3xSSC/0.1%SDS. 
D4Z4-labeled membranes were washed first with 2xSSC/0.05%SDS and second 
with 0.1xSSC/0.1%SDS. Finally, the membranes were exposed to a phosphor-imager 
screen and signal intensities were analyzed and quantified with ImageQuant software 
(Molecular Dynamics).
Figure 1
Schematic overview of the CpoI methylation analyses on chromosomes 4q and 10q. 
Genomic DNA was digested with either Eco91I/BlnI (A, B) or Eco91I/XapI (C, D) to separate D4Z4 
repeat units on chromosome 4q from those on chromosome 10q. Subsequently, DNA was digested with 
the methylation-sensitive restriction enzyme CpoI. Lines represent the different fragment sizes obtained 
after digestion, Southern blotting and visualization by hybridization with the p13E-11 probe for the 
proximal D4Z4 repeat unit (A, C) or with the D4Z4 probe for internal D4Z4 repeat units (B, D). 
Probe recognition sequences are indicated with black boxes. In the repeat unit the location of the DUX4 
open reading frame (ORF) is indicated.
Besides the schematic overview of each methylation analysis a final gel picture showing three DNA 
samples as examples is depicted.
next page
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For methylation analysis of the region proximal to the p13E-11 region and the D4Z4 
repeat array on either chromosome 4q or chromosome 10q, we applied a method 
illustrated in Supplemental Figure S1 and modified from methods described previously 
[24]. 5 μg of genomic DNA was first digested with the restriction enzyme BseMI (MBI 
Fermentas). Next, the methylation-sensitive restriction enzyme SmaI (MBI Fermentas) 
was used. All digestion reactions were performed according to the manufacturer’s 
instructions. After digestion, DNA was separated by linear gel electrophoresis 
followed by Southern blotting of the DNA as described above for the CpoI methylation 
analysis. Next, the membranes were hybridized with the p13E-11 (D4F104S1) probe 
[7]. Hybridization, washing conditions and quantification of signal intensities were as 
described above for the CpoI methylation analysis.
StAtiSticAl ANAlySeS
Samples showing an incorrect ratio of signal intensities with the p13E-11 hybridization 
were excluded from the analyses; appropriate 4:10 ratios can only be obtained upon full 
digestion. In case of a disomic individual with two 4-type D4Z4 repeats and two 10-type 
D4Z4 repeats the ratio of signal intensities between all bands representing chromosome 
4q and all bands representing chromosome 10q should be 1:1. In monosomic and 
trisomic individuals with respectively one 4-type D4Z4 repeat and three 10-type 
D4Z4 repeats or three 4-type D4Z4 repeats and one 10-type D4Z4 repeat, the correct 
signal intensities are 1:3 and 3:1. In addition, at random samples were spiked with an 
equimolar amount of plasmid DNA containing one D4Z4 repeat to test for complete 
digestion by hybridization with an empty vector probe (Supplemental Figure S2).
Statistical evaluation of the methylation levels between the different groups was done 
by either Mann-Whitney U tests or independent Student’s T-tests. The mean of a data 
set is given as mean ± standard deviation. To determine whether the occurrence of at 
least one repeat on the pathogenic 4qA161 haplotype in FSHD2 patients was not due 
to chance, we compared the frequency of nine possible 4q haplotypes in the 18 FSHD2 
patients with the frequency of the same nine 4q haplotypes in 222 control individuals 
using Pearson Chi-Square test.
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results
For all experiments described in this paper, muscle cell and lymphocyte DNA of control 
individuals and FSHD patients was used. Not all individuals carried a standard allele 
constitution of two 4-type (BlnI-resistant) D4Z4 repeat arrays on chromosome 4q and 
two 10-type (XapI-resistant) D4Z4 repeat arrays on chromosome 10q (Supplemental 
Figure S3A; disomic). Instead, large groups of individuals with either a translocated 
10-type repeat on one chromosome 4q (Supplemental Figure S3B; monosomic) or a 
translocated 4-type repeat on chromosome 10q (Supplemental Figure S3C; trisomic) 
were studied. An important advantage of using DNA material from these individuals 
is that by judicious use of specific restriction enzymes, methylation levels can be 
determined on a single allele (i.e. a single 4-type D4Z4 repeat array on chromosome 4q 
in case of monosomic individuals or a single 10-type D4Z4 repeat array on chromosome 
10q in case of trisomic individuals) without the interference of the methylation level of 
the second allele. We used the restriction enzyme BlnI to digest 10-type repeat units; for 
digestion of 4-type repeat units the restriction enzyme XapI was added. In monosomic 
individuals with a single 4-type repeat on chromosome 4q, the translocated repeat on 
chromosome 4q is composed of both 4- and 10-type repeat units (Supplemental Figure 
S3B) [29]. In trisomic individuals with a single 10-type repeat on chromosome 10q, the 
translocated repeat on chromosome 10q is homogenous, thus consists solely of 4-type 
repeat units (Supplemental Figure S3C) [29-30].
D4Z4 hypomethylAtioN oN chromoSome 4q iN FShD1 pAtieNtS
To confirm previous observations of D4Z4 hypomethylation in patients with FSHD1, 
we analyzed a large group of controls and FSHD1 patients at the CpoI site in the proximal 
D4Z4 repeat unit on chromosome 4q (Figure 1A). For most analyses DNA isolated from 
PBLs was used. As with two other tested previously tested restriction sites [24], FSHD1 
patients displayed significantly lower methylation levels compared with controls (Figure 
2A; P≤0.010). The hypomethylation was most pronounced in monosomic FSHD1 
patients where the methylation status was determined specifically on the contracted 
allele (P<0.001). As FSHD primarily affects skeletal muscle, we also measured 
methylation levels in muscle cell lines, which also showed D4Z4 hypomethylation in 
FSHD1 patients. In addition, differentiation of myoblasts to myotubes did not change 
D4Z4 methylation (Supplemental Figure S4A).
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Next, using the same membranes that were used to determine the CpoI methylation 
level at the proximal D4Z4 unit, but instead performing a hybridization with the D4Z4 
probe [28], we determined the average methylation level of internal D4Z4 repeat units 
on chromosome 4q (Figure 1B). We also observed significant hypomethylation of the 
CpoI site in internal D4Z4 units of disomic FSHD1 patients (Figure 2A; P=0.013). 
However, methylation levels on internal units were 20-25% higher than on the proximal 
unit, which may be explained by the numerical overrepresentation of CpoI sites with a 
high methylation level on the normal-sized allele in FSHD1 patients. Also the results for 
internal units in monosomic FSHD1 patients were much higher than expected (Figure 
2A), but translocated 10-type repeats on chromosome 4q are mixtures of both 4q- and 
10q-derived units [29] and therefore obscure the analysis of internal repeat units in the 
disease allele.
D4Z4 hypomethylAtioN oN chromoSome 4q iN coNtrolS
Since only the 4qA161 haplotype is associated with FSHD [17], we hypothesized that 
D4Z4 hypomethylation may be restricted to this haplotype. The group of controls 
described above included one individual with a 24 kb D4Z4 repeat array on the non-
pathogenic haplotype 4qA166, thus not resulting in FSHD [17]. The methylation level 
at the proximal CpoI site in this individual was very low (33%), similar to the levels 
on disease alleles of FSHD1 patients (Figure 2A). As we were unable to test additional 
controls carrying a single contracted 4-type repeat array on a non-pathogenic haplotype, 
we included disomic FSHD1 patients with two contracted D4Z4 repeats, one on the 
pathogenic 4qA161 allele and one on a non-pathogenic haplotype. The methylation 
levels on proximal and internal units in this group of FSHD1 patients were significantly 
reduced compared to the methylation levels in the group of patients with a single 
contracted allele (Figure 2B; P≤0.033). Thus, we conclude that D4Z4 hypomethylation 
is not restricted to the disease haplotype on chromosome 4q, but also occurs in 
contracted repeats of other 4q haplotypes.
D4Z4 hypomethylAtioN oN chromoSome 10q
Next, we investigated whether D4Z4 contraction-dependent hypomethylation is 
chromosome-specific and studied CpoI methylation in proximal and internal units on 
chromosome 10q. As before, we applied methylation-sensitive Southern blotting, but 
instead of adding the restriction enzyme BlnI to remove 10-type repeats from our assay, 
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Figure 2
Bar diagrams of CpoI methylation analyses in proximal and internal D4Z4 
repeat units on chromosome 4q.
Below each bar an example of a representative gel picture is shown. Below the graphs the number of 
tested individuals per group and the allele constitution of each group are indicated. In monosomic 
individuals the methylation level of a single repeat on chromosome 4q was determined (indicated by 
a single button). In disomic individuals the methylation level of both repeats on chromosome 4q is 
measured simultaneously (indicated by two buttons). A grey button represents a normal-sized (>40 kb) 
repeat, a black button denotes a contracted (<40 kb) repeat. 
A. CpoI methylation on chromosome 4q in PBL DNA from FSHD1 patients, control individuals 
and FSHD2 patients (upper panel: methylation level of proximal D4Z4 repeat unit; lower panel: 
methylation level of internal D4Z4 repeat units). *P<0.05 versus controls with a single 4-type repeat 
(monosomic) and P<0.05 versus controls with two 4-type repeats (disomic). #P<0.05 versus FSHD1 
patients with two 4-type repeats (disomic). Data are presented as mean ± s.d.
B. CpoI methylation on chromosome 4q in PBL DNA from FSHD1 patients with two contracted 
repeats or from FSHD1 patients with one contracted repeat and one normal-sized repeat (upper panel: 
methylation level of proximal D4Z4 repeat unit; lower panel: methylation level of internal D4Z4 
repeat units). *P<0.05. Data are presented as mean ± s.d.
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we added the restriction enzyme XapI which specifically removes 4-type repeats. Next, 
we hybridized each membrane with the p13E-11 probe [6] to determine methylation 
on the proximal repeat unit (Figure 1C) and subsequently with the D4Z4 probe [28] to 
establish methylation at internal repeat units (Figure 1D). We analyzed individuals with 
a standard allele constitution (Supplemental Figure S3A) or with a single 10-type repeat 
on chromosome 10q (Supplemental Figure S3C).
First, we compared CpoI methylation levels between controls and FSHD1 patients. 
No significant differences were observed; not in the proximal unit and not in internal 
units (Figure 3A). Also, methylation levels in muscle cell lines of controls and FSHD1 
patients were comparable (Supplemental Figure S4B). Second, to mimic the situation 
on chromosome 4q, we looked at CpoI methylation on chromosome 10q by dividing 
all individuals into four groups; two groups containing individuals, both controls and 
FSHD1 patients, with a repeat array smaller than 40 kb and two groups containing 
individuals, both controls and FSHD1 patients, with a repeat array larger than 40 kb. 
Similar to the results on chromosome 4q, a D4Z4 repeat array <40 kb on chromosome 
10q resulted in a significantly lower methylation level at the CpoI site, both in proximal 
and internal units (Figure 3B; P≤0.032). We conclude that D4Z4 methylation is repeat 
size-dependent but does not depend on either the haplotype or the chromosome in 
which it resides, as the presence of a contracted repeat on chromosome 10q also results 
in D4Z4 hypomethylation.
D4Z4 hypomethylAtioN oN chromoSomeS 4q AND 10q:  A threSholD eFFect
Previously, we reported that in the proximal D4Z4 repeat unit FSHD1 patients with 
1-3 residual repeat units show pronounced hypomethylation; FSHD1 patients with 
4-8 residual repeat units show large interindividual variation in hypomethylation. In 
controls, no clear linear relationship between D4Z4 methylation and the repeat length 
was established [31]. However, for these studies only a small group of monosomic FSHD1 
patients with a single 4-type repeat array was available. As disomic FSHD1 patients 
with two contracted repeats on chromosome 4q showed significantly lower D4Z4 
methylation levels than disomic FSHD1 patients with a single contracted repeat (Figure 
2B), we aimed to study disomic individuals grouped for comparable repeat sizes on 
chromosomes 4q or 10q in a more extensive correlation study.
We determined CpoI methylation in disomic individuals with two repeats of 
approximately 30 kb (7 D4Z4 repeat units), 55 kb (14 D4Z4 repeat units), 80 kb 
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Figure 3
bAr DiAgrAmS oF cpoi methylAtioN ANAlySeS iN proXimAl AND iNterNAl D4Z4 repeAt 
uNitS oN chromoSome 10q. 
Below each bar an example of a representative gel picture is shown. Below the graphs the number of tested 
individuals per group and the allele constitution of each group are indicated. In disomic individuals 
the methylation level of both repeats on chromosome 10q is measured simultaneously (indicated by 
two buttons). In trisomic individuals the methylation level of a single repeat on chromosome 10q was 
determined (indicated by a single button). A grey button represents a normal-sized (>40 kb) repeat, a 
black button denotes a contracted (<40 kb) repeat. 
A. CpoI methylation on chromosome 10q in PBL DNA from FSHD1 patients and control individuals 
(upper panel: methylation level of proximal D4Z4 repeat unit; lower panel: methylation level of 
internal D4Z4 repeat units). Data are presented as mean ± s.d. 
B. CpoI methylation on chromosome 10q in PBL DNA from individuals with one repeat <40 kb (1-
10 units) and one repeat >40 kb (≥11 units), in individuals with two repeats >40 kb (≥11 units) 
and in FSHD2 patients (upper panel: methylation level of proximal D4Z4 repeat unit; lower panel: 
methylation level of internal D4Z4 repeat units). *P<0.05 versus individuals with a single 10-type 
repeat >40 kb (trisomic) and P<0.05 versus individuals with two 10-type repeats >40 kb (disomic). 
#P<0.05 versus individuals with one 10-type repeat <40 kb and one 10-type repeat >40 kb 
(disomic). Data are presented as mean ± s.d.
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(22 D4Z4 repeat units) or 105 kb (30 D4Z4 repeat units) on chromosomes 4q or 
10q (Figure 4). Both on proximal and internal units on chromosomes 4q and 10q, 
methylation was significantly lower in the 30 kb group (P≤0.024), while in the 55 kb 
group methylation levels reached levels comparable to those observed in the 80 kb 
and 105 kb groups. This absence of a linear relationship between repeat size and DNA 
methylation was not an artifact of DNA saturation in the Southern blot procedure, as in 
serial dilutions of four DNA samples we found similar methylation levels in the range 
of 1.25 to 5 μg of genomic DNA (data not shown). Thus, our results suggest a clear 
reduction in D4Z4 methylation below a certain threshold of repeat units, while above 
this threshold methylation levels are overall not strongly influenced by repeat size.
hypomethylAtioN iS reStricteD to the D4Z4 repeAt oN chromoSomeS 4q AND 10q
In a subset of control individuals and FSHD1 patients we also tested the methylation-
sensitive SmaI restriction site immediately proximal to D4Z4 (Supplemental Figure 
S1). No differences in DNA methylation were observed between FSHD1 patients 
and controls, not on chromosome 4q and not on chromosome 10q (Figure 5). Thus, 
hypomethylation of the FSHD locus seems to be restricted to the D4Z4 repeat.
Figure 4
A threshold effect for DNA methylation at the D4Z4 repeat array. 
CpoI methylation levels on chromosomes 4q and 10q in PBL DNA from individuals with homozygous 
30 kb (7 units), 55 kb (14 units), 80 kb (22 units) or 105 kb (30 units) D4Z4 repeats. *P<0.05 
versus all groups. Data are presented as mean ± s.d.
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D4Z4 hypomethylAtioN oN chromoSomeS 4q AND 10q iN FShD2 pAtieNtS
In addition to FSHD1, a subset of patients with FSHD does not have D4Z4 contractions 
(FSHD2). Currently, we have collected fifteen of those FSHD2 families totaling 19 
patients (Table 1). These patients were assigned as FSHD2 patients when (1) a phenotype 
consistent with FSHD1 was observed, (2) no D4Z4 contraction was identified by pulsed 
field gel electrophoresis (PFGE) and (3) a methylation level of ≤20% was measured at 
the FseI restriction site. The FseI site was previously used to study D4Z4 methylation. 
Methylation levels ≤20% were only detected in a small cohort of FSHD2 patients while 
FSHD1 patients showed on average 33% methylation at the FseI restriction site [24]. 
Some FSHD2 cases have been described before [24, 25], but most of them were collected 
recently. In all of them, we observed significant CpoI hypomethylation in proximal and 
internal units on chromosomes 4q and 10q (Figure 2A, 3A and 3B; P≤0.002). Like in 
FSHD1 patients, the proximal SmaI restriction site showed normal methylation levels 
Figure 5
Hypomethylation is restricted to the D4Z4 repeat array in FSHD. 
Bar diagrams of methylation levels on chromosomes 4q and 10q in the proximal D4Z4 repeat unit 
(CpoI site) and in the region immediately proximal to D4Z4 (SmaI site). Methylation levels were 
determined in PBL DNA from control individuals, FSHD1 patients and FSHD2 patients. Below each 
bar of the SmaI site an example of a representative gel picture is shown. Below the graphs the number 
of tested individuals per group and the allele constitution of each group are indicated. *P<0.05 versus 
control. #P<0.05 versus FSHD1. Data are presented as mean ± s.d.
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in patients with FSHD2 (Figure 5). Importantly, we noticed that all FSHD2 patients 
that met the three criteria stated above carried at least one repeat on the pathogenic 
4qA161 haplotype (Table 1; P=0.005). Only in two potential FSHD2 patients of a large 
family (Table 1; 2.3 & 2.5) no 4qA161 allele was identified. However, in these patients 
also no D4Z4 hypomethylation was observed, suggestive of the possible presence of an 
additional muscular dystrophy in this family. In addition, in one of these two patients 
there was insufficient clinical certainty of FSHD [25].
dIscussIon
Previously, we reported that an epigenetic mechanism, D4Z4 hypomethylation, might 
play a role in the pathogenesis of FSHD. At that time, two CpGs in the proximal D4Z4 
repeat unit on chromosome 4q were investigated and PFGE analysis suggested that the 
methylation level at the proximal repeat unit was representative for the entire repeat 
array [24]. In the present study, we investigated the methylation level at the proximal 
and internal D4Z4 repeat units on chromosomes 4q and 10q in controls and patients 
with FSHD using methylation-sensitive Southern blot analysis. Southern blot-based 
methylation analysis can be applied to a large number of individuals and all additional 
CpGs we tested using this method with the use of other methylation-sensitive restriction 
enzymes showed a similar degree in loss of DNA methylation in FSHD1 patients (Figure 
6A). This proves that Southern blot-based methylation analysis of D4Z4 is a reliable 
and robust method to study DNA methylation changes in this repeat. In contrast, 
bisulphite conversion-based methylation analysis of D4Z4 is very challenging because 
of the dispersion of numerous D4Z4 homologous sequences in the human genome. This 
method would necessitate separation of D4Z4 alleles prior to bisulphite conversion 
precluding the analysis of large cohorts of individuals.
coNtrActioN-DepeNDeNt hypomethylAtioN At D4Z4 iS A geNeric mechANiSm
We demonstrated that contraction-associated hypomethylation is not restricted to 
FSHD1 patients. On the contrary, both on chromosomes 4q and 10q, a repeat <40 kb 
is associated with significant D4Z4 hypomethylation at the CpoI site, irrespective of the 
haplotype of the repeat (Figure 2 and 3). We also observed D4Z4 hypomethylation in 
controls carrying a repeat <40 kb on 4qA166, 4qB163 and 10qA166 haplotypes. This 
suggests that hypomethylation as a consequence of repeat contraction is a common 
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Figure 6
The combination of an epigenetic change in D4Z4 on a 4qA161 haplotype unifies 
FSHD1 and FSHD2.
A. Schematic overview of four methylation-sensitive restriction sites in the D4Z4 repeat array. The 
methylation levels on the BsaAI and FseI restriction sites were reported earlier [24]. The methylation 
levels on the CpoI site are presented in this paper. The methylation levels on the FspI site are unpublished 
results. Compared to control individuals the D4Z4 methylation level on these four sites is on average 
32-44% reduced in FSHD1 patients.
B. D4Z4 contraction-induced chromatin changes are the cause for FSHD1 while a yet unidentified 
factor that affects the D4Z4 chromatin structure causes FSHD2. Importantly, this phenomenon needs 
to occur on the 4qA161 haplotype. Binding of CTCF to the proximal end of the D4Z4 repeat may 
prevent spreading of hypomethylation proximally in patients with FSHD.
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mechanism. A similar mechanism may apply to other macrosatellite repeat arrays with a 
high GC content, like RNU2 [3, 32] and DXZ4 [2, 33]. It will be interesting to determine the 
relationship between repeat length and DNA methylation in these two macrosatellite 
repeats.
D4Z4 repeAt SiZe AND chromoSomAl coNteXt DetermiNe D4Z4 methylAtioN
At the CpoI site, the D4Z4 repeats on chromosomes 4q and 10q behaved mostly in 
a similar fashion, but some discrete differences were noted (Figure 4). First, on 
chromosome 10q the proximal unit was almost similarly methylated as in internal units. 
In contrast on chromosome 4q the proximal unit was clearly less methylated compared 
to internal sites. Second, the sudden decrease in D4Z4 methylation below the threshold 
of 40 kb (11 D4Z4 repeat units) is more prominent on chromosome 4q. Third, while 
methylation levels remained constant above 40 kb on chromosome 4q, a small increase 
in methylation levels, especially when all repeat units were measured simultaneously, 
with increasing D4Z4 repeat length was observed on chromosome 10q. Therefore, we 
hypothesize that not only repeat size, but also chromosomal context, is important for 
D4Z4 methylation. We expect that a contracted repeat on chromosome 4q, irrespective 
of its composition, will show lower methylation levels than a contracted repeat on 
chromosome 10q. This idea is supported by data in a single control individual with a 
contracted 4qA166 repeat. In this individual a very low methylation level was detected, 
comparable to methylation levels in FSHD1 patients with a contracted repeat on the 
pathogenic 4qA161 haplotype and much lower than methylation levels in individuals 
with a contracted 10qA166 repeat. Interestingly, the sequence of the 4qA166 haplotype 
is most similar to the sequence of the 10qA166 haplotype on chromosome 10q 
(unpublished results) [17].
D4Z4 hypomethylAtioN iS NeceSSAry but Not SuFFicieNt For FShD DevelopmeNt
We observed a sudden decrease in D4Z4 methylation below a certain threshold on 
chromosomes 4q and 10q (Figure 4). This steep increase in D4Z4 methylation between 
repeats of 7 units (30 kb) and 14 units (55 kb) may explain the relatively abrupt transition 
from pathogenic D4Z4 repeat sizes (1-10 units) to non-pathogenic D4Z4 repeat 
sizes (≥11 units). However, as D4Z4 hypomethylation was also observed in controls 
with a contracted repeat on a non-pathogenic haplotype, we hypothesize that D4Z4 
hypomethylation is necessary but not sufficient to develop FSHD. Other epigenetic 
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factors or haplotype-specific sequence polymorphisms may eventually determine the 
development of the FSHD phenotype.
D4Z4 hypomethylAtioN iS reStricteD to the D4Z4 repeAt ArrAy
The observed D4Z4 hypomethylation in FSHD1 and FSHD2 patients is restricted to 
the D4Z4 repeat array, as no differences in DNA methylation were observed between 
FSHD patients and controls at the SmaI site immediately proximal to D4Z4 (Figure 
5). This argues against a cis spreading effect from D4Z4 in proximal direction. Also 
analysis of histone modifications in 4qter argues against this disease model for FSHD 
[22]. We propose that the recently identified CTCF binding site at the proximal end 
of the D4Z4 repeat (G. Filippova, personal communication) may prevent spreading 
of hypomethylation in a proximal direction. Also another CTCF binding site in the 
insulator portion of D4Z4 was recently reported on [34]. It will be interesting to study 
the methylation level at these sites in patients with FSHD and control individuals, since 
CTCF binding may be methylation-dependent and CTCF binding prevents propagation 
of DNA methylation [35]. 
Proximal to the D4Z4 repeat array several genes are located of which FSHD region 
gene 1 (FRG1), FSHD region gene 2 (FRG2) and adenine nucleotide translocator 
1 (ANT1) have been proposed to be causally involved based on their transcriptional 
deregulation in FSHD [36]. Interestingly, muscle-specific overexpression of FRG1 in 
transgenic mice leads to a muscular dystrophy phenotype with missplicing of muscle-
specific mRNAs [37]. Increased expression of ANT1 seems to sensitize muscle cells to 
oxidate stress and apoptosis [38]. The absence of FRG2 on the disease alleles in some 
FSHD patients with a proximal deletion makes this gene a less attractive candidate gene 
[39]. However, transcriptional deregulation of these candidate genes in patients with 
FSHD is still under debate, as several studies showed contradictory results [22, 40-43]. 
Based on our data showing that hypomethylation is restricted to the D4Z4 repeat and 
not spreading in a proximal direction in addition to previous data showing no change 
in the chromatin structure of proximal sequences in FSHD [22], we do not support a cis-




FShD1 AND FShD2 ShAre A commoN epigeNetic DiSeASe mechANiSm
FSHD2 patients showed D4Z4 hypomethylation not only on both chromosomes 4 but 
also on both chromosomes 10 (Figure 2 and 3). This argues that FSHD2 is not caused by 
a cis effect on chromosome 4q but that a genetic defect responsible for DNA methylation 
of D4Z4 underlies this condition. In addition, as judged from our methylation studies 
immediately proximal to D4Z4 also in these patients, hypomethylation does no spread 
beyond the D4Z4 repeat, arguing that a similar yet contraction-independent disease 
mechanism is operating in these patients.
Previously, we have sequenced several candidate genes involved in chromatin structure, 
including DNMT1, DNMT3A, DNMT3B, DNMT3L, MTHFS, LMNA, CBX2, CBX5 and 
SUV39H1, in a subset of FSHD2 patients. However, no disease-specific SNPs or 
mutations were identified [25]. Furthermore, the hypomethylation in FSHD2 patients 
seems restricted to D4Z4, as no hypomethylation of other repeats, including satellite 2 
and 3 DNA, α-satellite DNA and the NBL2 repeat, was observed in these patients [25]. 
As judged from the fact that all FSHD2 patients in our collection carry at least one 
pathogenic 4qA161 allele (Table 1), we hypothesize that to develop FSHD a change in 
the chromatin structure of D4Z4 and a 4qA161 allele are required, as was already noted 
in FSHD1 patients, where the D4Z4 contraction is always associated with the 4qA161 
haplotype [17]. Our data are further supported by a study of histone modifications in the 
D4Z4 repeat array.  A loss of the histone modification histone H3 lysine 9 trimethylation 
followed by a secondary loss of the heterochromatin protein 1g and the cohesin complex 
to the D4Z4 repeat array was observed in both FSHD1 and FSHD2 patients [44]. It will 
be crucial to identify 4qA161-specific sequence polymorphisms and show their effect 
on the binding of proteins to the D4Z4 repeat or on the production of transcripts from 
the D4Z4 repeat. Expression of two different transcripts from D4Z4 was reported 
previously [45, 46]. While the first transcript is transcribed from internal repeat units, 
the second transcript is transcribed from the distal D4Z4 repeat unit. Importantly, the 
pLAM sequence distal to the D4Z4 repeat may provide a polyadenylation signal for the 
second transcript and this sequence is only present on 4qA alleles [17, 45]. Recently, new 
evidence was presented on the complex transcriptional activity of the D4Z4 repeat 
[47]. We hypothesize that the observed changes in DNA methylation in both FSHD1 
and FSHD2 patients may affect the transcriptional activity on the 4qA161 haplotype. 
In conclusion, in this study we showed that D4Z4 hypomethylation is not restricted 
to FSHD1 patients. A contracted repeat (<40 kb) on a non-pathogenic haplotype 
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tAble 1
FSHD2 patients have at least one hypomethylated 4qA161 repeat.
Overview of fifteen FSHD2 families consisting of 19 FSHD2 patients with pronounced 
hypomethylation in the proximal D4Z4 repeat unit at the FseI restriction site [24]. Only the 
combination of a 4qA161 allele and D4Z4 hypomethylation results in FSHD. Family 1, 2, 3, 4 
and 5 were described previously [25].
Status 4q repeat (1) 4q repeat (2) FseI methylation
1.1 Control 96 kb 4qA161 173 kb 4qB163 68%
1.2 FSHD2 96 kb 4qA161 170 kb 4qA161 12%
1.3 FSHD2 96 kb 4qA161 170 kb 4qA161 19%
1.4 Control 75 kb 4qB163 170 kb 4qA161 16%
2.1 FSHD2 50 kb 4qA161 90 kb 4qB163 5%
2.2 FSHD2 50 kb 4qA161 135 kb 4qB163 4%
2.3 FSHD? 48 kb 4qB163 90 kb 4qB163 41%
2.4 Control 90 kb 4qB163 128 kb 4qB168 53%
2.5 FSHD? 90 kb 4qB163 130 kb 4qB168 63%
3.1 FSHD2 65 kb 4qA161 110 kb 4qA161 17%
3.2 Control 65 kb 4qA161 75 kb 4qB163 47%
4.1 Control 75 kb 4qA161 160 kb 4qB163 56%
4.2 FSHD2 50 kb 4qA161 70 kb 4qA161 15%
4.3 Control 90 kb 4qB163 160 kb 4qB163 55%
5.1 FSHD2 48 kb 4qA161 120 kb 4qB168 13%
6.1 FSHD2 55 kb 4qA161 70 kb 4qA161 13%
6.2 FSHD2 55 kb 4qA161 60 kb 4qB163 17%
7.1 FSHD2 42 kb 4qA161 65 kb 4qB163 2%
8.1 Control 80 kb 4qA161 95 kb 4qB162 36%
8.2 FSHD2 75 kb 4qA161 80 kb 4qA161 14%
8.3 Control 48 kb 4qA161 80 kb 4qA161 64%
8.4 FSHD2 48 kb 4qA161 95 kb 4qB162 9%
8.5 Control 48 kb 4qA161 75 kb 4qA161 49%
9.1 FSHD2 48 kb 4qA161 205 kb 4qA161 7%
10.1 FSHD2 48 kb 4qA161 100 kb 4qA166 12%
11.1 FSHD2 46 kb 4qA161 128 kb 4qA161 10%
12.1 FSHD2 65 kb 4qA161 160 kb 4qA161 13%
12.2 Control 65 kb 4qA161 160 kb 4qA161 50%
12.3 Control 131 kb 4qA161 160 kb 4qB168 45%
12.4 Control 145 kb 4qB163 160 kb 4qB168 11%
13.1 FSHD2 40 kb 4qA161 155 kb 4qA161 16%
14.1 FSHD2 40 kb 4qA161 100 kb 4qB163 17%
15.1 FSHD2 50 kb 4qA161 147 kb 4qB168 20%
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also results in significantly lower methylation levels. Thus, our results suggest that a 
general mechanism of DNA hypomethylation occurs upon D4Z4 repeat contraction. 
Furthermore, the methylation defect in FSHD2 patients also includes hypomethylation 
on chromosome 10q. A genetic defect in D4Z4 methylation may underlie the disease 
in these patients. Finally, we noted that all FSHD2 patients carried at least one repeat 
on the pathogenic 4qA161 haplotype. Therefore, we conclude that there are two 
different conditions predisposing to the development of FSHD: contraction-dependent 
and contraction-independent epigenetic changes in D4Z4. In both forms of FSHD, the 
resultant D4Z4 hypomethylation needs to occur on the 4qA161 haplotype (Figure 6B). 
This commonality will facilitate and guide the identification of the molecular basis for 
FSHD. 
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SupplemeNtAl Figure S1
Schematic overview of the SmaI methylation analysis on chromosomes 4q and 10q. 
Genomic DNA was digested with BseMI to separate D4Z4 repeat units on chromosome 4q from 
those on chromosome 10q. Subsequently, DNA was digested with the methylation-sensitive restriction 
enzyme SmaI. Lines represent the different fragment sizes obtained after digestion, Southern blotting 
and visualization by hybridization with the p13E-11 probe (indicated with black box). Besides the 
schematic overview a final gel picture showing three DNA samples as examples is depicted.
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Supplemental Figure S2
Control experiment to confirm complete digestion by the methylation-sensitive 
restriction enzyme CpoI.
A. At random, samples were spiked with an equimolar amount of plasmid DNA (pBluescript vector 
containing a single D4Z4 KpnI repeat unit) to test for complete digestion by CpoI. Complete digestion 
of the plasmid DNA gives a single ~5 kb band after hybridization with the empty pBluescript vector, 
while a second band of ~6 kb appears in case of incomplete digestion.
B. An example of the control experiment to confirm complete digestion. First, complete digestion 
was verified by hybridization using the empty pBluescript vector as a probe (left panel). Second, the 
methylation levels at the CpoI site were determined after hybridization of the same membrane with 
the p13E-11 probe (right panel). In the right panel, the band obtained after hybridization with the 




Schematic overview of the allele constitution on chromosomes 4q and 10q in DNA 
of all individuals tested. 
A. A disomic individual has a standard allele constitution; two 4-type repeat arrays on chromosome 
4q and two 10-type repeat arrays on chromosome 10q. 
B. A monosomic individual has a single 4-type repeat on chromosome 4q. The most proximal units of 
the second chromosome 4q allele are 10-derived repeat units. In monosomic individuals the methylation 
level of a single repeat on chromosome 4q can be measured. 
C. A trisomic individual has a single 10-type repeat on chromosome 10q. The second chromosome 10q 
allele is composed of only 4-type repeat units. In trisomic individuals the methylation status of a single 
repeat on chromosome 10q can be determined.
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SupplemeNtAl Figure S4
Bar diagrams of CpoI methylation analysis in DNA isolated from muscle cell 
lines.
A. CpoI methylation levels on chromosome 4q in myoblasts and myotubes from two controls and 
two FSHD1 patients on proximal (upper panel) and internal (lower panel) D4Z4 repeat units. 
Methylation data of individual cell lines are shown. 
B. CpoI methylation levels on chromosome 10q in myoblasts and myotubes from two controls and 
two FSHD1 patients on proximal (upper panel) and internal (lower panel) D4Z4 repeat units. 
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no eFFect oF FolIc acId and methIonIne 
supplementatIon on d4Z4 methylatIon 
In patIents wIth FacIoscapulohumeral 
muscular dystrophy




Facioscapulohumeral muscular dystrophy (FSHD) is associated with a contraction of the 
D4Z4 allele on chromosome 4qter. There is also marked DNA hypomethylation of the 
D4Z4 allele. The DNA hypomethylation may have a central role in the pathogenesis of 
FSHD. Supplemental folic acid can boost DNA methylation. We evaluated the effect of 
oral folic acid and methionine supplementation on the methylation level of 4qter D4Z4 
alleles in peripheral blood lymphocytes of nine patients affected with FSHD and six 
healthy controls. Methylation levels did not change, while recommended serum folate 
concentrations were reached.
IntroductIon
Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) is associated with 
contraction of the polymorphic D4Z4 repeat array on chromosome 4qter. In healthy 
individuals, D4Z4 consists of 11–100 units on both chromosomes, whereas individuals 
with FSHD carry one 4q array of 1–10 units (4q-linked FSHD). This contraction is 
associated with marked hypomethylation of the shortened D4Z4 allele. About 5% of 
individuals with phenotypic FSHD do not have a contraction of D4Z4 on chromosome 
4q. However, both their D4Z4 alleles show hypomethylation. These findings suggest a 
central role of D4Z4 hypomethylation in the pathogenesis of FSHD [1].
Chromatin of eukaryotic organisms can roughly be divided into relatively hypomethylated 
euchromatin and highly methylated heterochromatin. In general, euchromatin has an 
open chromatin structure and is associated with active DNA transcription. In contrast, 
heterochromatin tends to be tightly packed and is associated with transcriptional 
inactivity or repression. DNA methylation comprises the addition of a methyl group to 
the carbon 5 position of cytosine within the so-called CpG dinucleotides. Approximately 
70–80% of all CpG dinucleotides are methylated, except for dense CpG clusters, 
termed CpG islands, which are often located in or near promoter or coding sequences. 
The chromatin structure of these hypomethylated CpG islands is open, which makes 
the DNA sequence accessible for transcription. The CpG islands not associated with 
promoting or coding sequences, i.e., transcriptional silent sequences, are often 
methylated. Therefore, the level of DNA methylation has an important function in these 
interrelated processes of chromatin structure modulation, transcriptional regulation and 
gene silencing. The three best-characterized genetic diseases caused by impaired DNA 
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methylation-dependent gene control pathways are ICF, Rett and fragile X syndromes 
[2]. Changes in levels and patterns of DNA methylation also have an important role in 
oncogenesis [3].
In healthy individuals, the chromatin structure of the D4Z4 region on chromosome 4q35 
is highly methylated, and resembles that of heterochromatin or transcriptional inactive 
euchromatin [4-6]. A currently favored hypothesis is that the marked hypomethylation 
of the D4Z4 region in FSHD might cause a change in the chromatin structure, and 
consequently a transcriptional deregulation of one or more genes in the vicinity, or at a 
distance of the D4Z4 repeat array [1, 6].
As DNA methylation and demethylation are reversible processes, DNA methylation 
levels and patterns can potentially be influenced [2]. Folic acid and vitamin B12 are 
essential for the synthesis of methionine and S-adenosyl methionine (SAM), the 
common methyl donor required for the maintenance of DNA methylation. When 
the concentration of folic acid, vitamin B12 and methionine is low, SAM synthesis is 
reduced, leading to a reduced methylation of DNA [7]. Optimal micronutrient levels 
and dietary requirements for DNA functioning and maintenance are not yet known. 
Intervention studies in humans taking folic acid and/or vitamin B12 supplements 
show that DNA hypomethylation, chromosome breaks and uracil misincorporation are 
minimized when serum concentration of folate is higher than 34 nmol/l, and serum 
vitamin B12 concentration is higher than 300 pmol/l. These concentrations can only 
be achieved at intake levels of more than 400 μg folic acid and more than 2 μg vitamin 
B12 per day [3, 8].
We performed a pilot study to evaluate the effect of supplemental folic acid and 
methionine on the methylation level of D4Z4 alleles on chromosome 4qter in 
peripheral blood lymphocytes (PBLs) of patients with FSHD (both 4q-linked FSHD and 
phenotypic FSHD) and in healthy controls in order to decide whether a larger clinical 
trial might be warranted.
materIal	and	methods
SubjectS
We recruited a convenient sample of six patients clinically affected with 4q-linked 
FSHD and one young, asymptomatic patient, all with proven contraction and 
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hypomethylation of D4Z4 at 4q35 (in PBLs). We also included two clinically affected 
sibs from a known phenotypic FSHD family without a contraction of D4Z4, but with 
proven hypomethylation of the repeat array. A convenient sample of five non-affected, 
first-degree relatives and one spouse served as controls. Patients and controls were 
between 18 and 60 years. Exclusion criteria were: serum vitamin B12 < 160 pmol/l; 
use of folic acid, vitamin B12 or multivitamin supplements during the last 6 months; 
cardiovascular disease or more than two cardiovascular risk factors (e.g., hypertension, 
diabetes mellitus, smoking); pregnancy or breastfeeding. The local ethics committee 
approved the study. Informed consent was obtained from all subjects involved in the 
study.
DeSigN
After the baseline visit subjects started using folic acid (5 mg, orally, once daily) and 
methionine (1 g, orally, three times a day) until after the final visit at 12 weeks. The 
baseline visit consisted of a general medical history and physical examination to verify 
eligibility, obtain anthropometrical measures, including blood pressure and pulse rate 
and a clinical severity score. Venous blood samples were taken to measure methylation 
levels of D4Z4 alleles and total DNA in PBLs, and concentrations of serum folate, 
serum vitamin B12 and plasma homocysteine. The final visit consisted of an event 
history (including side effects), anthropometrics and drawing of blood samples.
outcome meASureS; cliNicAl Severity Score
As an indication of disease severity, all subjects were scored according to the 10-grade 
Clinical Severity Scale (CSS) formulated by Ricci et al [9]. The original score ranged from 
1 indicating only facial weakness to 10 for wheelchair bound patients. We added score 0 
for clinically unaffected patients and healthy controls.
outcome meASureS; DNA methylAtioN At D4Z4
Our primary outcome measure was the DNA methylation level of the D4Z4 alleles on 
4qter in PBLs. The methylation level of two CpG methylation-sensitive restriction sites 
(BsaAI and FseI) in the first (proximal) unit of the D4Z4 repeat array on chromosome 
4q35 was determined, as described previously [1]. As shown earlier, these results are 
representative of the entire array [1].
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outcome meASureS; totAl DNA methylAtioN
A nonisotopic cytosine extension assay was used to estimate CpG island methylation of 
the whole genome [10].
outcome meASureS; Serum FolAte level
Serum folate concentration was measured using a competitive immunoassay (DPC 
Immulite 2000 system).
outcome meASureS; Serum vitAmiN b12 level
Serum vitamin B12 concentration was measured using a solid-phase, competitive 
chemiluminescent enzyme immunoassay involving an automated alkaline denaturation 
procedure (DPC Immulite 2000 system).
outcome meASureS; plASmA homocySteiNe level
To check for unintended rises of plasma homocysteine due to methionine loading 
total, non-fasting homocysteine concentration was measured in EDTA plasma by 
automated high-performance liquid chromatography with reverse-phase separation and 
fluorescent detection (Gilson 232-401 sample processor, Spectra-Physics 8800 solvent-
delivery system, Spectra-Physics LC 304 fluorometer). We used the method described 
by Fiskerstrand et al. with some modifications [11].
outcome meASureS; StAtiSticAl ANAlySiS
Independent-sample t tests or Mann-Whitney U tests were used to test for equality 
between the patient and control group at baseline (P=0.05). To test for statistical 
differences in outcome measures before and after treatment, paired-sample t tests or 





Baseline characteristics are presented in Table 1. CSS scores of the 4q-linked FSHD 
patients were 0, 4, 5, 8, 10, 10 and 10. The CSS scores of the two phenotypic FSHD sibs 
were 6 and 7. All controls scored zero. Residual D4Z4 fragment sizes of the 4q-linked 
FSHD patients were 2, 3, 3, 5, 6, 6 and 7 units. All subjects completed the study.
bASeliNe vAlueS
Baseline values of outcome measures are presented in Table 2. As expected, the 
methylation level of the two CpG sites was significantly lower in patients as compared 
to controls (BsaAI, P=0.003; FseI, P=0.001). Serum folate levels of all subjects were 
below the recommended 34 nmol/l needed to minimize DNA hypomethylation [3, 8]. 
Four patients and five controls had vitamin B12 values below the recommended 300 
pmol/l [3, 8]. Mean vitamin B12 concentration was significantly higher for patients 
than for controls (P=0.036). Homocysteine levels were within normal range for all 
subjects.
outcomeS
Study medication was well tolerated; no side effects were reported. There were 
no significant changes in the methylation levels of BsaAI and FseI in both patients 
and controls between the baseline and final visit (Table 2). Total DNA methylation 
level increased in five patients and four controls, did not change in two patients and 
one control, and decreased in one patient. Total DNA methylation assay failed in 
tAble 1
Baseline characteristics of patients and controls involved in the study. 
Values are mean ± 1 SD.
FSHD (n=9) Control (n=6)
Female/male (n) 4/5 2/4
Age (years) 43 ± 16 50 ± 18
Length (cm) 172 ± 16 172 ± 10
Weight (kg) 76 ± 20 89 ± 12
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two subjects. Serum folate levels rose significantly, and all individual levels reached 
above the recommended 34 nmol/l. For both groups, mean values for vitamin B12 
and homocysteine, weight, blood pressure and pulse rate did not show significant 
changes.
dIscussIon
Despite the fact that the recommended serum folate level to minimize DNA 
hypomethylation was reached in all subjects and total DNA methylation levels increased 
in the majority of subjects, our pilot study did not show effect of supplemental folic acid 
and methionine on the methylation level of 4qter D4Z4 alleles in PBLs of patients with 
FSHD and controls. Several in vivo folate depletion and repletion studies with similar 
dosing regimens had shown positive effects on genomic DNA methylation and the 
expression of methylation-regulated genes in PBLs and several body tissues [3, 7, 12]. Other 
studies indicate that the effect of folate status on DNA methylation is more complex, 
highly dose-dependent, and, of importance, even tissue-specific [13]. The absence of any 
noticeable effect in both patients and controls might be caused by a relatively low folic 
acid dose to change D4Z4 methylation. It can also implicate a, maybe even heritable, 
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BsaAI methylation level (%)
FseI methylation level (%)
Serum folate level (nmol/l)
Serum vitamin B12 level (pmol/l)






















D4Z4 DNA methylation, serum folate, serum vitamin B12 and plasma 
homocysteine levels before and after supplementation.
Values are mean ± 1 SD. a Statistical differences (P<0.05) between the patient and control group at 
baseline. b Statistical differences (P<0.05) before and after treatment.
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present, there is insufficient ground for a larger clinical study on folic acid supplements 
in FSHD. We are considering a second pilot study on the effects of supplemental folic 
acid, combined with supplemental vitamin B12, on DNA hypomethylation and allelic 
expression in PBLs and in skeletal muscle cells.
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More than fifteen years ago, facioscapulohumeral muscular dystrophy (FSHD) was 
linked to D4Z4 repeat array contractions in the subtelomere of chromosome 4q [1-3]. 
Since then, several putative candidate genes in the 4q35 region have been identified, 
including ANT1, FRG1, FRG2 and DUX4 [4-8]. Because of lack of consistent evidence of 
transcriptional deregulation of these candidate genes in patients with FSHD [9-13], other 
disease mechanisms have been postulated. One of these includes an epigenetic disease 
mechanism, which was supported by observation of D4Z4 hypomethylation at two 
CpG dinucleotides within the D4Z4 repeat array [14]. However, the existence of D4Z4 
hypomethylation in patients with an unrelated syndrome, namely the immunodeficiency, 
centromeric instability and facial anomalies (ICF) syndrome [15], and without muscle 
pathology, challenged a causal role for D4Z4 hypomethylation in FSHD [14]. 
In this thesis, the epigenetic disease mechanism was further scrutinized. Additional 
epigenetic factors, some of which potentially discriminating between FSHD and ICF, 
were identified (Chapters 2 and 3). Next, the necessity of a more open chromatin 
structure at D4Z4, although alone insufficient to develop disease, was underscored 
(Chapter 4). Finally, a small intervention pilot study focusing on closing the chromatin 
structure at D4Z4 by folic acid and methionine supplementation was performed 
(Chapter 5).
2	 hypomethylatIon	Is	restrIcted	to	the	d4Z4	repeat	array	In	Fshd2
To understand the epigenetic similarities between two unrelated disorders, i.e. the 
muscular dystrophy FSHD and the primary immunodeficiency ICF, and to further 
determine whether D4Z4 hypomethylation is causally related to development of FSHD, 
in Chapter 2 a study is presented that searched for commonalities and differences 
between the two disorders. The DNA methylation level of non-D4Z4 repeat arrays [15, 
16], the tendency of mitogen-stimulated lymphocytes to present with pericentromeric 
abnormalities [17] and the levels of the immunoglobulins IgA, IgG and IgM [17], all features 
of ICF syndrome, were analyzed in several FSHD2 cases without D4Z4 contraction. 
As FSHD2 patients, unlike FSHD1 patients but similar to ICF patients, show D4Z4 
hypomethylation at both chromosome 4q alleles [14], a defect in a pathway similar to that 
of ICF syndrome was predicted. However, no commonalities were identified between 
FSHD2 patients and ICF patients other than the earlier reported D4Z4 hypomethylation 
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[14]. While several repeat arrays including D4Z4 are hypomethylated in ICF patients [15, 16, 
18], in FSHD2 lower DNA methylation levels seem to be restricted to D4Z4. In addition, 
no ICF-like symptoms such as low immunoglobulin levels and radial chromosome 




In Chapter 3, loss or gain of other epigenetic factors in patients with FSHD are 
described. The presence of several histone modifications at the D4Z4 repeat array 
was studied by chromatin immunoprecipitation (ChIP). Four of the six histone 
modifications six studied could be identified at D4Z4; trimethylation of histone H3 at 
lysine 9 (H3K9me3) and lysine 27 (H3K27me3), both repressive chromatin marks [19], 
and dimethylation of histone H3 at lysine 4 (H3K4me2) and acetylation of histone H3 
(H3Ac), both associated with a more permissive chromatin structure [20]. One of these 
histone modifications, H3K9me3, was specifically lost at D4Z4 in patients with FSHD, 
both in FSHD1 and FSHD2 patients. Importantly, loss of H3K9me3 was not observed 
to the same extent in ICF patients. In addition, control cells treated with 5-azacytidine, 
a demethylating agent, also showed high levels of H3K9me3 at D4Z4, suggesting that 
H3K9me3 may be upstream of DNA methylation at D4Z4. 
Also in Chapter 3, evidence is presented that heterochromatin protein 1 g (HP1g) 
and cohesin binding to the D4Z4 repeat array is lost in patients with FSHD. Most 
importantly, no HP1g/cohesin binding to D4Z4 was observed in lymphoblastoid cell 
lines; neither in FSHD patients nor in control individuals who have high H3K9me3 
levels at D4Z4. These results cells suggest that a possible tissue-specific component is 
involved in the binding of HP1g/cohesin to D4Z4, as these two proteins do bind to 
D4Z4 in fibroblasts and myoblasts. 
4	 common	 epIGenetIc	 chanGes	 oF	 d4Z4	 In	 contractIon-dependent	
	 and	contractIon-Independent	Fshd
In FSHD1 patients, loss of DNA methylation seems to be restricted to the contracted 
allele. In FSHD2 patients, D4Z4 hypomethylation seems much more pronounced, 
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which can be explained by loss of DNA methylation on both chromosome 4q alleles 
[14]. We therefore hypothesized that a gene defect responsible for the occurrence of the 
D4Z4 hypomethylation is causally underlying FSHD2. In FSHD1, the contraction of 
the D4Z4 repeat array may precede the D4Z4 hypomethyation. Interestingly, patients 
with FSHD1 always carry a contracted repeat array in association with the 4qA161 
haplotype. Haplotype-specific sequence variations may therefore determine why only 
a contracted repeat on this specific haplotype results in disease [21]. Alternatively, there 
may be a different epigenetic response to D4Z4 contractions in the different haplotypes. 
Therefore, an important question to answer was whether D4Z4 hypomethylation of 
contracted repeats is restricted to the 4qA161 haplotype. Also other important questions 
on the role of D4Z4 hypomethylation in FSHD pathogenesis had remained unanswered 
for some years, including the methylation levels of D4Z4 on chromosome 10q and the 
exact relationship between D4Z4 repeat length and D4Z4 methylation.
In Chapter 4, the results of an extensive DNA methylation study, both on chromosomes 
4q and 10q, is presented. The results clearly show that D4Z4 hypomethylation is not 
4qA161-specific or FSHD-specific. Individuals carrying a contracted repeat on a non-
pathogenic 4qA166, 4qB163 or 10qA166 haplotype also presented with a significant 
loss of DNA methylation at D4Z4. These results suggest that D4Z4 hypomethylation is 
necessary, but not sufficient, to develop FSHD; other epigenetic factors, like H3K9me3, 
may be important. Another possibility, not necessarily mutually exclusive, is that 
sequence variations determine the development of FSHD, while a change in chromatin 
structure, as evidenced by D4Z4 hypomethylation, facilitates the function of these 
sequence variations. Next, we reported in Chapter 4 that the methylation defect in 
FSHD2 patients extends to chromosome 10q; a chromatin modifier responsible for D4Z4 
methylation on chromosomes 4q and 10q may therefore be defective in these patients. 
Importantly, all FSHD2 patients carry a 4qA161-type D4Z4 repeat array, unifying 
FSHD1 and FSHD2 since all FSHD1 patients carry a contracted D4Z4 repeat array 
in association with the 4qA161 haplotype [21]. Further, no linear relationship between 
D4Z4 repeat length and D4Z4 methylation was detected; neither on chromosome 4q 
nor on chromosome 10q. However, a threshold effect was observed that may explain 
the abrupt transition from pathogenic to non-pathogenic repeat arrays; below 40 kb 
a significant drop in D4Z4 methylation was observed. Finally, we showed that D4Z4 
hypomethylation is restricted to this repeat array, as similar methylation levels were 
observed between controls and patients with FSHD at the proximal SmaI restriction site.
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5	 no	 eFFect	 oF	 FolIc	 acId	 and	 methIone	 supplementatIon	 on	 d4Z4	
	 methylatIon	In	patIents	wIth	Fshd
The chromatin structure of the D4Z4 repeat array is changed in FSHD patients; 
loss of DNA methylation and H3K9me3 followed by loss of HP1g/cohesin binding 
is observed. Therefore, we aimed at closing the chromatin structure of the D4Z4 
repeat array. A rather simple method to affect chromatin structure of D4Z4 is through 
elevation of the DNA methylation levels, as DNA methylation is a reversible process [22]. 
DNA methylation levels may be influenced by supplementation with folic acid, which 
is important for the synthesis of S-adenosylmethionine (SAM), the common methyl 
donor needed for DNA methylation maintenance [23].
In Chapter 5, data of a pilot study performed in a small group of FSHD patients, both 
FSHD1 and FSHD2, and in unaffected family members is presented. Supplementation 
for three months with folic acid (5 mg, daily) and methionine (1 g, three times a 
day) was performed. Outcome measures of this study were clinical severity score 
determined by the Ricci score [24], DNA methylation at the D4Z4 repeat array and 
total DNA methylation levels, serum folate levels, serum vitamin B12 levels and plasma 
homocysteine levels. Although serum folate levels rose significantly and genome-wide 
DNA methylation levels increased in most subjects, no significant change in DNA 
methylation at D4Z4 was observed, neither in controls nor in FSHD patients.
6	 recent	advances	In	epIGenetIc	Fshd	research	
Several other groups have also focused on a possible epigenetic role in the pathogenesis 
of FSHD. I will now discuss some of the recent advances that were made in this field.
6.1 A NucleAr mAtriX AttAchmeNt Site proXimAl to the D4Z4 repeAt ArrAy
Besides DNA methylation and histone modifications, the organization of DNA into loop 
domains may contribute to the chromatin structure of a region and thus may have an 
effect on transcriptional regulation [25]. These loop domains are anchored to the nuclear 
matrix via specific sequences, the scaffold/matrix-associated regions (S/MAR regions) 
[26]. Recently, Petrov et al reported the presence of three S/MAR sites in the vicinity 
of D4Z4. One of these sites was immediately upstream of D4Z4, between the FSHD 
candidate genes FRG1 and FRG2; the other two sites were located proximal to FRG1 and 
distal to D4Z4. It was hypothesized that the former S/MAR site separates the FSHD 
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candidate genes from the D4Z4 repeat array into two distinct DNA loop domains. 
Interestingly, in myoblasts from FSHD patients, dissociation of this S/MAR from the 
nuclear matrix seems to occur. As a consequence, the upstream candidate genes and the 
D4Z4 repeat array are residing in a single loop domain in patients with FSHD [27]. Since 
the 5’ end of the D4Z4 repeat array was reported to contain a strong transcriptional 
enhancer, this may affect the transcriptional regulation of FRG1 and FRG2 in patients 
with FSHD [28]. However, there is still debate on the transcriptional deregulation of 
FRG1 and FRG2 in FSHD [9-13]. Furthermore, part of the D4Z4 repeat array seems to 
function as a transcriptional repressor; the D4Z4 binding element (DBE) that binds 
the transcriptional repressor complex YY1-HMGB2-nucleolin [9]. In addition, when 
myoblasts were transfected with an increasing number of D4Z4 repeat units preceding 
the FRG2 promoter in a luciferase reporter assay, luciferase activity initially increased 
with one D4Z4 repeat unit, but subsequently decreased with the addition of extra D4Z4 
repeat units. This suggests that D4Z4 may act as a transcriptional activator or repressor 
depending on the context [7]. It is thus unclear what the exact effect on transcription 
will be if FRG1 and FRG2 reside in the same DNA loop. Finally, as changes in DNA 
methylation seem restricted to the D4Z4 repeat array in FSHD (no hypomethylation was 
observed on the proximal SmaI restriction site which is located in the S/MAR sequence 
in FSHD patients (Chapter 4)), it is yet unclear why the loop domain organization in 
patients with FSHD is lost. The methyl-binding protein MeCP2 has been implicated in 
loop domain organization [29]. Although no changes in DNA methylation were observed 
between controls and FSHD patients at the S/MAR site, it will be interesting to study 
binding of MeCP2 and other proteins that mediate specific association of DNA with the 
nuclear matrix in myoblasts of controls and patients with FSHD.
6.2 DNA methylAtioN AND chromAtiN DNASei SeNSitivity; A role For the iNSulAtor 
 proteiN ctcF At D4Z4
We have described that D4Z4 contraction results in significant D4Z4 hypomethylation. 
This hypomethylation occurs irrespective of the chromosomal background of the 
contracted repeat array and the hypomethylation is restricted to the D4Z4 repeat 
array. Recently, Tsumagari et al also performed a thorough DNA methylation analysis 
of the D4Z4 repeat array using cancer tissues that normally present with high DNA 
methylation throughout the D4Z4 repeat array. Additionally, they performed chromatin 
DNaseI sensitivity assays in and adjacent to the D4Z4 repeat array. They identified a 2 
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kb region in the proximal D4Z4 repeat unit that seems resistant to DNA methylation 
and shows differential DNaseI accessibility compared to the remainder of the repeat 
array. Therefore, they hypothesized the presence of a boundary element at the junction 
of D4Z4 and the AT-rich p13E-11 region [30]. This boundary element may represent the 
recently identified CTCF binding site at the proximal end of the D4Z4 repeat array. 
CTCF may function as an insulator at this site and prevent spreading of hypomethylation 
in a proximal direction. Interestingly, increased CTCF binding at this site was observed 
in patients with FSHD (G. Filippova, personal communication). Our recent results on 
the methylation level of the BstBI restriction site in the p13E-11 region, located ~200 
bp from the proximal D4Z4 repeat unit, support these findings. We observed high 
methylation levels at the BstBI restriction site and, unlike the significant hypomethylation 
in the proximal D4Z4 repeat unit in FSHD patients, no differences in DNA methylation 
were observed between controls and FSHD patients (unpublished results). Thus, the 
enriched binding of CTCF in patients with FSHD may indeed prevent the spreading of 
the D4Z4 hypomethylation towards the p13E-11 region.
6.3 the three-DimeNSioNAl Structure oF the 4q Subtelomeric regioN
To determine the spatial proximity of genes of the 4q subtelomeric region and the 
D4Z4 repeat array and thus to further explore the higher order chromatin structure of 
the region, Pirozhkova et al performed chromatin conformation capture (3C) assays. 
This technique evaluates the spatial proximity of two genomic fragments based upon 
their tendency to become crosslinked in vivo [31, 32]. Using this technique it was shown 
that in normal myoblasts the distal part of the FRG1 and FRG2 promoters interact; 
this interaction was lost in myoblasts derived from a FSHD patient. Furthermore, they 
showed that in normal myoblasts the inverted D4Z4 repeat DUX4c interacts strongly 
with the distal part of the FRG1 promoter and that there is also an interaction, albeit 
to a lower extent, with the FRG2 promoter and with the subtelomeric region proximal 
to the 4qA/4qB marker. Interestingly, in FSHD myoblasts novel interactions between 
both the proximal and the distal part of the FRG1 promoter and the 4qA/4qB marker 
and between the ANT1 promoter and the 4qA/4qB marker were identified. Finally, 
they showed that in normal myoblasts the D4Z4 repeat array interacts with the region 
proximal to DUX4c. 
In conclusion, the 4qA/4qB marker seems to have a very important role in FSHD, 
as multiple novel interactions with this region were identified in myoblasts derived 
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from an FSHD patient. This hypothesis is further supported by the observation that the 
4qA allele contains a transcriptional enhancer [33]. However, recently several additional 
4q haplotypes, both of the 4qA-type and the 4qB-type, were identified [21]. It will be 
important to test whether non-pathogenic 4qA haplotypes and non-pathogenic 4qB 
haplotypes do not act as transcriptional enhancers. Furthermore, additional 3C assays 
studying myoblasts from control individuals carrying a short D4Z4 repeat array on 
either a non-pathogenic 4q haplotype or on chromosome 10 will be necessary. The 
experiments described in this thesis suggest that changes in chromatin structure are not 
restricted to patients with FSHD; D4Z4 hypomethylation was also observed in controls 
with a short repeat on a non-pathogenic haplotype (Chapter 4).
7	 an	InteGratIve	model	For	Fshd	pathoGenesIs
Although the D4Z4 repeat contraction in patients with FSHD was discovered more 
than 15 years ago, the exact molecular mechanism causing FSHD still remains elusive. 
It seems unlikely that a single candidate gene is responsible for the development of 
FSHD. Probably, a complex epigenetic disease mechanism involving the deregulation 
of multiple genes, both in cis and in trans, underlies its pathogenesis. One of the major 
challenges for future FSHD research will be to integrate all thus far reported disease 
mechanisms into a unifying model and to obtain consistent evidence supporting this 
model. 
I hypothesize that the D4Z4 repeat array and its chromatin structure will be central 
in such a model, because every patient with FSHD shows genetic and/or epigenetic 
changes at this repeat array. Most importantly, all FSHD patients carry a hypomethylated 
4qA161-type repeat array. I propose that in control individuals the D4Z4 repeat 
array is packaged in a relatively closed chromatin structure, probably as facultative 
heterochromatin. In patients with FSHD, this chromatin structure is more open. As 
a consequence, proteins may bind to D4Z4, influencing the regulation of candidate 
genes and the interaction with the nuclear envelope (Figure 1). Sequence variations 
residing within or close to the D4Z4 repeat array may be important for binding of such 
proteins and thus determine why FSHD is specifically linked to the 4qA161 haplotype 
[21]. Alternatively, the open chromatin structure facilitates only steady state expression 
levels of D4Z4 transcripts in the presence of critical SNPs in the 4qA161 haplotype.




An integrative model for FSHD pathogenesis.
A. In control individuals the D4Z4 repeat array is organized as facultative heterochromatin. In 
patients with FSHD1 only below 11 D4Z4 repeat units, a more open chromatin structure is induced. 
Below this threshold insufficient levels of a protein (complex) responsible for H3K9me3 and D4Z4 
methylation or a presently unidentified chromatin modifier (complex) may be present at D4Z4. In 
patients with FSHD2, changes in chromatin structure may occur because of a yet unidentified gene 
defect responsible for the epigeneticmodifications in D4Z4. Therefore, a more open chromatin structure 
is present in these patients even above the critical threshold of 10 D4Z4 repeat units. Because of the 
more open chromatin structure in patients with FSHD, binding of protein(s) to D4Z4 that normally 
do not bind may occur. This will most likely occur either proximal or distal to D4Z4 or to a critical 
D4Z4 element, since the amount of repeat units with an open chromatin structure differs significantly 
between FSHD1 and FSHD2 patients, while their phenotypes are highly similar. In addition, specific 
SNPs discriminating between the different haplotypes may be important for the binding of these 
proteins.
B. When the chromatin structure is in a more open conformation, candidate genes may be deregulated 
in cis (upper panel) and the interaction with the nuclear envelope may be disturbed (lower panel).
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more than 10 D4Z4 repeat units still present the chromatin structure is kept in a 
closed state, for example because of a sufficient level of binding of proteins that attract 
SUV39H1, the histone methyltransferase responsible for H3K9me3 and possibly DNA 
methylation at D4Z4, or the binding of yet unidentified chromatin modifiers. When less 
than 11 D4Z4 repeat units are left, the critical threshold is reached, resulting in loss of 
H3K9me3 and loss of DNA methylation at D4Z4. 
In FSHD2, a presently unidentified gene defect may disturb the recruitment of 
SUV39H1 or other chromatin modifiers to D4Z4 with consequent loss of H3K9me3 
and DNA methylation, thus also resulting in a more open chromatin structure at D4Z4. 
Since the number of D4Z4 repeat units with an open chromatin structure differs 
significantly between FSHD1 and FSHD2 patients (1–10 repeats versus >10 repeats), 
it seems unlikely that a protein that binds to each D4Z4 repeat unit, e.g. the D4Z4 
repressor complex [9], plays an important role in FSHD development. If this were the 
case, differences in phenotype between FSHD1 and FSHD2 were to be expected. More 
likely, binding of a protein just upstream or downstream of D4Z4 or binding to a specific 
D4Z4 element (e.g. the proximal or distal unit) seems to be critical. Interestingly, the 
chromatin structure of the p13E-11 region just upstream of D4Z4 is different from 
the remainder of the D4Z4 repeat array [10, 30] and this open chromatin configuration 
extends into the proximal D4Z4 repeat unit just distal to p13E-11 in both controls and 
patients with FSHD [30]. Also, this region harbors haplotype-specific SNPs that may be 
critical to disease development. Apparently, there is an unusual small transition zone 
from a very open to a compact chromatin structure. Changes in this transition zone may 
uncover presently unidentified D4Z4 elements essential for the pathogenesis of FSHD. 
It is therefore imperative to investigate whether such a transition zone also exists at the 
distal end of the repeat. In addition, a DUX4 transcript from the distal D4Z4 repeat 
unit was reported recently [34], which is provided with a polyadenylation signal by the 
distally located pLAM sequence. Interestingly, the pLAM sequence is only present on 
4qA alleles [34, 35]. 
Currently, I cannot explain the large clinical intra- and interfamilial variability observed 
in FSHD, varying from gene carriers without symptoms to patients that eventually 
become wheelchair-bound [36]. This intrafamilial variability also applies for FSHD2 
families, in which a non-affected family member with significant D4Z4 hypomethylation 
and a D4Z4 repeat array on a 4qA161 haplotype was identified. However, the 4qA161-
type repeat array in this family member is relatively large in size, while most FSHD2 
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patients carry a 4qA161-type repeat <100 kb. Further analysis of D4Z4 chromatin structure 
in gene carriers will be essential. Second, because of the lack of the FSHD phenotype when 
D4Z4 is contracted on 10q alleles, 4qB alleles and 4qA166 alleles, it will be important to 
study chromatin changes other than DNA methylation in individuals carrying such a short 
repeat array [21, 37-39]. In Chapter 4 it is already described that D4Z4 hypomethylation occurs 
upon repeat contraction irrespective of the haplotype the contracted repeat array is residing 
in. It will also be important to study H3K9me3 and HP1g/cohesin binding in control 
individuals with a contracted repeat on non-pathogenic haplotypes. Finally, the differences 
between all recently identified haplotypes need to be studied in detail as SNPs in the D4Z4 
repeat array may affect binding of proteins or affect steady state expression levels of D4Z4-




In <5% of patients with FSHD, no D4Z4 contraction is observed by pulsed field gel 
electrophoresis (PFGE). Nevertheless, these patients do show loss of similar repressive 
chromatin marks as FSHD1 patients; D4Z4 hypomethylation on chromosomes 4q (Chapter 
2) [14] and loss of H3K9me3 with subsequent disturbed HP1g/cohesin binding to D4Z4 
(Chapter 3). Furthermore, these patients show additional D4Z4 hypomethylation on 
chromosomes 10q (Chapter 4). Because of the epigenetic overlap between FSHD1 and 
FSHD2, the presence of a more open chromatin structure at the D4Z4 repeat array seems 
essential for FSHD pathogenesis.
At present, most FSHD2 patients identified are single cases within a family. In addition, 
all FSHD2 cases with pronounced D4Z4 hypomethylation carry at least one allele of the 
4qA161 haplotype, similar to all FSHD1 patients. This suggests that also the presence of a 
4qA161 allele is indispensable for the development of FSHD in addition to the changes in 
chromatin structure at D4Z4.
8.1.1 geNotype-pheNotype StuDy iN FShD2
The phenotype of FSHD1 patients and FSHD2 patients seems identical, although the 
epigenetic defect is not completely overlapping (additional D4Z4 hypomethylation is 
observed on chromosome 10q alleles in patients with FSHD2 (Chapter 4)). There is also 
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a large difference in amount of D4Z4 repeat units present with an open chromatin 
structure, both on chromosomes 4q and 10q, in patients with FSHD2. Hence, it will 
be important to perform a thorough genotype-phenotype study with the objectives to 
compare clinically FSHD1 and FSHD2 patients and to determine whether the more 
pronounced and more widespread hypomethylation observed in FSHD2 has additional 
effects on the phenotype. The FSHD phenotype is not restricted to the muscles; 
epilepsy, mental retardation, sensorineural hearing loss and retinal vasculopathy have 
been reported [40-42]. When performing such a genotype-phenotype study, these non-
muscular symptoms also have to be included in the examination.
8.1.2 geNome-wiDe SNp StuDieS iN FShD2
I anticipate that a mutation in a gene responsible for the repressive chromatin marks at 
the D4Z4 repeat array underlies the pathogenesis of FSHD2. Already several candidate 
genes, mainly genes involved in the establishment and/or maintenance of chromatin 
structure, have been tested for FSHD2, but thus far no mutations were identified 
(Chapter 2) [43]. A reasonable alternative is to perform genome-wide SNP studies to 
identify the disease locus in this small group of FSHD patients. First, it will be crucial 
to determine the inheritance pattern of FSDH2. With multiple affected siblings 
and unaffected parents in one family (Family 8, Chapter 4) and an affected mother-
daughter pair (Family 2, Chapter 4), it is yet difficult to rule out either a dominant or a 
recessive inheritance pattern. Importantly, some unaffected family members also show 
pronounced hypomethylation at the D4Z4 repeat array (Chapter 2), suggesting that 
the gene defect in FSHD2 patients is not fully penetrant. Another explanation for this 
observation is that these unaffected family members with D4Z4 hypomethylation are 
gene carriers of the D4Z4 methylation defect but do not have a 4qA161-type repeat 
array. However, this last explanation does not explain all unaffected family members 
with D4Z4 hypomethylation (Individual 1.4, Chapter 2). Thus, it will be very important 
to rule out the diagnosis of FSHD in these individuals. 
8. 2 icF SyNDrome
The two unrelated disorders FSHD and ICF share an epigenetic hallmark, namely D4Z4 
hypomethylation [14, 44]. In patients with FSHD, the loss of DNA methylation at D4Z4 
seems to occur as a consequence of loss of H3K9me3 at D4Z4 (Chapter 3). In most 
ICF cases, the loss of DNA methylation at specific genomic loci, including D4Z4, can 
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be explained by the presence of mutations in the DNA methyltransferase 3B (DNMT3B) 
gene (ICF1) [45, 46].
To date, it is still unknown how mutations in DNMT3B cause ICF syndrome. It seems 
unlikely that loss of DNA methylation at D4Z4 plays an important role in ICF pathogenesis, 
since patients with FSHD show no symptoms of a primary immunodeficiency as 
observed in ICF patients (Chapter 2). It also seems unlikely that hypomethylation of 
α-satellite repeat DNA is important for ICF pathogenesis, as loss of DNA methylation 
in this repetitive DNA is only observed in patients with ICF2 syndrome, thus in patients 
in whom no mutation in the DNMT3B gene can be detected [16]. ICF2 patients cannot 
be discriminated from ICF1 patients based on their phenotype [47]. More likely, a yet 
to be identified mechanism involving hypomethylation of a specific repeat array or 
another locus may cause the ICF phenotype in both patient groups. Thus far, it has been 
speculated that hypomethylation of the Sat2 repeat array is crucial for pathogenesis, but 
evidence for this is lacking [48].
Similar as suggested above for FSHD2, it will be important to perform genome-wide 
SNP studies in patients with ICF2. As it is anticipated that ICF2, like ICF1, is inherited 
in an autosomal recessive fashion, consanguineous families will be instrumental in such 
studies. Using the method of homozygosity mapping, large regions of homozygosity 
that may contain the disease gene can be readily identified in a small set of patients [49]. 
As the number of ICF2 patients is limited (thus far ~50 ICF cases, both ICF1 and ICF2, 
have been described in literature [47]), combining homozygosity mapping with genome-
wide expression studies in patients with ICF2 may facilitate the identification of the 
ICF2 disease locus considerably. I expect that genes operating in a similar pathway are 
affected in both types of ICF syndrome, as no prominent differences in phenotype are 
observed [47].
8.3 epigeNetic cAuSeS AND coNSequeNceS iN FShD
FSHD can be considered an epigenetic disorder, since loss of H3K9me3 and DNA 
methylation are observed in the D4Z4 repeat array of both FSHD1 and FSHD2 patients 
(Chapter 3) [14]. However, although necessary for FSHD development, the causes and 
consequences of the loss of these repressive chromatin marks are unknown. I will now 
discuss some possible future experiments that can be performed to obtain a more 
comprehensive understanding of these causes and consequences.
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8.3.1 ADDitioNAl hiStoNe moDiFicAtioN ANAlySeS
We were unable to develop primers that specifically amplify the contracted allele in 
FSHD patients for our histone modification analyses (Chapter 3). As a result, histone 
modification levels at D4Z4 were determined on both chromosomes 4 and in addition 
on the homologous D4Z4 repeat array on both chromosomes 10. It was thus surprising 
that we observed such a pronounced loss of H3K9me3 in FSHD1, comparable with the 
loss observed in FSHD2 where the loss of DNA methylation is much more extensive 
(Chapter 4) [14]. Therefore, we speculated that loss of H3K9me3 may also occur on the 
other D4Z4 repeat arrays in addition to the contracted repeat array. This is in contrast 
with the loss of DNA methylation, which only occurs on the contracted allele in FSHD1 
(Chapter 4) [14]. It will be crucial to develop primers that are 10q-specific to investigate 
in more detail the loss of H3K9me3. Besides, also 4qA161-specific primers should 
be developed which may be used to study the contracted allele specifically in patients 
in which the normal allele is of the 4qB-type and determine whether a relationship 
between H3K9me3 levels and clinical severity score (CSS) exists [24]. Furthermore, 
other histone modifications may also be changed in patients with FSHD, but they may 
not have been tested yet or they may have been missed if the changes are restricted to 
the contracted allele. 
Another unanswered question is whether loss of DNA methylation is downstream of 
H3K9me3 loss or whether it occurs independently. The relationship between histone 
modifications and DNA methylation seems different for other genomic loci. DNA 
methylation may recruit histone deacetylases and histone methyltransferases via the 
methyl-binding protein MeCP2 [50]. On the other hand, specific histone modifications 
may recruit DNA methyltransferases resulting in methylation at CpG dinucleotides [51]. 
At D4Z4, I speculate that H3K9me3 is independent or upstream of DNA methylation, 
as no loss of H3K9me3 was observed in ICF patients with D4Z4 hypomethylation 
and this histone modification was also still present in control cells treated with the 
demethylating agent 5-azacytidine. However, the occurrence of D4Z4 hypomethylation 
without loss of H3K9me3 in the unaffected mother of two FSHD2 cases argues against 
this hypothesis (Chapter 3). To study this process in more detail, ChIP experiments 
can be performed using antibodies against SUV39H1 and DNMT3B, the histone 
methyltransferase and DNA methyltransferase responsible for the repressive chromatin 
marks at D4Z4, in combination with siRNA knockdown experiments. If H3K9me3 is 
indeed upstream of DNA methylation at D4Z4, no DNMT3B binding to D4Z4 and no 
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D4Z4 methylation is expected after knockdown of SUV39H1. In addition, when cells 
are treated with siRNA against DNMT3B, it is expected that SUV39H1 can still bind 
to D4Z4. However, it will be first necessary to determine where DNMT3B binds to 
D4Z4, as DNMT3B binding to DNA may be restricted to specific DNA sequences [52].
Finally, it will be essential to study the presence of histone modifications and DNA 
methylation at those D4Z4 regions that are implicated in transcription [34, 53], e.g. 
the distal D4Z4 repeat unit and the adjacent pLAM sequence, which may contain a 
polyadenylation signal [34]. Thus far, only a small part of the D4Z4 repeat array has been 
studied for chromatin changes [14, 30, 44]. Interestingly, although the maximum level of 
DNA methylation differs between different CpG dinucleotides tested in our lab, the 
percentage of reduction in DNA methylation between controls and FSDH1 patients is 
~35% on each site investigated (Chapter 4). Furthermore, loss of H3K9me3 was only 
studied in one region of approximately 300 bp. A limited set of data on the border of 
the p13E-11 region and the first partial D4Z4 repeat unit suggests that no H3K9me3 is 
present at this region, neither in FSHD patients nor in controls (Chapter 3).
8.3.2 hp1g/coheSiN biNDiNg to D4Z4
D4Z4 contraction, D4Z4 hypomethylation and loss of H3K9me3 at D4Z4 can be 
observed in different cell types. Thus far, lymphoblastoid cells, fibroblasts and myoblasts 
were tested. The observation that HP1g/cohesin binding may be tissue-specific, as it 
could not be detected at D4Z4 in lymphoblastoid cells of control and FSHD individuals 
(Chapter 3), is very intriguing and may perhaps partly explain why FSHD patients 
mainly present with muscular symptoms. However, binding of these two proteins in 
additional primary cell lines has to be tested. Especially since lymphoblastoid cell lines 
are obtained by infection of PBLs with Epstein-Barr virus (EBV). Such treatment may 
have an effect on mechanisms like histone modifications and DNA methylation. If indeed 
no HP1g/cohesin binding to D4Z4 is observed in several additional cell types, it will be 
crucial to determine the function and consequences of HP1g/cohesin binding to D4Z4.
For some years, it has been speculated that FSHD may be regarded as a nuclear 
envelopathy. The observation that the subtelomere of chromosome 4q localizes to the 
nuclear periphery [54, 55], but also the overlap in expression profiles between patients 
with FSHD and Emery-Dreifuss muscular dystrophy (EDMD) [56], have fueled this 
hypothesis. Our data deliver additional evidence for a possible link between FSHD 
pathogenesis and the nuclear envelope, because HP1 is known for its interaction with 
140
chapter 6
the lamin B receptor (LBR) in the nuclear lamina [57]. As a result of loss of HP1g binding 
to D4Z4 in patients with FSHD, this interaction with the nuclear lamina may be lost. 
An initial experiment to study this hypothesis is to perform a ChIP study using an 
antibody against LBR in cells of controls and FSHD patients followed by (quantitative) 
PCR with D4Z4-specific primers. Another method is to knock down HP1g by siRNA 
and determine the binding of LBR to D4Z4 by ChIP. If indeed this interaction with the 
nuclear lamina is lost, other interactions, for example via the DNA binding protein 
barrier to autointegration factor (BAF), may also be lost. All these interactions can be 
studied in more detail using ChIP and treating control cells with siRNA against different 
proteins in the nuclear lamina. 
Another important experiment will be to determine whether the nuclear peripheral 
organization of the subtelomere of chromosome 4q is lost in FSHD, e.g. using 3D-FISH. 
Previously, two studies could not observe a significant change in peripheral organization 
in FSHD patient cells, although one of these studies observed a small non-significant 
detachment from the nuclear periphery [54, 55]. This indicates that the changes may be 
very subtle; thus, larger groups of patients and controls have to be studied. Treatment 
of control cells with siRNA against HP1g may increase the differences in peripheral 
organization. Finally, as HP1g binding to D4Z4 may be tissue-specific, it may be 
interesting to study peripheral organization of 4qter in different cell types. Thus far, the 
peripheral localization of the subtelomere of chromosome 4q was studied in a limited 
amount of lymphoblastoid, fibroblast and myoblast cell lines. In these studies, D4Z4 
was located in the nuclear periphery in all tested cell types [54, 55]. Therefore, it seems 
unlikely that HP1g has a major role in D4Z4 tethering to the nuclear periphery, but still 
HP1g loss may greatly influence the interactions between D4Z4 and the nuclear lamina.
The protein cohesin is mainly known for its role during mitosis where it holds the sister 
chromatids together [58]. Recently, an additional function of cohesin together with the 
insulator protein CTCF was reported [59]. Importantly, four different CTCF binding 
sites were identified in the D4Z4 repeat array. CTCF binding to these sites is enriched in 
patients with FSHD (G. Filippova, personal communication) [60]. As CTCF and cohesin 
proteins may compete for similar binding sites [61], the loss of cohesin binding to D4Z4 
in FSHD patients may explain the increased binding of CTCF. To study this in more 
detail, a cohesin ChIP using primers that specifically amplify the four CTCF binding 
sites may be performed.
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8.4 hAplotype-SpeciFic SequeNce vAriAtioNS;
 the eFFect oN trANScriptioN AND proteiN biNDiNg
We observed that D4Z4 contraction results in a more open chromatin structure 
irrespective of the haplotype of the contracted allele (Chapter 4). Therefore, it seems 
crucial to study the effect of haplotype-specific sequence changes and particularly 
4qA161-specific, thus FSHD-specific, sequence variations. First, transcription of FSHD 
candidate genes, like DUX4, FRG1 and FRG2, may be affected. Second, binding of certain 
proteins may vary between the different haplotypes because of sequence variations. 
To study the first option, transfection studies with D4Z4 elements representing the 
different haplotypes and/or haplotype-specific SNPs may be informative. Both RNA and 
protein levels of the DUX4 candidate gene could be determined. Using a similar system, 
DUX4 expression was measured for the first time two years ago. Both an intronless 
transcript from each D4Z4 repeat unit [53] and a transcript with two introns which 
is transcribed from the most distal D4Z4 repeat unit [34] were identified. In addition, 
several new sense and antisense transcripts originating from D4Z4 were recognized 
very recently. All identified transcripts seem to be generated from the DUX4 transcript 
from the distal D4Z4 repeat unit and not only novel mRNAs but also mi/siRNA-sized 
RNA fragments were identified [62]. Another possibility is to use luciferase reporter 
assay that determine the effect of specific SNPs and/or haplotypes on the promoter 
activity of the FSHD candidate genes. Previously, this method was successfully applied 
to determine the effect of one or multiple D4Z4 repeat units on FRG2 promoter 
activity [7]. However, it is still unclear which transcript(s) is(are) responsible for FSHD 
pathogenesis; it has been hypothesized that a combinatorial action of candidate genes 
may underlie this disease. Therefore, a third possibility is to quantitatively compare 
RNA isolated from cells transfected with the different haplotypes on a genome-wide 
scale using either expression arrays covering the whole genome or performing genome-
wide deep sequencing of (mi)RNA transcripts. This way, not only the expression of 
thus far identified FSHD candidate genes is determined. Instead, genome-wide 
expression differences between the different haplotypes of chromosomes 4q and 10q 
are determined. Preferably, all studies should be performed in human muscle cells.
Second, the haplotype-specific SNPs may affect the binding of certain proteins to the 
D4Z4 region. Examples of proteins that bind to the D4Z4 repeat array are YY1 and 
indirectly HMGB2 and nucleolin [9]. Thus far, no difference in binding of this repressor 
complex in FSHD patients and control individuals has been observed. However, FSHD 
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research is complicated by the presence of homologous D4Z4-like sequences on many 
chromosomes, including the highly homologous repeat array on chromosome 10q [63, 
64]. Therefore, it will be very important to develop haplotype-specific primers that can 
be used in ChIP experiments to specifically study the binding of proteins to the different 
haplotypes. Alternatively, one could focus on the identification of additional proteins 
that bind to the D4Z4 repeat array. Using the sequences of the different haplotypes 
and software programs that specifically identify protein binding sites, proteins that 
bind haplotype-specific may be identified. Next, these protein binding sites may be 
confirmed by electrophoretic mobility shift assay (EMSA) and ChIP; techniques that 
study protein binding to DNA in vitro or in vivo, respectively. Also the recently developed 
PICh (proteomics of isolated chromatin segments) technique that identifies the proteins 
bound to a specific genomic region by combining ChIP and mass spectrometric analysis 
may be suitable for this type of experiments [65].
8.5 treAtmeNt oF pAtieNtS with FShD
As described in Chapter 5, supplementation with folic acid and methionine did not 
significantly increase the methylation level at the D4Z4 repeat array, neither in FSHD 
patients nor in control individuals. It is unclear whether the intervention was sufficient 
to remethylate D4Z4 and whether the D4Z4 locus is susceptible to DNA remethylation. 
Therefore, different conditions can be tested by in vitro treatment of myoblasts of FSHD 
patients with different concentrations of folic acid for different time periods. Further, 
the addition of vitamin B12 as a supplement may increase the remethylation of D4Z4 
significantly, since vitamin B12 is an important co-regulatory enzyme in the folate cycle 
[23]. 
A more specific method to remethylate D4Z4 may be by the use of short methylated 
oligonucleotides which induce DNA methylation at specific loci. When such 
oligonucleotides were applied to the proximal promoter region of the human oncogene 
Bcl-2, gene silencing of the gene occurred [66]. However, Bcl-2 is a single-copy gene, 
while D4Z4-like sequences can be found on many chromosomes [63, 64, 67]. In addition, 
to apply this method in FSHD patients more information on transcription from the 
D4Z4 region is needed, as the oligonucleotides have to be directed towards the regions 
responsible for FSHD pathogenesis. Finally, we observed that DNA methylation may be 
downstream of H3K9me3 at D4Z4 (Chapter 3); thus, the lack of results in the initial 
pilot study with folic acid and methionine may partly be explained by this. The addition 
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of the two supplements may not have resulted in higher methylation levels at D4Z4 
because H3K9me3 levels were still low. Probably, higher levels of H3K9me3 have to be 
present at D4Z4 to recruit DNMT3B and thus to remethylate D4Z4. However, since 
DNMT3B is considered a de novo DNA methyltransferase that mainly functions during 
embryogenesis [68], this treatment may not be effective.
A better idea might be to perform an experiment to determine whether addition of 
the histone methyltransferase SUV39H1 has an effect on H3K9me3 levels at D4Z4 
and consequently on D4Z4 methylation levels. An initial experiment studying the 
effect of transfection of FSHD myoblasts with a construct containing the SUV39H1 
sequence may be performed. Such a SUV39H1 construct has already been successfully 
used to transfect human cells [69]. Readouts of a SUV39H1 overexpression experiment 
will be the determination of H3K9me3 levels at D4Z4 by ChIP, the D4Z4 methylation 
levels by methylation-sensitive Southern blot analysis and the expression levels of 
FSHD candidate genes by RT-PCR. Also, control cells may be transfected with the 
construct to determine the side-effects of the treatment. A disadvantage of this method 
is that SUV39H1 not only targets the D4Z4 repeat array but also additional genomic 
regions. However, SUV39H1 mainly localizes to pericentromeric heterochromatin 
and telomeres, because of its main function in heterochromatic gene silencing [70]. 
Probably, most histone H3 proteins associated with these genomic regions will already 
be completely methylated. Nevertheless, the risk exists that regions that are normally 
unmethylated become methylated and a consequence is that genes that are normally 
expressed may be silenced. This is especially dangerous when SUV39H1 overexpression 
affects tumor suppressor genes. Therefore, it will be better to design a construct that 
is only recruited to the genomic region that has to be treated. The design of such a 
construct will be hindered by the presence of D4Z4 repeats not only on chromosomes 
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Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary muscle disorder that 
is characterized by weakness and wasting of the muscles of the face (facio), the shoulder 
(scapulo) and the upper arms (humeral). Usually the first disease symptoms are observed 
before the age of 20, but these symptoms may vary significantly, in presentation and 
severity. The severity of the disease not only varies between patients from different 
families but also between patients from the same family.
Almost 20 years ago it was discovered that FSHD is caused by a loss of a piece of repetitive 
DNA that is located on the end of the long arm of chromosome 4 (4q35). While in 
control individuals this piece of repetitive DNA, called the D4Z4 repeat, is present 
as 11-100 copies on each chromosome 4 end, most FSHD patients carry only 1-10 
copies of the repeat on one of their chromosome 4 ends (FSHD1). As a consequence 
of this discovery, for many years the presence of a gene within the D4Z4 repeat that 
might explain the occurrence of FSHD in individuals carrying a short repeat array was 
anticipated. However, until two years ago the identification of a functional gene within 
the D4Z4 repeat was unsuccessful. Therefore, research has focused on different disease 
models that might explain the causative mechanism behind FSHD. One of these disease 
models, which is not necessarily mutually exclusive with the presence of a gene within 
the repeat, hypothesizes the involvement of an epigenetic or chromatin component in 
the development of FSHD. Epigenetics concerns the occurrence of hereditary changes 
in gene function without changes in the sequence of the base pairs of the DNA in our cell 
nucleus. An example of an epigenetic modification is DNA methylation. Our DNA may 
contain additional methyl groups and these methyl groups are attached to the cytosine 
(C) bases in our DNA by enzymes called DNA methyltransferases. The presence of 
methyl groups on DNA has an influence on the on- or off status of genes.
More than 5 years ago it was observed that patients with FSHD carry less methyl groups 
on the DNA of the first D4Z4 repeat in comparison with control individuals. What 
made this observation even more interesting was that low DNA methylation was also 
observed in a small group of patients with a muscle disease clinically indistinguishable 
152
from FSHD (FSHD2). Because these patients carry more than 10 D4Z4 repeats on 
each chromosome 4 end, previously the phenotype in these individuals could not 
be confirmed by genetic tests. Now it was found that a commonality in chromatin 
structure exists between both patient groups. However, low DNA methylation on the 
first D4Z4 repeat was also observed in patients suffering from the ICF syndrome. ICF 
is an abbreviation for Immunodeficiency, Centromeric instability and Facial anomalies 
syndrome. The most prominent complaints in these patients are repetitive infections 
as a consequence of an immunodeficiency, but these patients do not have any muscular 
complaints. Therefore, the exact role of DNA methylation in the disease mechanism of 
FSHD remained unknown.
FSHD research is complicated by several factors. First, on chromosome 10 a highly 
similar repeat as on the chromosome 4 end is present. This complicates the DNA 
diagnosis of FSHD. Also on chromosome 10 less than 11 repeats can be present. 
However, individuals carrying a short repeat on chromosome 10 do not develop FSHD. 
Second, several genetic variants of the chromosome 4 end have been identified. Thus 
far, nine different variants were recognized. Remarkably, in all patients with FSHD 
the disease chromosome is always of the 4qA161 genetic variant. Besides this variant, 
4qB163 and 4qA166 are highly prevalent variants. Individuals with less than 11 D4Z4 
repeats on a 4qB163 or a 4qA166 variant do not develop FSHD.
In this thesis several studies are described that focused on the further unraveling of 
the epigenetic disease mechanism responsible for the development of FSHD. In 
chapter 2 a study is presented that made a detailed comparison between patients with 
FSHD and patients with ICF to determine whether there is an additional epigenetic, 
chromatin structure or clinical overlap besides the low DNA methylation on the first 
D4Z4 repeat. In chapter 3 a study is described that searched for a chromatin factor 
that differs between patients with FSHD and patients with ICF. Because this factor is 
only lowered in patients with FSHD (both in FSHD1 patients with less than 11 D4Z4 
repeats and in FSHD2 patients with more than 10 D4Z4 repeats), but not in control 
individuals and in patients with ICF or in patients with another type of muscle disorder, 
it is concluded that indeed the chromatin structure of D4Z4 plays an important role in 
the development of FSHD. In chapter 4 a detailed DNA methylation study is described 
that tried to determine whether changes in chromatin structure explain the occurrence 
of FSHD only in individuals with less than 11 D4Z4 repeats on the 4qA161 variant of 
chromosome 4, while individuals with less than 11 D4Z4 repeats on the 4qA166 and 
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4qB163 variants and on chromosome 10 are healthy. Finally, in chapter 5 a pilot study 
is described in which we tried to change the chromatin structure of the D4Z4 repeat in 
patients with FSHD by folic acid supplementation.
low DNA methylAtioN iS reStricteD to the D4Z4 repeAt iN pAtieNtS with FShD2 
(chApter 2)
To better understand why two completely different diseases, the myopathy FSHD 
and the immunodeficiency ICF, share an epigenetic component, namely low DNA 
methylation on the first D4Z4 repeat, a study was performed in which these two patient 
groups were compared in detail. One of the hypotheses was that especially patients with 
FSHD2 show an overlap with patients with ICF and that possibly these patients might 
share a defect in the same DNA methylation mechanism.
Besides low DNA methylation on the D4Z4 repeat, it was shown that in patients with ICF 
other pieces of repetitive DNA also contain less methyl groups. This may be explained 
by the presence of a defect in one of the DNA methyltransferase enzymes in some 
patients with ICF. One of the experiments in the study consisted of the determination of 
the DNA methylation level of these other repeats with less DNA methylation in patients 
with FSHD2. However, in patients with FSHD2 the DNA methylation level was not low 
on these other repeats and thus the overlap in low DNA methylation levels between 
FSHD2 and ICF seems to be restricted to the D4Z4 repeat. Also other characteristics 
of patients with ICF, like certain types of chromosomal abnormalities in white blood 
cells, which are only visible after treatment with phytohaemagglutinin (HA), and low 
levels of the immunoglobulins IgA, IgG and IgM were not observed in patients with 
FSHD2. In conclusion, the overlap between patients with FSHD2 and patients with ICF 
is restricted to the low DNA methylation level on the D4Z4 repeat.
loSS oF methyl groupS oN lySiNe 9 oF hiStoNe h3 AND loSS oF biNDiNg oF the 
proteiNS hp1g AND coheSiN to the D4Z4 repeAtS iN FShD (chApter 3)
Besides DNA methylation other important epigenetic factors are the histone 
modifications. To fit the enormous amount of DNA in the nucleus of a cell, our DNA 
is wrapped around specific proteins. These proteins, the histones, may contain methyl 
groups at their tails, just like DNA. Histone tails can also contain acetyl groups. 
Depending on the location of the methyl and acetyl groups and the amount of methyl and 
acetyl groups, genes can be switched on or off. With the study described in chapter 3 we 
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have tried to map the presence and amount of methyl and acetyl groups on the histone 
proteins in the D4Z4 repeat. We identified several different histone modifications, both 
active as well as repressive. In addition, we observed that patients with FSHD1 and 
FSHD2 have fewer methyl groups on a specific location (the amino acid lysine 9) of 
histone H3, both in comparison with control individuals and patients with ICF. Finally, 
we observed a secondary loss of the proteins HP1g and cohesin. The discovery that 
these proteins bind to D4Z4 in skin and muscle cells but almost not in blood cells is 
intriguing, because thus far it is unclear why patients with FSHD present mainly with 
muscle complaints, while the defect in the DNA and the low DNA methylation and the 
loss of methyl groups on lysine 9 of H3 seems present in all types of cells.
DNA methylAtioN ANAlySiS oF the D4Z4 repeAtS oN chromoSome 4 AND chromoSome 
10 (chApter 4)
To better understand the role of DNA methylation in the development of FSHD and to 
determine why the presence of less than 11 D4Z4 repeats only on the 4qA161 variant 
results in FSHD, a detailed DNA methylation analysis of the D4Z4 repeat on chromosome 
4 and chromosome 10 was performed. Contrary to previous studies in which only DNA 
methylation of the first D4Z4 repeat was determined, in this study also the methylation 
level of all following D4Z4 repeat units was measured. The results of the study are 
presented in chapter 4 and it is clear that low DNA methylation on the D4Z4 repeat is 
not FSHD-specific. Instead, it seems related to the number of D4Z4 repeats present. 
Also in control individuals with short repeat arrays on a non-4qA161 chromosome 
4 end or on chromosome 10, low DNA methylation levels were observed. Thus, the 
results suggest thus that low DNA methylation on the D4Z4 repeat is necessary but not 
sufficient to develop FSHD. We now postulate that the presence of the 4qA161 variant 
critically determines the occurrence of FSHD and that differences in the DNA sequence 
of the different chromosome 4 ends may explain FSHD development. This hypothesis 
is supported by other results of the study presented in chapter 4. DNA methylation 
was examined in detail in patients with FSHD2. Not only on chromosome 4, but also 
on chromosome 10, very low DNA methylation levels were observed, unrelated to 
the repeat size. These results suggest the presence of gene defect responsible for DNA 
methylation of the D4Z4 repeat in patients with FSHD2, both on chromosome 4 and on 
chromosome 10. The most remarkable result of this study is that all patients with FSHD 
carry at least one 4qA161 chromosome 4 end with low DNA methylation.  In summary, 
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there seem to be two ways to develop FSHD. In most patients with FSHD a reduction 
of the amount of D4Z4 repeats is observed on the 4qA161 variant (FSHD1). As a 
consequence the number of methyl groups present on the D4Z4 repeat is reduced. In a 
small group of patients with FSHD, although more than 10 D4Z4 repeats are present on 
each chromosome, because of a yet unknown gene defect very low DNA methylation 
levels are present on chromosomes 4 and 10, and most importantly also on the 4qA161 
variant (FSHD2). The combination of the 4qA161 variant and low DNA methylation 
seems to be a necessary prerequisite for the development of FSHD.
No eFFect oF Folic AciD AND methioNiNe SupplemeNtAtioN oN the DNA methylAtioN 
level oF the D4Z4 repeAt iN pAtieNtS with FShD
As presented in this thesis, patients with FSHD show important chromatin structure 
alterations, namely low D4Z4 methylation and loss of methyl groups on lysine 9 of 
histone H3 and lower binding of the proteins HP1g and cohesin to the D4Z4 repeat. 
Because these epigenetic abnormalities seem to play a very central role in FSHD1 
and FSHD2 patients, in the study presented in chapter 5 we tried to restore part of 
these epigenetic abnormalities. Folic acid is an important vitamin that together with 
the amino acid methionine can raise the DNA methylation level in our cells. A small 
pilot study was therefore conducted in FSHD1 patients, FSHD2 patients and control 
individuals. During three months individuals were supplemented with 5 milligram folic 
acid once a day and 1 gram methionine three times a day. Blood samples were drawn 
before and after these three months and several factors were tested in these samples, 
including serum folate and vitamin B12 levels, DNA methylation on the D4Z4 repeat of 
chromosome 4 and DNA methylation on the total DNA bases in a blood cell. Although 
the total amount of methyl groups present on the DNA in a blood cell was raised, the 
DNA methylation level on the D4Z4 repeat was not changed, neither in patients with 
FSHD nor in control individuals.
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Facioscapulohumerale spierdystrofie (FSHD) is een erfelijke spierziekte die 
wordt gekenmerkt door verzwakking van de aangezichtspieren (facio), de spieren 
rond de schouderbladen (scapulo) en de bovenarmspieren (humeral). De eerste 
ziekteverschijnselen beginnen meestal voor het twintigste levensjaar en die kunnen zeer 
variabel zijn in presentatie en ernst. De ernst van de ziekte varieert echter niet alleen 
tussen patiënten uit verschillende families maar ook tussen patiënten uit dezelfde familie.
Al bijna 20 jaar geleden werd ontdekt dat FSHD wordt veroorzaakt door de vermindering 
van een repeterend stuk DNA op het uiteinde van de lange arm van chromosoom 4 
(4q35). Terwijl in controlepersonen dit stuk repeterend DNA, genaamd de D4Z4 
repeat, 11 tot 100 keer voorkomt op elk chromosoom 4 uiteinde, hebben de meeste 
patiënten met FSHD slechts 1 tot 10 D4Z4 repeats op één van hun chromosomen 4 
(FSHD1). Als gevolg van deze ontdekking heeft men vele jaren onderzoek gedaan naar 
de aanwezigheid van een gen in de D4Z4 repeat die het ontstaan van FSHD in personen 
met een verkort stuk DNA zou kunnen verklaren. Tot twee jaar geleden was men echter 
niet succesvol in het aantonen van een functioneel gen in de D4Z4 repeat, vandaar 
dat onderzoek zich ook op andere modellen heeft gericht die het ontstaan van FSHD 
proberen te verklaren. Eén van deze modellen voorspelt bijvoorbeeld een epigenetische 
component die betrokken is bij het ontstaan van FSHD. Epigenetica betreft overerfbare 
veranderingen in genfunctie die optreden zonder wijzigingen in de volgorde van 
de basenparen van het DNA in de celkern. Een voorbeeld van een epigenetische 
modificatie is DNA methylatie. Ons DNA kan extra methylgroepen bevatten en deze 
methylgroepen worden aan cytosine (C) bouwstenen van ons DNA gekoppeld door 
enzymen die DNA methyltransferases heten. De aanwezigheid van methylgroepen op 
het DNA heeft invloed op het aan- of uitschakelen van genen.
Al vijf jaar geleden werd aangetoond dat in patiënten met FSHD minder methylgroepen 
aanwezig zijn op het DNA van de eerste D4Z4 repeat in vergelijking met controlepersonen. 
Wat deze ontdekking nog interessanter maakte was dat ook lage DNA methylatie werd 
gevonden in een kleine groep van patiënten met een spierziekte die qua klachten niet 
samenvattInG
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te onderscheiden valt van FSHD (FSHD2). Omdat deze patiënten echter meer dan 10 
D4Z4 repeats hebben kon eerder de diagnose van FSHD in een DNA test niet worden 
bevestigd. Nu werd echter aangetoond dat op epigenetisch niveau een overeenkomst 
bestaat tussen beide patiëntengroepen. Maar lage DNA methylatie op de eerste D4Z4 
repeat werd ook gevonden in patiënten met het ICF syndroom. ICF is de afkorting 
voor Immuundeficiëntie, Centromerische instabiliteit en Faciale anomalieën syndroom. 
De meest prominente klachten van deze patiënten omvatten herhaaldelijke infecties als 
gevolg van een immuundeficiëntie, maar zij hebben geen spierklachten. Daarom bleef 
de rol van DNA methylatie in het ontstaan van FSHD onduidelijk.
FSHD onderzoek wordt gecompliceerd door een aantal factoren. Ten eerste bevindt zich 
op chromosoom 10 een soortgelijk stuk repeterend DNA als op chromosoom 4. Dit maakt 
de diagnose van FSHD door middel van DNA onderzoek een stuk gecompliceerder. Ook 
op chromosoom 10 kan een vermindering van het aantal D4Z4 repeats plaatsvinden tot 
minder dan 11 eenheden. Personen met minder dan 11 D4Z4 repeats op chromosoom 
10 ontwikkelen echter geen FSHD. Ten tweede bestaan er meerdere genetische 
varianten van het uiteinde van chromosoom 4. Dusver zijn negen verschillende varianten 
geïdentificeerd. Opvallend is het dat alle patiënten met FSHD de 4qA161 variant dragen 
op hun ziektechromosoom. Naast 4qA161 zijn 4qB163 en 4qA166 veel voorkomende 
varianten van het chromosoom 4 uiteinde. Personen met minder dan 11 D4Z4 repeats 
op een 4qB163 of een 4qA166 variant ontwikkelen echter geen FSHD.
In dit proefschrift worden studies beschreven die zich richtten op het verder ontrafelen 
van het epigenetische mechanisme betrokken bij het ontstaan van FSHD. In hoofdstuk 
2 wordt een studie beschreven die zeer nauwkeurig een vergelijking heeft gemaakt 
tussen patiënten met FSHD en patiënten met ICF om te bepalen of er meer overlap 
bestaat op epigenetisch of klinisch niveau behalve de lage DNA methylatie van de 
eerste D4Z4 repeat. In hoofdstuk 3 wordt juist een studie beschreven waar gezocht 
is naar een epigenetisch factor die verschilt tussen patiënten met FSHD en patiënten 
met ICF. Omdat deze factor alleen verlaagd is in patiënten met FSHD1 en FSHD2 en 
niet in controlepersonen en patiënten met ICF of patiënten met andere spierziektes, 
blijkt inderdaad de epigenetica van D4Z4 een belangrijke rol in het ontstaan van FSHD 
te spelen. In hoofdstuk 4 wordt vervolgens een zeer gedetailleerde DNA methylatie 
studie beschreven om te bepalen of epigenetische factoren verklaren waarom slechts 
personen met minder dan 11 D4Z4 repeats op de 4qA161 variant van chromosoom 4 
FSHD ontwikkelen terwijl personen met minder dan 11 D4Z4 repeats op de varianten 
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4qA166 en 4qB163 en op chromosoom 10 gezond zijn. Tot slot wordt in hoofdstuk 5 
een pilot studie beschreven waarin is geprobeerd de epigenetische structuur van de 
D4Z4 repeat te veranderen in patiënten met FSHD met behulp van foliumzuur.
lAge DNA methylAtie beperkt Zich tot De D4Z4 repeAt iN pAtiëNteN met FShD2 
(hooFDStuk 2)
Om beter te begrijpen waarom twee totaal verschillende ziektebeelden, de spierziekte 
FSHD en de immuundeficiëntie ICF, een epigenetische component delen, namelijk lage 
DNA methylatie op de eerste D4Z4 repeat, werd een studie uitgevoerd waarin deze twee 
patiëntengroepen uitvoerig werden vergeleken. Eén van de achterliggende ideeën was 
dat in het bijzonder patiënten met FSHD2 overlap vertonen met patiënten met ICF en 
dat mogelijk deze patiënten een defect in hetzelfde DNA methylatie mechanisme hebben.
Naast lage DNA methylatie op de D4Z4 repeat is aangetoond dat in patiënten met ICF 
verschillende andere repeterende stukken DNA ook minder methylgroepen bevatten. 
Dit kan verklaard worden omdat sommige patiënten met ICF een defect in één van de 
DNA methyltransferase enzymen hebben. Eén van de experimenten in deze studie was de 
bepaling van het DNA methylatie niveau van deze andere repeats met verminderde DNA 
methylatie in patiënten met FSHD2. In patiënten met FSHD2 bleek DNA methylatie niet 
lager op andere repeats en dus is de DNA methylatie overeenkomst tussen patiënten met 
FSHD2 en patiënten met ICF gelimiteerd tot de D4Z4 repeat. Ook andere kenmerken 
van patiënten met ICF, zoals bepaalde chromosomale afwijkingen in witte bloedcellen, 
die alleen zichtbaar zijn na behandeling met de stof phytohaemagglutinin (PHA), en 
lage hoeveelheden van de immuunglobulines IgA, IgG en IgM werden niet gevonden in 
patiënten met FSHD2. In conclusie, de overlap tussen patiënten met FSHD2 en patiënten 
met ICF beperkt zich tot de verlaagde DNA methylatie op de D4Z4 repeat.
verlieS vAN methylgroepeN op lySiNe 9 vAN hiStoN h3 eN verlieS vAN De biNDiNg 
vAN De eiwitteN hp1g eN coheSiNe AAN De D4Z4 repeAtS iN FShD (hooFDStuk 3)
Naast DNA methylatie zijn histon modificaties belangrijke epigenetische factoren. Om 
de enorme hoeveelheid DNA in de kern van een lichaamscel te accommoderen, wordt 
ons DNA om specifieke eiwitten gevouwen. Deze eiwitten, de histonen, kunnen ook 
methylgroepen bevatten, net als DNA. Ook kunnen histonen acetylgroepen bevatten. 
Afhankelijk van de plaats van de methyl- en acetylgroepen en de hoeveelheid van de 
methyl- en acetylgroepen worden genen aan- of uitgezet. Met de studie beschreven in 
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hoofdstuk 3 is geprobeerd de mate van methyl- en acetylgroepen op de histon eiwitten 
in kaart te brengen op de D4Z4 repeat. Niet alleen verschillende histonen met hun 
methyl- en acetylmodificaties werden gevonden, ook bleek dat patiënten met FSHD1 en 
FSHD2 minder methylgroepen hadden op een specifieke plek (het aminozuur lysine 9) 
van het histon H3, zowel in vergelijking tot controlepersonen als tot patiënten met ICF. 
Als gevolg van de vermindering van de methylgroepen op lysine 9 van H3 bleken twee 
andere eiwitten, HP1g en cohesine, die normaal gesproken aan de D4Z4 repeat binden, 
minder goed te kunnen binden in patiënten met FSHD. De ontdekking dat deze eiwitten 
in huidcellen en spiercellen aan D4Z4 binden, maar niet in bloedcellen, is interessant, 
want tot nu toe is het onduidelijk waarom patiënten met FSHD vooral spierklachten 
hebben, terwijl het defect in het DNA en de lage DNA methylatie en het verlies van 
methylgroepen op lysine 9 van histon H3 in alle typen lichaamscellen lijkt voor te komen.
DNA methylAtie ANAlySe vAN De D4Z4 repeAtS op chromoSoom 4 eN chromoSoom 
10 (hooFDStuk 4)
Om beter te begrijpen wat de rol is van DNA methylatie bij het ontstaan van FSHD 
en uit te vinden waarom de aanwezigheid van minder dan 11 D4Z4 repeats op alleen 
de 4qA161 variant leidt tot FSHD, is een gedetailleerde DNA methylatie analyse 
uitgevoerd van de D4Z4 repeats op chromosomen 4 en 10. In tegenstelling tot eerdere 
studies waarin slechts DNA methylatie van de eerste D4Z4 repeat werd bepaald, werd 
in deze studie ook het methylatie niveau van alle D4Z4 repeats bepaald. De resultaten 
van de studie worden besproken in hoofdstuk 4 en brengen heel duidelijk naar voren 
dat lage DNA methylatie op de D4Z4 repeat niet FSHD-specifiek is, maar gerelateerd 
aan de hoeveelheid D4Z4 repeats. Ook in controlepersonen met korte repeats op een 
niet-4qA161 chromosoom 4 uiteinde of op chromosoom 10 werd lage DNA methylatie 
gevonden. Deze resultaten tonen dat hoewel lage DNA methylatie op de D4Z4 repeat 
nodig is, het niet voldoende is om FSHD te ontwikkelen. Wij postuleren nu dat de 
aanwezigheid van de 4qA161 variant alles bepalend is voor het ontstaan van FSHD 
en dat mogelijk verschillen in de DNA volgorde van de verschillende chromosoom 4 
uiteindes verklarend zijn. Deze hypothese wordt gesteund door de andere resultaten 
van de studie gepresenteerd in hoofdstuk 4. DNA methylatie werd namelijk ook 
uitvoerig bekeken in patiënten met FSHD2. Niet alleen op chromosoom 4, maar 
ook op chromosoom 10, werden zeer lage methylatie niveaus gemeten, hoewel in de 
meeste FSHD2 patiënten op beide chromosomen het aantal D4Z4 repeats groter dan 
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10 was. Deze resultaten suggereren dat in patiënten met FSHD2 een defect aanwezig 
is in een gen dat verantwoordelijk is voor DNA methylatie van de D4Z4 repeat op 
zowel chromosoom 4 als chromosoom 10. Het meest opvallende resultaat van deze 
studie is echter dat alle patiënten met FSHD2 naast lage DNA methylatie op zowel 
chromosoom 4 als chromosoom 10 tenminste één 4qA161 uiteinde op chromosoom 
4 dragen. Samenvattend zijn er blijkbaar twee manieren om FSHD te ontwikkelen. In 
de meeste patiënten met FSHD is een vermindering van het aantal D4Z4 repeats op de 
4qA161 variant aanwezig (FSHD1). Hierdoor neemt ook het aantal methylgroepen op 
de D4Z4 repeat af. In een kleine groep van patiënten met FSHD, hoewel het aantal D4Z4 
repeats meer dan 10 bedraagt, zijn door een nog onbekend gendefect zeer lage DNA 
methylatie niveaus aanwezig op zowel chromosoom 4 als 10, en meest belangrijk ook 
op een 4qA161 variant (FSHD2). De combinatie van een 4qA161 variant en lage DNA 
methylatie lijkt dus een belangrijke voorwaarde te zijn voor het ontstaan van FSHD.
geeN eFFect vAN FoliumZuur eN methioNiNe SupplemeNtAtie op het DNA methylAtie 
NiveAu vAN De D4Z4 repeAt iN pAtiëNteN met FShD
Zoals gepresenteerd in dit proefschrift vertonen patiënten met FSHD belangrijke 
epigenetische afwijkingen, namelijk lage D4Z4 methylatie en verlies van methylgroepen 
op lysine 9 van histon H3 en een lagere binding van de eiwitten HP1g en cohesine 
aan de D4Z4 repeat. Omdat deze epigenetische afwijkingen een zeer centrale rol 
lijken te spelen, ze worden namelijk geobserveerd in zowel FSHD1 als FSHD2, is in 
de studie gepresenteerd in hoofdstuk 5 geprobeerd een deel van deze veranderingen 
in chromatine structuur weer te herstellen tot normale niveaus. Foliumzuur is een 
belangrijk vitamine dat samen met het aminozuur methionine het DNA methylatie 
niveau in onze cellen kan verhogen. Een kleine pilot studie werd daarom uitgevoerd in 
FSHD1 patiënten, FSHD2 patiënten en controlepersonen. Gedurende drie maanden 
werden deze personen gevraagd eenmaal daags 5 milligram foliumzuur en driemaal 
daags 1 gram methionine te slikken. Bloedmonsters werden zowel voor als na deze 
drie maanden afgenomen en verschillende factoren werden vervolgens getest in deze 
monsters, zoals serum folaat en vitamine B12 niveaus, DNA methylatie op de D4Z4 
repeat van chromosoom 4 en DNA methylatie van al het DNA in een bloedcel. Hoewel 
het totale aantal methylgroepen van het DNA in een bloedcel toenam, was het DNA 
methylatie niveau niet hoger geworden op de D4Z4 repeat, noch in patiënten met 
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getiteld “Epigenetic causes of facioscapulohumeral muscular dystrophy” uitgevoerd 
bij de afdeling Humane Genetica van het Leids Universitair Medisch Centrum onder 
begeleiding van dr. T Rijkers, Prof. dr. ir. SM van der Maarel en Prof. dr. RR Frants. 
In september 2004 is zij begonnen als assistent in opleiding bij de afdeling Humane 
Genetica op het onderwerp “Studies of the epigenetic disease mechanism in FSHD” 
onder supervisie van Prof. dr. ir. SM van der Maarel en Prof. dr. RR Frants. Het daar 
uitgevoerde onderzoek staat beschreven in dit proefschrift. Sinds januari 2009 is zij 
werkzaam als postdoctoraal onderzoeker bij deze afdeling op het project “The role of 
H3K9me3 and HP1g loss in the pathogenesis of FSHD”.
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Stellingen behorende bij het proefschrift van JC de Greef 
Stellingen
1 D4Z4 chromatine structuurveranderingen op het 4qA161 
uiteinde van chromosoom 4 verenigen FSHD1 en FSHD2.
 Dit proefschrift, hoofdstuk 4
2 De benaming “non-4q-linked FSHD” voor FSHD2 is incorrect.
 Dit proefschrift, hoofdstuk 4
3 FSHD2 verdient meer diagnostische aandacht.
 Dit proefschrift, hoofdstuk 4
4 D4Z4 hypomethylatie beperkt zich niet tot FSHD patiënten en 
is daarom geen geschikte diagnostische marker voor FSHD.
 Dit proefschrift, hoofdstuk 2 en 4
5 Het celtype-specifieke verlies van HP1γ/cohesine in patiënten met FSHD 
kan een eerste verklaring zijn voor het spier-specifieke fenotype.
 Dit proefschrift, hoofdstuk 3
6 De studie naar macrosatelliet repeats is zeer belangrijk voor ons begrip 
van de genomische organisatie en regulatie van het humane genoom.
 Warburton PE, BMC Genomics (2008), 7;9:533
7 Het venijn zit in de staart: de distale D4Z4 repeat is zeer 
waarschijnlijk pathogeen aangezien het een potentieel 
polypeptide produceert dat myogenese kan remmen.
 Snider L, Hum Mol Genet (2009),18(13):2414-30
7 De huidige DNA methylatie experimenten leveren geen bewijs 
dat de chromatine structuur van de S/MAR site veranderd is in 
FSHD patiënten zoals door Petrov et al wordt beweerd.
 Petrov A, Proc Natl Acad Sci U S A (2006), 103(18):6982-7
 Dit proefschrift, hoofdstuk 4
8 Onderzoek aan asymptomatische gendragers draagt bij aan 
het begrip van het pathogene mechanisme van FSHD.
 Arashiro P, Proc Natl Acad Sci U S A (2009), 106(15):6220-5
9 Een voedingssupplement zoals foliumzuur dient 
een voedingssupplement te blijven.
10 Elke dag een Sudoku puzzel is een goede training voor het brein.
11 De beste ontspanning na een drukke werkdag 
in het lab is het aaien van een kat.
Jessica de Greef
19 november 2009
